Index	Sentence	Entity	Entity_Startindex	Entity_Stopindex	Entity_Info
PMC7431904_OgerInput.txtOger_out.csv:1	 A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. 	cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:3	In the mid-20th Century the relationship between drug metabolism and toxicity became appreciated, and the roles of cytochrome P450 (P450) enzymes began to be defined in the 1960s. 	cytochrome P450	271	286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:3	In the mid-20th Century the relationship between drug metabolism and toxicity became appreciated, and the roles of cytochrome P450 (P450) enzymes began to be defined in the 1960s. 	cytochrome P450	271	286	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:11	Much has been written about cytochrome P450 (P450, CYP). 	cytochrome P450	1543	1558	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:11	Much has been written about cytochrome P450 (P450, CYP). 	cytochrome P450	1543	1558	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:116	In 1976, an international series of biennial meetings on the cytochrome P450 enzymes was established as a means of facilitating contact of scientists in this area working in Eastern Bloc and western countries but has developed into a timely international biennial series with meetings rotating among Europe, Asia, North America, and Australia. 	cytochrome P450	15580	15595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:116	In 1976, an international series of biennial meetings on the cytochrome P450 enzymes was established as a means of facilitating contact of scientists in this area working in Eastern Bloc and western countries but has developed into a timely international biennial series with meetings rotating among Europe, Asia, North America, and Australia. 	cytochrome P450	15580	15595	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:61	Another DDI grading difference relates to strong enzyme inducers (eg carbamazepine, phenytoin, St Johns Wort) which are contraindicated in the COVID-19 website with drugs metabolized by cytochrome P450, given the risk of treatment failure and difficulty of managing the DDI. 	cytochrome P450	10063	10078	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:61	Another DDI grading difference relates to strong enzyme inducers (eg carbamazepine, phenytoin, St Johns Wort) which are contraindicated in the COVID-19 website with drugs metabolized by cytochrome P450, given the risk of treatment failure and difficulty of managing the DDI. 	cytochrome P450	10063	10078	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:78	COVID-19 drugs are also potential victims of a DDI when co-administered with strong cytochrome P450 inducers, as are chloroquine, hydroxychloroquine and remdesivir. 	cytochrome P450	12590	12605	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:78	COVID-19 drugs are also potential victims of a DDI when co-administered with strong cytochrome P450 inducers, as are chloroquine, hydroxychloroquine and remdesivir. 	cytochrome P450	12590	12605	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:30	In addition to mitochondria-that are considered the most relevant source of ROS-and to peroxisomes and microsomes, the endoplasmic reticulum stress and enzymes as NADPH oxidase, cytochrome P450 2E1, cyclooxygenases, and lipoxygenases also produce Reactive Oxidative Species. 	cytochrome P450	8008	8023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:30	In addition to mitochondria-that are considered the most relevant source of ROS-and to peroxisomes and microsomes, the endoplasmic reticulum stress and enzymes as NADPH oxidase, cytochrome P450 2E1, cyclooxygenases, and lipoxygenases also produce Reactive Oxidative Species. 	cytochrome P450	8008	8023	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:50	In addition, the wild F. filiformis genome contained 107 cytochrome P450 family genes and 674 genes encoding secretory proteins. 	cytochrome P450	10205	10220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:50	In addition, the wild F. filiformis genome contained 107 cytochrome P450 family genes and 674 genes encoding secretory proteins. 	cytochrome P450	10205	10220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:88	Two putative cytochrome P450 genes (gene 9114 and gene 7212) were also significantly upregulated in the dikaryotic mycelium compared to the monokaryotic mycelium of the wild strain (7.61- and 7.50- fold change, respectively) and the cultivar strain mycelium (2.1- and 1.7- fold change, respectively). 	cytochrome P450	18563	18578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:88	Two putative cytochrome P450 genes (gene 9114 and gene 7212) were also significantly upregulated in the dikaryotic mycelium compared to the monokaryotic mycelium of the wild strain (7.61- and 7.50- fold change, respectively) and the cultivar strain mycelium (2.1- and 1.7- fold change, respectively). 	cytochrome P450	18563	18578	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:103	We identified 107 genes in the cytochrome P450 family, including nine putative trichodiene oxygenases, 31 O-methylsterigmatocystin oxidoreductases, five benzoate 4-monooxygenases, two linoleate 10R-lipoxygenases, two ent-kaurene oxidases, lanosterol 14-alpha and flavonoid hydroxylases and other candidate cytochrome P450s. 	cytochrome P450	22289	22304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:103	We identified 107 genes in the cytochrome P450 family, including nine putative trichodiene oxygenases, 31 O-methylsterigmatocystin oxidoreductases, five benzoate 4-monooxygenases, two linoleate 10R-lipoxygenases, two ent-kaurene oxidases, lanosterol 14-alpha and flavonoid hydroxylases and other candidate cytochrome P450s. 	cytochrome P450	22289	22304	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:103	We identified 107 genes in the cytochrome P450 family, including nine putative trichodiene oxygenases, 31 O-methylsterigmatocystin oxidoreductases, five benzoate 4-monooxygenases, two linoleate 10R-lipoxygenases, two ent-kaurene oxidases, lanosterol 14-alpha and flavonoid hydroxylases and other candidate cytochrome P450s. 	cytochrome P450	22564	22579	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:103	We identified 107 genes in the cytochrome P450 family, including nine putative trichodiene oxygenases, 31 O-methylsterigmatocystin oxidoreductases, five benzoate 4-monooxygenases, two linoleate 10R-lipoxygenases, two ent-kaurene oxidases, lanosterol 14-alpha and flavonoid hydroxylases and other candidate cytochrome P450s. 	cytochrome P450	22564	22579	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:105	Twenty-six CYP450 genes were upregulated in the mycelium of the wild strain compared to the cultivar strain and the cytochrome P450 (gene 5820-D3) had the highest expression level, with more than a 500-fold change. 	cytochrome P450	22793	22808	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:105	Twenty-six CYP450 genes were upregulated in the mycelium of the wild strain compared to the cultivar strain and the cytochrome P450 (gene 5820-D3) had the highest expression level, with more than a 500-fold change. 	cytochrome P450	22793	22808	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:200	It has been reported that a more divergent cytochrome P450 oxidase could be involved in secondary biosynthesis. 	cytochrome P450	39561	39576	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:200	It has been reported that a more divergent cytochrome P450 oxidase could be involved in secondary biosynthesis. 	cytochrome P450	39561	39576	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:202	a = view) to obtain the annotated gene for cytochrome P450. 	cytochrome P450	39904	39919	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:202	a = view) to obtain the annotated gene for cytochrome P450. 	cytochrome P450	39904	39919	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:4	This highly regulated pathway involves several cytochrome P450, as well as different dehydrogenases and reductases. 	cytochrome P450	381	396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:4	This highly regulated pathway involves several cytochrome P450, as well as different dehydrogenases and reductases. 	cytochrome P450	381	396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:8	After phylogenetic analysis, domain prediction, and molecular docking studies, 22 candidates encoding 2,3-oxidosqualene cyclase, alcohol dehydrogenase, cytochrome P450, acyltransferase, and esterase were proposed to be potential genes involved in azadirachtin A biosynthesis. 	cytochrome P450	1121	1136	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:8	After phylogenetic analysis, domain prediction, and molecular docking studies, 22 candidates encoding 2,3-oxidosqualene cyclase, alcohol dehydrogenase, cytochrome P450, acyltransferase, and esterase were proposed to be potential genes involved in azadirachtin A biosynthesis. 	cytochrome P450	1121	1136	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:59	Five kinds of putative enzymes, oxidosqualene cyclase, cytochrome P450, alcohol dehydrogenase, acyltransferase, and esterase were proposed in the putative biosynthetic pathway. 	cytochrome P450	8371	8386	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:59	Five kinds of putative enzymes, oxidosqualene cyclase, cytochrome P450, alcohol dehydrogenase, acyltransferase, and esterase were proposed in the putative biosynthetic pathway. 	cytochrome P450	8371	8386	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:87	One of them (transcript/14554) was annotated as the neem NADPH-cytochrome P450 reductase 2. 	cytochrome P450	12397	12412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:87	One of them (transcript/14554) was annotated as the neem NADPH-cytochrome P450 reductase 2. 	cytochrome P450	12397	12412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:10	All three kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for adverse interactions when kratom is co-consumed with drugs metabolized by these enzymes. 	cytochrome P450	1459	1474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:10	All three kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for adverse interactions when kratom is co-consumed with drugs metabolized by these enzymes. 	cytochrome P450	1459	1474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:95	Mitragynine has been reported to inhibit several cytochrome P450s (CYPs)^,--, which could lead to increased systemic exposure to co-consumed drugs, including opioids, and potential adverse effects. 	cytochrome P450	15968	15983	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:95	Mitragynine has been reported to inhibit several cytochrome P450s (CYPs)^,--, which could lead to increased systemic exposure to co-consumed drugs, including opioids, and potential adverse effects. 	cytochrome P450	15968	15983	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:110	Consistent with previous literature, our results raise concern about potential drug interactions that may occur when kratom is consumed concurrently with opiates or other drugs metabolized by the cytochrome P450s. 	cytochrome P450	19278	19293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:110	Consistent with previous literature, our results raise concern about potential drug interactions that may occur when kratom is consumed concurrently with opiates or other drugs metabolized by the cytochrome P450s. 	cytochrome P450	19278	19293	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7705728_OgerInput.txtOger_out.csv:131	For example, in Arabidopsis thaliana, gene groups including two to five terpene synthases clustered together with prenyltransferase-, cytochrome P450- and glycosyltransferase genes^. 	cytochrome P450	17991	18006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7705728_OgerInput.txtOger_out.csv:131	For example, in Arabidopsis thaliana, gene groups including two to five terpene synthases clustered together with prenyltransferase-, cytochrome P450- and glycosyltransferase genes^. 	cytochrome P450	17991	18006	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:2	Degradation of polychlorinated biphenyls (PCBs) is initiated by cytochrome P450 (CYP) enzymes and includes PCB oxidation to OH-metabolites, which often display a higher toxicity than their parental compounds. 	cytochrome P450	172	187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:2	Degradation of polychlorinated biphenyls (PCBs) is initiated by cytochrome P450 (CYP) enzymes and includes PCB oxidation to OH-metabolites, which often display a higher toxicity than their parental compounds. 	cytochrome P450	172	187	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:113	Taking these results into account, we decided to subject PCB 28 to in vitro metabolism by a human liver-like cytochrome P450 cocktail (rhCYP cocktail)^,. 	cytochrome P450	18397	18412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:113	Taking these results into account, we decided to subject PCB 28 to in vitro metabolism by a human liver-like cytochrome P450 cocktail (rhCYP cocktail)^,. 	cytochrome P450	18397	18412	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:151	Metabolization takes place by cytochrome P450 (CYP) enzymes, which are very well conserved between invertebrates and vertebrates. 	cytochrome P450	25009	25024	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:151	Metabolization takes place by cytochrome P450 (CYP) enzymes, which are very well conserved between invertebrates and vertebrates. 	cytochrome P450	25009	25024	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:13	The expression level of nitronate monooxygenase (NMO), glutathione S-transferase (GST) and cytochrome P450s (CYP72A1 and CYP72A2) varied broadly among populations and individual plants within the populations. 	cytochrome P450	1867	1882	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:13	The expression level of nitronate monooxygenase (NMO), glutathione S-transferase (GST) and cytochrome P450s (CYP72A1 and CYP72A2) varied broadly among populations and individual plants within the populations. 	cytochrome P450	1867	1882	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:36	EMR is considered to be polygenically inherited, involving multiple genes encoding for metabolic enzymes such as cytochrome P450 monooxygenase (P450), glucosyl transferases (GT), glutathione S-transferases (GST), esterases and ABC transporters (;. 	cytochrome P450	5084	5099	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:36	EMR is considered to be polygenically inherited, involving multiple genes encoding for metabolic enzymes such as cytochrome P450 monooxygenase (P450), glucosyl transferases (GT), glutathione S-transferases (GST), esterases and ABC transporters (;. 	cytochrome P450	5084	5099	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:227	Two cytochrome P450 genes (CYP81A12 and CYP81A21) were found to be overexpressed and associated with resistance to ALS inhibitors in Echinochloa phyllopogon. 	cytochrome P450	33744	33759	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7769757_OgerInput.txtOger_out.csv:227	Two cytochrome P450 genes (CYP81A12 and CYP81A21) were found to be overexpressed and associated with resistance to ALS inhibitors in Echinochloa phyllopogon. 	cytochrome P450	33744	33759	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:156	The metabolism of this polycyclic aromatic hydrocarbon molecule by oxidation reaction through cytochrome P450 enzyme from human host and monooxygenases and dioxygenase enzymes from bacterial species of skin microbiome is known from experimental studies, and reference databases such as the University of Minnesota Biocatalysis/Biodegradation Database (;. 	cytochrome P450	29721	29736	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:156	The metabolism of this polycyclic aromatic hydrocarbon molecule by oxidation reaction through cytochrome P450 enzyme from human host and monooxygenases and dioxygenase enzymes from bacterial species of skin microbiome is known from experimental studies, and reference databases such as the University of Minnesota Biocatalysis/Biodegradation Database (;. 	cytochrome P450	29721	29736	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:159	The ingestion of BaP is known to be toxic due to its metabolism by human cytochrome P450 enzyme and the products of its oxidation are known to cause carcinogenicity and other adverse health effects by reacting with the host DNA (;. 	cytochrome P450	30459	30474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:159	The ingestion of BaP is known to be toxic due to its metabolism by human cytochrome P450 enzyme and the products of its oxidation are known to cause carcinogenicity and other adverse health effects by reacting with the host DNA (;. 	cytochrome P450	30459	30474	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:6	In separate experiments, 3,5-DCNB cytotoxicity was reduced by pretreating IKC with antioxidants and cytochrome P450, flavin monooxygenase and peroxidase inhibitors, while 3,5-DCPHA cytotoxicity was attenuated by two nucleophilic antioxidants (glutathione and N-acetyl-L-cysteine). 	cytochrome P450	935	950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:6	In separate experiments, 3,5-DCNB cytotoxicity was reduced by pretreating IKC with antioxidants and cytochrome P450, flavin monooxygenase and peroxidase inhibitors, while 3,5-DCPHA cytotoxicity was attenuated by two nucleophilic antioxidants (glutathione and N-acetyl-L-cysteine). 	cytochrome P450	935	950	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7814671_OgerInput.txtOger_out.csv:18	Stipitaldehyde 8 represents a branching point in Tropolone Sesquiterpenoids biosynthesis (Scheme ): in the case of xenovulene A 2, stipitaldehyde 8 is oxidised by the cytochrome P450 AsR2 to the corresponding hemiacetal 9 and subsequent elimination of water yields the reactive quinomethide 10 that undergoes an enzymecatalyzed hetero Diels-Alder reaction with ALPHAhumulene 6, synthesised by an unusual terpene cyclase, yielding xenovulene B 11 (Scheme. 	cytochrome P450	3986	4001	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7814671_OgerInput.txtOger_out.csv:18	Stipitaldehyde 8 represents a branching point in Tropolone Sesquiterpenoids biosynthesis (Scheme ): in the case of xenovulene A 2, stipitaldehyde 8 is oxidised by the cytochrome P450 AsR2 to the corresponding hemiacetal 9 and subsequent elimination of water yields the reactive quinomethide 10 that undergoes an enzymecatalyzed hetero Diels-Alder reaction with ALPHAhumulene 6, synthesised by an unusual terpene cyclase, yielding xenovulene B 11 (Scheme. 	cytochrome P450	3986	4001	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7814671_OgerInput.txtOger_out.csv:43	Unique to the eup2 Biosynthetic Gene Clusters and pyc Biosynthetic Gene Clusters are shortchain dehydrogenase encoding genes (eupL4 and pycL2; homologous to eupfE) and a cytochrome P450 (eupR6, pycR5) homologous to eupfD, previously shown to be responsible for C10 hydroxylation of the terpene moiety. 	cytochrome P450	9350	9365	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7814671_OgerInput.txtOger_out.csv:43	Unique to the eup2 Biosynthetic Gene Clusters and pyc Biosynthetic Gene Clusters are shortchain dehydrogenase encoding genes (eupL4 and pycL2; homologous to eupfE) and a cytochrome P450 (eupR6, pycR5) homologous to eupfD, previously shown to be responsible for C10 hydroxylation of the terpene moiety. 	cytochrome P450	9350	9365	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:30	Cytochromes are classified based on their lowest electronic energy absorption band in their reduced state: cytochrome P450 (450 nm), cytochrome c (550 nm), cytochromes b (565 nm), cytochromes a (605 nm). 	cytochrome P450	5203	5218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:30	Cytochromes are classified based on their lowest electronic energy absorption band in their reduced state: cytochrome P450 (450 nm), cytochrome c (550 nm), cytochromes b (565 nm), cytochromes a (605 nm). 	cytochrome P450	5203	5218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7958869_OgerInput.txtOger_out.csv:6	Notably, in doing so we have identified a non-canonical cytochrome P450 that catalyzes the remarkable ring expansion reaction required to produce the distinct carbon scaffold of colchicine. 	cytochrome P450	923	938	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7958869_OgerInput.txtOger_out.csv:6	Notably, in doing so we have identified a non-canonical cytochrome P450 that catalyzes the remarkable ring expansion reaction required to produce the distinct carbon scaffold of colchicine. 	cytochrome P450	923	938	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7958869_OgerInput.txtOger_out.csv:198	For yeast expression of CYP genes, we utilized S. cerevisiae strain WAT11 (ade2), which harbors a chromosomal copy of the Arabidopsis thaliana NADPH-cytochrome P450 reductase 1 gene. 	cytochrome P450	36894	36909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7958869_OgerInput.txtOger_out.csv:198	For yeast expression of CYP genes, we utilized S. cerevisiae strain WAT11 (ade2), which harbors a chromosomal copy of the Arabidopsis thaliana NADPH-cytochrome P450 reductase 1 gene. 	cytochrome P450	36894	36909	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:141	Comparison of two human cell lines (HepG2 and HepaRG) with different activities of cytochrome P450 enzymes revealed that Ze 339 and its single constituents petasin, isopetasin, neopetasin, isopetasol, and petasol exerted higher toxicity in cells having a higher cytochrome activity. 	cytochrome P450 enzymes	22394	22417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:1	 A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. 	cytochrome P450 enzymes	27	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:116	In 1976, an international series of biennial meetings on the cytochrome P450 enzymes was established as a means of facilitating contact of scientists in this area working in Eastern Bloc and western countries but has developed into a timely international biennial series with meetings rotating among Europe, Asia, North America, and Australia. 	cytochrome P450 enzymes	15580	15603	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:10	All three kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for adverse interactions when kratom is co-consumed with drugs metabolized by these enzymes. 	cytochrome P450 enzymes	1459	1482	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	P450 enzymes	5980	5992	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:77	These results suggest that these P450 enzymes likely catalyze three sequential oxygenations of friedelin into an alcohol, and further to a carboxylic acid via an aldehyde. 	P450 enzymes	13027	13039	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:77	These results suggest that these P450 enzymes likely catalyze three sequential oxygenations of friedelin into an alcohol, and further to a carboxylic acid via an aldehyde. 	P450 enzymes	13027	13039	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:140	In triterpenoid biosynthesis, the formation of a triterpene backbone is usually followed by oxidations catalyzed by P450 enzymes. 	P450 enzymes	24082	24094	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:140	In triterpenoid biosynthesis, the formation of a triterpene backbone is usually followed by oxidations catalyzed by P450 enzymes. 	P450 enzymes	24082	24094	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	P450 enzymes	3508	3520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:21	Output includes metabolism to oxysterols by the cytochrome P450 enzymes Cytochromes P450 27a1 and CYP46A1, the photoreceptor phagocytosis, and efflux to lipoprotein particles, which circulate in the intraretinal space. 	P450 enzymes	3508	3520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	P450 enzymes	716	728	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:4	Furthermore, different reconstituted fractions of extract (petasins and fatty acid fraction) were examined in three in vitro test systems using hepatocytes: Two human cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2, HepaRG) as well as a rodent cell line with high cytochrome P450 activity (H4IIE), were used. 	P450 enzymes	716	728	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:23	The analysis focused on three different in vitro test systems of hepatocytes: two human hepatic cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2 and HepaRG, respectively, (Andersson, Kanebratt, & Kenna, ; Guillouzo et al., )) and a rat cell line (H4IIE [Fujimura, Murakami, Miwa, Aruga, & Toriumi, ; Westerink, Stevenson, & Schoonen, ]) were used. 	P450 enzymes	3864	3876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:23	The analysis focused on three different in vitro test systems of hepatocytes: two human hepatic cell lines, with lower and higher activity of cytochrome P450 enzymes (HepG2 and HepaRG, respectively, (Andersson, Kanebratt, & Kenna, ; Guillouzo et al., )) and a rat cell line (H4IIE [Fujimura, Murakami, Miwa, Aruga, & Toriumi, ; Westerink, Stevenson, & Schoonen, ]) were used. 	P450 enzymes	3864	3876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:34	Isolated cytochrome P450 enzymes and phosphate buffer were obtained from BD Gentest (Switzerland). 	P450 enzymes	5715	5727	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:34	Isolated cytochrome P450 enzymes and phosphate buffer were obtained from BD Gentest (Switzerland). 	P450 enzymes	5715	5727	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:141	Comparison of two human cell lines (HepG2 and HepaRG) with different activities of cytochrome P450 enzymes revealed that Ze 339 and its single constituents petasin, isopetasin, neopetasin, isopetasol, and petasol exerted higher toxicity in cells having a higher cytochrome activity. 	P450 enzymes	22405	22417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:141	Comparison of two human cell lines (HepG2 and HepaRG) with different activities of cytochrome P450 enzymes revealed that Ze 339 and its single constituents petasin, isopetasin, neopetasin, isopetasol, and petasol exerted higher toxicity in cells having a higher cytochrome activity. 	P450 enzymes	22405	22417	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:140	In this direction, this study is an attempt to provide a complete picture of P450 enzymes in different cyanobacterial species as these enzymes are the key players in primary and secondary metabolism of organisms, including the production of different secondary metabolites. 	P450 enzymes	21141	21153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7014017_OgerInput.txtOger_out.csv:140	In this direction, this study is an attempt to provide a complete picture of P450 enzymes in different cyanobacterial species as these enzymes are the key players in primary and secondary metabolism of organisms, including the production of different secondary metabolites. 	P450 enzymes	21141	21153	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:11	As these Cytochrome P450 enzymes differ significantly between species, drug biotransformation and hepatotoxicity can only be evaluated in freshly isolated primary human hepatocytes^. 	P450 enzymes	1820	1832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:11	As these Cytochrome P450 enzymes differ significantly between species, drug biotransformation and hepatotoxicity can only be evaluated in freshly isolated primary human hepatocytes^. 	P450 enzymes	1820	1832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:22	Hepatocyte-Like Cells differ from Primary Human Hepatocytes at the transcriptional, proteomic, and epigenetical level, and specifically express low levels of hepatic transcription factors and Cytochrome P450 enzymes^,,,. 	P450 enzymes	3432	3444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:22	Hepatocyte-Like Cells differ from Primary Human Hepatocytes at the transcriptional, proteomic, and epigenetical level, and specifically express low levels of hepatic transcription factors and Cytochrome P450 enzymes^,,,. 	P450 enzymes	3432	3444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:29	We also show that extracellular amino acids represent a tool to drive both metabolic maturation and the expression of Cytochrome P450 enzymes, and this in both Hepatocyte-Like Cells and HepG2 hepatoma cells. 	P450 enzymes	4487	4499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:29	We also show that extracellular amino acids represent a tool to drive both metabolic maturation and the expression of Cytochrome P450 enzymes, and this in both Hepatocyte-Like Cells and HepG2 hepatoma cells. 	P450 enzymes	4487	4499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	P450 enzymes	12773	12785	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	P450 enzymes	12773	12785	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:69	The top deregulated pathways when comparing HLC Liver Differentiation Medium D20 with Primary Human Hepatocytes contained several genes involved in AA catabolism, glucose metabolism, metabolic pathways, and metabolism of xenobiotics by Cytochrome P450 enzymes and AMP-activated protein kinase), we next stratified these into four quadrants. 	P450 enzymes	13577	13589	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:69	The top deregulated pathways when comparing HLC Liver Differentiation Medium D20 with Primary Human Hepatocytes contained several genes involved in AA catabolism, glucose metabolism, metabolic pathways, and metabolism of xenobiotics by Cytochrome P450 enzymes and AMP-activated protein kinase), we next stratified these into four quadrants. 	P450 enzymes	13577	13589	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	P450 enzymes	6514	6526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	P450 enzymes	6514	6526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:1	 A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. 	P450 enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:1	 A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. 	P450 enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:116	In 1976, an international series of biennial meetings on the cytochrome P450 enzymes was established as a means of facilitating contact of scientists in this area working in Eastern Bloc and western countries but has developed into a timely international biennial series with meetings rotating among Europe, Asia, North America, and Australia. 	P450 enzymes	15591	15603	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:116	In 1976, an international series of biennial meetings on the cytochrome P450 enzymes was established as a means of facilitating contact of scientists in this area working in Eastern Bloc and western countries but has developed into a timely international biennial series with meetings rotating among Europe, Asia, North America, and Australia. 	P450 enzymes	15591	15603	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:10	All three kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for adverse interactions when kratom is co-consumed with drugs metabolized by these enzymes. 	P450 enzymes	1470	1482	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:10	All three kratom alkaloids tested inhibited select cytochrome P450 enzymes, suggesting a potential risk for adverse interactions when kratom is co-consumed with drugs metabolized by these enzymes. 	P450 enzymes	1470	1482	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6783651_OgerInput.txtOger_out.csv:165	However, both CYP2C8 3 and 6 LCPUFA metabolites are proangiogenic and inhibition of CYP2C8 decreases ocular neovascularization (Shao et al, ; Gong et al, ,). 	CYP2C8	27099	27105	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6783651_OgerInput.txtOger_out.csv:165	However, both CYP2C8 3 and 6 LCPUFA metabolites are proangiogenic and inhibition of CYP2C8 decreases ocular neovascularization (Shao et al, ; Gong et al, ,). 	CYP2C8	27099	27105	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6783651_OgerInput.txtOger_out.csv:165	However, both CYP2C8 3 and 6 LCPUFA metabolites are proangiogenic and inhibition of CYP2C8 decreases ocular neovascularization (Shao et al, ; Gong et al, ,). 	CYP2C8	27169	27175	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6783651_OgerInput.txtOger_out.csv:165	However, both CYP2C8 3 and 6 LCPUFA metabolites are proangiogenic and inhibition of CYP2C8 decreases ocular neovascularization (Shao et al, ; Gong et al, ,). 	CYP2C8	27169	27175	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C8	26248	26254	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C8	26248	26254	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2C8	11218	11224	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2C8	11218	11224	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2C8	13812	13818	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2C8	13812	13818	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2C8	19533	19539	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2C8	19533	19539	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2C8	19764	19770	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP2C8	19764	19770	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:131	Extend of metabolism was 54%/44%/71% for CYP2C8 (human) and 51%/8%/58% for CYP2C9 (human) versus 94%/72%/75% for CYP2C6 (rat) and 55%/74%/84% for CYP2C11 (rat). 	CYP2C8	20464	20470	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:131	Extend of metabolism was 54%/44%/71% for CYP2C8 (human) and 51%/8%/58% for CYP2C9 (human) versus 94%/72%/75% for CYP2C6 (rat) and 55%/74%/84% for CYP2C11 (rat). 	CYP2C8	20464	20470	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2C8	21305	21311	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:134	In HepaRG cells, the effect of cytochrome inhibition on the toxic effects of Ze 339 was investigated; addition of quinidine (CYP2D6 inhibitor) and montelukast (CYP2C8 inhibitor) attenuated (p < .001 and p = .041, respectively); most of the cytotoxic effect of Ze 339 demonstrated for the highest concentration studied (100 g/ml). 	CYP2C8	21305	21311	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2C8	24942	24948	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:152	Inhibition of different cytochromes in HepaRG showed an attenuation of the toxic effects, which was pronounced for CYP2D6 and to a minor extend CYP2C8. 	CYP2C8	24942	24948	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2C8	17270	17276	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2C8	17270	17276	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:234	The first association of genetic polymorphisms with the metabolism of an anti-epileptic drug has been reported in the association of variation in drug-metabolizing enzymes CYP2C9 and CYP2C19 with phenytoin dose, providing hope for individualized therapy for patients. 	CYP2C9	44344	44350	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP2C9	31456	31462	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP2C9	32163	32169	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2C9	11239	11245	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2C9	13790	13796	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2C9	19551	19557	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:127	For CYP2C9, diverging effects were observed (8% and 58%), and for CYP2B6, virtually no metabolism (13% and 20%) was noted. 	CYP2C9	19790	19796	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:131	Extend of metabolism was 54%/44%/71% for CYP2C8 (human) and 51%/8%/58% for CYP2C9 (human) versus 94%/72%/75% for CYP2C6 (rat) and 55%/74%/84% for CYP2C11 (rat). 	CYP2C9	20498	20504	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2C9	21032	21038	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2C9	13281	13287	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2C9	13398	13404	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2C9	13466	13472	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	CYP2C9	15196	15202	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2C9	21066	21072	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP2C9	22182	22188	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP2C9	49351	49357	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2C9	16579	16585	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:104	Enzalutamide, recognized as a strong CYP3A4 and a moderate CYP2C9 and CYP2C19 inducer, significantly reduces concentrations of several anti-HIV agents such as darunavir, ritonavir, etravirine, and raltegravir. 	CYP2C9	16674	16680	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	CYP2C9	34190	34196	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:74	On the other hand, lopinavir/ritonavir induces CYP1A2, CYP2C9, CYP2C19 and glucuronidation. 	CYP2C9	12166	12172	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2C9	8193	8199	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2C9	15762	15768	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP2C9	16275	16281	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP2C9	16434	16440	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP2C9	16996	17002	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP2C9	32371	32377	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP2C9	32532	32538	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP2C9	32802	32808	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP2C9	33113	33119	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2C9	17278	17284	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2C9	18619	18625	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2C9	25798	25804	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP2C9	13452	13458	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2C9	14022	14028	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:80	In reference to the CYP2C9 and CYP2C19 genes (n = 183, n = 186), the majority phenotype was EM (57.38%, n = 105; 47.85%, n = 89). 	CYP2C9	14898	14904	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2C9	3025	3031	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:127	CYP1A1*2A is also associated with some hormone-related diseases due to its involvement in the biotransformation of sex hormones. 	CYP1A1	17043	17049	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:127	CYP1A1*2A is also associated with some hormone-related diseases due to its involvement in the biotransformation of sex hormones. 	CYP1A1	17043	17049	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:128	For example, CYP1A1*2A increases the risk of prostate cancer, cervical cancer, and recurrent pregnancy loss in humans, ^,. 	CYP1A1	17185	17191	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:128	For example, CYP1A1*2A increases the risk of prostate cancer, cervical cancer, and recurrent pregnancy loss in humans, ^,. 	CYP1A1	17185	17191	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:129	CYP1A1*2C (SNP ID: rs1048943) contains an A to G transition at 2455, which results in the modification of the protein from isoleucine to valine. 	CYP1A1	17295	17301	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:129	CYP1A1*2C (SNP ID: rs1048943) contains an A to G transition at 2455, which results in the modification of the protein from isoleucine to valine. 	CYP1A1	17295	17301	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:130	CYP1A1*2C is reported to be associated with a variety of cancers and hormone-related diseases, including prostate cancer, breast cancer, and male infertility, ^,. 	CYP1A1	17440	17446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:130	CYP1A1*2C is reported to be associated with a variety of cancers and hormone-related diseases, including prostate cancer, breast cancer, and male infertility, ^,. 	CYP1A1	17440	17446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:143	As mentioned earlier, CYP1A1 and CYP1A2 are involved in the biotransformation of multiple estrogens, and thus are important for maintaining the balance of estrogens. 	CYP1A1	19437	19443	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:143	As mentioned earlier, CYP1A1 and CYP1A2 are involved in the biotransformation of multiple estrogens, and thus are important for maintaining the balance of estrogens. 	CYP1A1	19437	19443	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:155	Epidemiologic studies also discussed the relationship between CYP1A1 polymorphisms and prostate cancer risk^,. 	CYP1A1	20928	20934	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:155	Epidemiologic studies also discussed the relationship between CYP1A1 polymorphisms and prostate cancer risk^,. 	CYP1A1	20928	20934	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:156	It was reported that CYP1A1 Single Nucleotide Polymorphisms (rs4646903 and rs1048943) were positively correlated with prostate cancer^,^,. 	CYP1A1	20998	21004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:156	It was reported that CYP1A1 Single Nucleotide Polymorphisms (rs4646903 and rs1048943) were positively correlated with prostate cancer^,^,. 	CYP1A1	20998	21004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:157	CYP1A1 hydroxylates testosterone at the C-6 site, which produces hydrophilic metabolites and promotes the excretion of testosterone. 	CYP1A1	21116	21122	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:157	CYP1A1 hydroxylates testosterone at the C-6 site, which produces hydrophilic metabolites and promotes the excretion of testosterone. 	CYP1A1	21116	21122	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:158	Therefore, CYP1A1 mutants may interfere with the normal physiological concentration of testosterone, and eventually lead to the occurrence and development of prostate cancer. 	CYP1A1	21260	21266	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:158	Therefore, CYP1A1 mutants may interfere with the normal physiological concentration of testosterone, and eventually lead to the occurrence and development of prostate cancer. 	CYP1A1	21260	21266	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:179	In fact, CYP1A1*4 (2453C > A) and rs1048943 (2455A > G) may interfere with the metabolism of testosterone and estrogen, and are reported to be positively correlated with male infertility. 	CYP1A1	24069	24075	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:179	In fact, CYP1A1*4 (2453C > A) and rs1048943 (2455A > G) may interfere with the metabolism of testosterone and estrogen, and are reported to be positively correlated with male infertility. 	CYP1A1	24069	24075	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:182	Recent studies have shown that CYP1A1 may affect the biological function of placenta, which may be due to its estrogen metabolism^,. 	CYP1A1	24516	24522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:182	Recent studies have shown that CYP1A1 may affect the biological function of placenta, which may be due to its estrogen metabolism^,. 	CYP1A1	24516	24522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:183	In fact, it is reported that the CYP1A1 SNP rs4646903 (3801T > C) is positively correlated with the risk of recurrent pregnancy loss in humans. 	CYP1A1	24651	24657	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:183	In fact, it is reported that the CYP1A1 SNP rs4646903 (3801T > C) is positively correlated with the risk of recurrent pregnancy loss in humans. 	CYP1A1	24651	24657	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:200	Epidemiological analysis showed that genetic polymorphisms of the CYP1A1 (rs4646903, rs1048943, rs4986883, and rs1799814) were not associated with the high risk of coronary artery disease. 	CYP1A1	26480	26486	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:200	Epidemiological analysis showed that genetic polymorphisms of the CYP1A1 (rs4646903, rs1048943, rs4986883, and rs1799814) were not associated with the high risk of coronary artery disease. 	CYP1A1	26480	26486	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:201	However, CYP1A1 SNP (rs1048943) and CYP1A2 Single Nucleotide Polymorphisms (rs762551, rs1133323, and rs1378942) are positively correlated with hypertension susceptibility^,. 	CYP1A1	26612	26618	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:201	However, CYP1A1 SNP (rs1048943) and CYP1A2 Single Nucleotide Polymorphisms (rs762551, rs1133323, and rs1378942) are positively correlated with hypertension susceptibility^,. 	CYP1A1	26612	26618	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:226	In this part, the Single Nucleotide Polymorphisms of CYP1A (11 for CYP1A1 and 9 for CYP1A2) studied most in recent 10 years are reviewed for the first time, and the relationship between CYP1A Single Nucleotide Polymorphisms and human diseases is summarized. 	CYP1A1	30201	30207	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:226	In this part, the Single Nucleotide Polymorphisms of CYP1A (11 for CYP1A1 and 9 for CYP1A2) studied most in recent 10 years are reviewed for the first time, and the relationship between CYP1A Single Nucleotide Polymorphisms and human diseases is summarized. 	CYP1A1	30201	30207	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:7	Treatment of antioxidant, CYP1A1 and CYP2A6 inhibitors, and chemodietary agents with antioxidant properties significantly reduced the Cell Culture Supernatant and CCS-EVs mediated HIV-1 replication in U1 cells. 	CYP1A1	1029	1035	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:7	Treatment of antioxidant, CYP1A1 and CYP2A6 inhibitors, and chemodietary agents with antioxidant properties significantly reduced the Cell Culture Supernatant and CCS-EVs mediated HIV-1 replication in U1 cells. 	CYP1A1	1029	1035	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:102	We used the following specific TaqMan TM probes (CYP1A1 (Hs01054794_m1), CYP2A6 (Hs00430021_m1), SOD1 (Hs00533490_m1), SOD2 (Hs00167309_m1), catalase (Hs00156308_m1), and PRDX6 (Hs00705355_s1)) and Glyceraldehyde 3-Phosphate Dehydrogenase as an endogenous control. 	CYP1A1	16556	16562	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:102	We used the following specific TaqMan TM probes (CYP1A1 (Hs01054794_m1), CYP2A6 (Hs00430021_m1), SOD1 (Hs00533490_m1), SOD2 (Hs00167309_m1), catalase (Hs00156308_m1), and PRDX6 (Hs00705355_s1)) and Glyceraldehyde 3-Phosphate Dehydrogenase as an endogenous control. 	CYP1A1	16556	16562	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:103	We used Western blotting to identify the presence of CYPs, antioxidants, and Human Papillomavirus proteins in Caski-derived Extracellular Vesicles and to calculate the relative protein fold expression level of CYPs and Antioxidant Enzymes in U1 cells upon treatment with CCS/CCS-Eversus We used the following primary antibodies: Glyceraldehyde 3-Phosphate Dehydrogenase Rabbit Mab, 1:2000 dilution (Cell Signaling Technology, Danvers, MA, USA), catalogue #2118; CYP1A1 rabbit Mab, 1:200 dilution (Proteintech Group, Inc., Rosemont, IL, USA), catalogue #13241-1-AP; CYP1B1 Rabbit Mab, 1:500 dilution (Santa Cruz Biotechnology, Dallas, TX, USA), catalogue #sc-32882; CYP2A6 Mouse Mab, 1:200 dilution (Abcam, Cambridge, MA, USA), catalogue #ab3570; SOD1 Mouse Mab, 1:1500 dilution, catalog #sc-101523; SOD2 Mouse Mab, 1:500 dilution, catalogue #sc-133254; Catalase Mouse Mab, 1:1200 dilution (Santa Cruz Biotechnology Inc., Dallas, TX, USA), catalog #21260-1-AP; PRDX6 Rabbit Mab, 1:500 dilution (LifeSpan Biosciences, Inc., Seattle, WA, USA), catalog #LS-C162131; CD63, Rabbit Pab, 1:200 dilution (Proteintech Group, Rosemont, IL, USA), catalog #25682-1-AP. 	CYP1A1	17234	17240	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:103	We used Western blotting to identify the presence of CYPs, antioxidants, and Human Papillomavirus proteins in Caski-derived Extracellular Vesicles and to calculate the relative protein fold expression level of CYPs and Antioxidant Enzymes in U1 cells upon treatment with CCS/CCS-Eversus We used the following primary antibodies: Glyceraldehyde 3-Phosphate Dehydrogenase Rabbit Mab, 1:2000 dilution (Cell Signaling Technology, Danvers, MA, USA), catalogue #2118; CYP1A1 rabbit Mab, 1:200 dilution (Proteintech Group, Inc., Rosemont, IL, USA), catalogue #13241-1-AP; CYP1B1 Rabbit Mab, 1:500 dilution (Santa Cruz Biotechnology, Dallas, TX, USA), catalogue #sc-32882; CYP2A6 Mouse Mab, 1:200 dilution (Abcam, Cambridge, MA, USA), catalogue #ab3570; SOD1 Mouse Mab, 1:1500 dilution, catalog #sc-101523; SOD2 Mouse Mab, 1:500 dilution, catalogue #sc-133254; Catalase Mouse Mab, 1:1200 dilution (Santa Cruz Biotechnology Inc., Dallas, TX, USA), catalog #21260-1-AP; PRDX6 Rabbit Mab, 1:500 dilution (LifeSpan Biosciences, Inc., Seattle, WA, USA), catalog #LS-C162131; CD63, Rabbit Pab, 1:200 dilution (Proteintech Group, Rosemont, IL, USA), catalog #25682-1-AP. 	CYP1A1	17234	17240	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:133	The four-day exposure of Cell Culture Supernatant significantly increased the expression of CYP1A1 and CYP2A6 at the mRNA level (A,B) but not at the protein level (C,D;. 	CYP1A1	22458	22464	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:133	The four-day exposure of Cell Culture Supernatant significantly increased the expression of CYP1A1 and CYP2A6 at the mRNA level (A,B) but not at the protein level (C,D;. 	CYP1A1	22458	22464	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:159	To confirm that HIV-1 replication is occurring via a CYP-mediated oxidative stress pathway, we treated the CCS-EVs exposed U1 cells with an antioxidant (resveratrol) CYP1A1-selective inhibitor (ellipticine), and CYP2A6-selective inhibitor (tryptamine). 	CYP1A1	27696	27702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:159	To confirm that HIV-1 replication is occurring via a CYP-mediated oxidative stress pathway, we treated the CCS-EVs exposed U1 cells with an antioxidant (resveratrol) CYP1A1-selective inhibitor (ellipticine), and CYP2A6-selective inhibitor (tryptamine). 	CYP1A1	27696	27702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:201	We particularly examined the expression of CYP1A1 and CYP2A6, because these enzymes are expressed in monocytic cells. 	CYP1A1	35197	35203	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:201	We particularly examined the expression of CYP1A1 and CYP2A6, because these enzymes are expressed in monocytic cells. 	CYP1A1	35197	35203	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:202	CYP1A1 and CYP2A6 are the major enzymes for metabolizing polyaryl hydrocarbons and nicotine present in cigarette smoke, respectively, as well as environmental contaminants. 	CYP1A1	35272	35278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:202	CYP1A1 and CYP2A6 are the major enzymes for metabolizing polyaryl hydrocarbons and nicotine present in cigarette smoke, respectively, as well as environmental contaminants. 	CYP1A1	35272	35278	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:211	This is consistently the case for CYP1A1 expression upon exposure to cigarette smoke condensate and benzo(a)pyrene. 	CYP1A1	36615	36621	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:211	This is consistently the case for CYP1A1 expression upon exposure to cigarette smoke condensate and benzo(a)pyrene. 	CYP1A1	36615	36621	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:216	Recently, we confirmed this association in vitro in U1 cells, in which we demonstrated that CYP1A1 metabolizes benzo(a)pyrene (a harmful carcinogen in cigarette smoke) and causes increased production of Reactive Oxygen Species, which subsequently triggers HIV-1 replication in the U1 cells. 	CYP1A1	37781	37787	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:216	Recently, we confirmed this association in vitro in U1 cells, in which we demonstrated that CYP1A1 metabolizes benzo(a)pyrene (a harmful carcinogen in cigarette smoke) and causes increased production of Reactive Oxygen Species, which subsequently triggers HIV-1 replication in the U1 cells. 	CYP1A1	37781	37787	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP1A1	8150	8156	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP1A1	8150	8156	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:106	In flies with RNAi-mediated silencing of Cyp307a2 (human orthologs: CYP1A1 and CYP1A2), the metabolite 3-OHCB 28 was not detected and 3-OHCB 28 was reduced by more than 70% compared to control levels. 	CYP1A1	17095	17101	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:106	In flies with RNAi-mediated silencing of Cyp307a2 (human orthologs: CYP1A1 and CYP1A2), the metabolite 3-OHCB 28 was not detected and 3-OHCB 28 was reduced by more than 70% compared to control levels. 	CYP1A1	17095	17101	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:173	Feeding experiments on rats with commercially available PCB mixtures such as Aroclor 1254, Fire-Master Bp-6 or individual congeners showed the induction of different CYPs depending on the position of the chlorine atoms on the phenyl ring^: Non-orthochlorinated coplanar PCBs such as PCB 126, PCB 169 and PCB 77 induce the expression of CYP1A1 and CYP1A2. 	CYP1A1	28696	28702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:173	Feeding experiments on rats with commercially available PCB mixtures such as Aroclor 1254, Fire-Master Bp-6 or individual congeners showed the induction of different CYPs depending on the position of the chlorine atoms on the phenyl ring^: Non-orthochlorinated coplanar PCBs such as PCB 126, PCB 169 and PCB 77 induce the expression of CYP1A1 and CYP1A2. 	CYP1A1	28696	28702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:175	Other structured PCBs such as PCB 118, PCB 138 and PCB 170 induce the expression of both CYP1A1 and CYP2B^. 	CYP1A1	28905	28911	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:175	Other structured PCBs such as PCB 118, PCB 138 and PCB 170 induce the expression of both CYP1A1 and CYP2B^. 	CYP1A1	28905	28911	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP1A2	11176	11182	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP1A2	11328	11334	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP1A2	11328	11334	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP1A2	13864	13870	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP1A2	13864	13870	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:125	Virtually no metabolism was observed for CYP1A2 (4%). 	CYP1A2	19606	19612	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:125	Virtually no metabolism was observed for CYP1A2 (4%). 	CYP1A2	19606	19612	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:128	Incubation with rat cytochromes revealed a different pattern of metabolism compared with human cytochromes: For CYP1A2, petasin was higher (43% versus 4%), and neopetasin (22% versus <1%) and isopetasin (<1% versus 21%) lower metabolized, respectively. 	CYP1A2	20021	20027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:128	Incubation with rat cytochromes revealed a different pattern of metabolism compared with human cytochromes: For CYP1A2, petasin was higher (43% versus 4%), and neopetasin (22% versus <1%) and isopetasin (<1% versus 21%) lower metabolized, respectively. 	CYP1A2	20021	20027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP1A2	21014	21020	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP1A2	21014	21020	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP1A2	15361	15367	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:87	On the other hand, all the screened molecules emerged as non-inhibitors of the cytochromes CYP1A2 and CYP2D6. 	CYP1A2	15361	15367	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:76	Of note, we also found an AAGLY-mediated induction of CYP1A2 and CYP2E1 in the embryonic kidney line, HEK293 (Supplementary Fig. 	CYP1A2	14978	14984	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:76	Of note, we also found an AAGLY-mediated induction of CYP1A2 and CYP2E1 in the embryonic kidney line, HEK293 (Supplementary Fig. 	CYP1A2	14978	14984	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP1A2	22170	22176	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP1A2	22170	22176	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP1A2	49339	49345	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP1A2	49339	49345	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP1A2	16571	16577	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP1A2	16571	16577	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	CYP1A2	34182	34188	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	CYP1A2	34182	34188	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:74	On the other hand, lopinavir/ritonavir induces CYP1A2, CYP2C9, CYP2C19 and glucuronidation. 	CYP1A2	12158	12164	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:74	On the other hand, lopinavir/ritonavir induces CYP1A2, CYP2C9, CYP2C19 and glucuronidation. 	CYP1A2	12158	12164	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP1A2	8184	8190	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP1A2	8184	8190	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP1A2	15754	15760	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP1A2	15754	15760	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:8	Following in vitro analysis using a liver-like CYP-cocktail, containing human orthologues of dCYP1A2, we confirm human CYP1A2 as a PCB 28 metabolizing enzyme. 	CYP1A2	1215	1221	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:8	Following in vitro analysis using a liver-like CYP-cocktail, containing human orthologues of dCYP1A2, we confirm human CYP1A2 as a PCB 28 metabolizing enzyme. 	CYP1A2	1215	1221	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:106	In flies with RNAi-mediated silencing of Cyp307a2 (human orthologs: CYP1A1 and CYP1A2), the metabolite 3-OHCB 28 was not detected and 3-OHCB 28 was reduced by more than 70% compared to control levels. 	CYP1A2	17106	17112	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:106	In flies with RNAi-mediated silencing of Cyp307a2 (human orthologs: CYP1A1 and CYP1A2), the metabolite 3-OHCB 28 was not detected and 3-OHCB 28 was reduced by more than 70% compared to control levels. 	CYP1A2	17106	17112	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP1A2	19274	19280	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP1A2	19274	19280	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:118	Particularly CYP1A2 as a single enzyme generated high levels of the OH-CB28 metabolites^. 	CYP1A2	19314	19320	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:118	Particularly CYP1A2 as a single enzyme generated high levels of the OH-CB28 metabolites^. 	CYP1A2	19314	19320	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:119	This confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28. 	CYP1A2	19406	19412	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:119	This confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28. 	CYP1A2	19406	19412	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:120	Since CYP1A2 is a human orthologue of Drosophila Cyp307a2, these results indicate a conservation at the level of activity against PCB28 between Drosophila melanogaster and the human system. 	CYP1A2	19493	19499	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:120	Since CYP1A2 is a human orthologue of Drosophila Cyp307a2, these results indicate a conservation at the level of activity against PCB28 between Drosophila melanogaster and the human system. 	CYP1A2	19493	19499	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP1A2	25790	25796	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP1A2	25790	25796	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:156	This result confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28, since CYP1A2 contained in the liver-like rhCYP cocktail is a human orthologue of Cyp307a2 in Drosophila^. 	CYP1A2	25947	25953	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:156	This result confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28, since CYP1A2 contained in the liver-like rhCYP cocktail is a human orthologue of Cyp307a2 in Drosophila^. 	CYP1A2	25947	25953	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:156	This result confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28, since CYP1A2 contained in the liver-like rhCYP cocktail is a human orthologue of Cyp307a2 in Drosophila^. 	CYP1A2	26034	26040	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:156	This result confirmed CYP1A2 as a central CYP in the formation of reactive OH-metabolites from PCB 28, since CYP1A2 contained in the liver-like rhCYP cocktail is a human orthologue of Cyp307a2 in Drosophila^. 	CYP1A2	26034	26040	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:173	Feeding experiments on rats with commercially available PCB mixtures such as Aroclor 1254, Fire-Master Bp-6 or individual congeners showed the induction of different CYPs depending on the position of the chlorine atoms on the phenyl ring^: Non-orthochlorinated coplanar PCBs such as PCB 126, PCB 169 and PCB 77 induce the expression of CYP1A1 and CYP1A2. 	CYP1A2	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:173	Feeding experiments on rats with commercially available PCB mixtures such as Aroclor 1254, Fire-Master Bp-6 or individual congeners showed the induction of different CYPs depending on the position of the chlorine atoms on the phenyl ring^: Non-orthochlorinated coplanar PCBs such as PCB 126, PCB 169 and PCB 77 induce the expression of CYP1A1 and CYP1A2. 	CYP1A2	28707	28713	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:178	The human CYP1A2, identified in this study is capable of oxidizing estradiol, resulting in the production of 2-hydroxy and 4-hydroxy metabolites^. 	CYP1A2	29228	29234	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:178	The human CYP1A2, identified in this study is capable of oxidizing estradiol, resulting in the production of 2-hydroxy and 4-hydroxy metabolites^. 	CYP1A2	29228	29234	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:179	Xenobiotic substrates of CYP1A2 include caffeine^, aflatoxin B1^ and paracetamol^. 	CYP1A2	29390	29396	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:179	Xenobiotic substrates of CYP1A2 include caffeine^, aflatoxin B1^ and paracetamol^. 	CYP1A2	29390	29396	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:180	It has been suggested that the increased function of CYP1A2 may be associated with an increased risk of breast cancer^, which could ultimately also be important for the metabolism of PCBs: In individual cases, existing exposure of PCBs in conjunction with genetic polymorphisms in CYP1A2 could lead to an increase in biological efficacy of PCBs (toxicity/mutagenicity), which could also result in an increased risk of disease. 	CYP1A2	29501	29507	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:180	It has been suggested that the increased function of CYP1A2 may be associated with an increased risk of breast cancer^, which could ultimately also be important for the metabolism of PCBs: In individual cases, existing exposure of PCBs in conjunction with genetic polymorphisms in CYP1A2 could lead to an increase in biological efficacy of PCBs (toxicity/mutagenicity), which could also result in an increased risk of disease. 	CYP1A2	29501	29507	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:180	It has been suggested that the increased function of CYP1A2 may be associated with an increased risk of breast cancer^, which could ultimately also be important for the metabolism of PCBs: In individual cases, existing exposure of PCBs in conjunction with genetic polymorphisms in CYP1A2 could lead to an increase in biological efficacy of PCBs (toxicity/mutagenicity), which could also result in an increased risk of disease. 	CYP1A2	29729	29735	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:180	It has been suggested that the increased function of CYP1A2 may be associated with an increased risk of breast cancer^, which could ultimately also be important for the metabolism of PCBs: In individual cases, existing exposure of PCBs in conjunction with genetic polymorphisms in CYP1A2 could lead to an increase in biological efficacy of PCBs (toxicity/mutagenicity), which could also result in an increased risk of disease. 	CYP1A2	29729	29735	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:182	Therefore, in further steps, CYP1A2 variants might be identified, that accelerate the metabolism of PCB 28 in humans. 	CYP1A2	30034	30040	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:182	Therefore, in further steps, CYP1A2 variants might be identified, that accelerate the metabolism of PCB 28 in humans. 	CYP1A2	30034	30040	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP1A2	13285	13291	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP1A2	13285	13291	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP1A2	13496	13502	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP1A2	13496	13502	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP1A2	14006	14012	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP1A2	14006	14012	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:77	The CYP1A2 gene was studied in 179 patients, with the most prevalent phenotype being HI (Higher Inducibility) (86.03%, n = 154). 	CYP1A2	14619	14625	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:77	The CYP1A2 gene was studied in 179 patients, with the most prevalent phenotype being HI (Higher Inducibility) (86.03%, n = 154). 	CYP1A2	14619	14625	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP1A2	15699	15705	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP1A2	15699	15705	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP1A2	21039	21045	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP1A2	21039	21045	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP1A2	21249	21255	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP1A2	21249	21255	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:117	This methodology has led to the discovery of a large number of cases in which there was a problem in the pharmacotherapy due to the metabolism mainly mediated by CYP1A2. 	CYP1A2	24667	24673	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:117	This methodology has led to the discovery of a large number of cases in which there was a problem in the pharmacotherapy due to the metabolism mainly mediated by CYP1A2. 	CYP1A2	24667	24673	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:208	For CYP2C19 (rs4244285) is the defining polymorphism of the CYP2C19*2 allele and is a synonymous G > A transition in exon 5 that creates an aberrant splice site, and this change alters the mRNA reading frame, which results in a truncated, non-functional protein. 	CYP2C19	39942	39949	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:208	For CYP2C19 (rs4244285) is the defining polymorphism of the CYP2C19*2 allele and is a synonymous G > A transition in exon 5 that creates an aberrant splice site, and this change alters the mRNA reading frame, which results in a truncated, non-functional protein. 	CYP2C19	39998	40005	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:209	This CYP2C19*2 allele is the most common CYP2C19 loss-of-function allele, with allele frequencies of approximately 12% in Caucasians, 15% in African-Americans, and 29-35% in Asians. 	CYP2C19	40206	40213	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:209	This CYP2C19*2 allele is the most common CYP2C19 loss-of-function allele, with allele frequencies of approximately 12% in Caucasians, 15% in African-Americans, and 29-35% in Asians. 	CYP2C19	40242	40249	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:210	The CYP2C19 poor metabolism phenotype was initially discovered by studies on impaired mephenytoin metabolism and the major molecular defect responsible for the trait is the CYP2C19*2 (rs4244285) loss-of-function allele. 	CYP2C19	40387	40394	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:210	The CYP2C19 poor metabolism phenotype was initially discovered by studies on impaired mephenytoin metabolism and the major molecular defect responsible for the trait is the CYP2C19*2 (rs4244285) loss-of-function allele. 	CYP2C19	40556	40563	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:211	For CYP2C19*2 Single Nucleotide Polymorphisms can cause a 40-nucleotide deletion and a frame shift which leads to a premature stop codon, result in the production of a truncated protein without enzymatic activity. 	CYP2C19	40607	40614	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:213	For CYP2C19 (rs4986893) is the defining polymorphism of the CYP2C19*3 allele and is a G > A transition in exon 4 that results in a premature termination codon at amino acid 212. 	CYP2C19	40911	40918	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:213	For CYP2C19 (rs4986893) is the defining polymorphism of the CYP2C19*3 allele and is a G > A transition in exon 4 that results in a premature termination codon at amino acid 212. 	CYP2C19	40967	40974	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:214	The CYP2C19*3 allele frequencies in most populations is below 1%; however, it is more prevalent among Asians (2-9%). 	CYP2C19	41089	41096	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:221	Poor CYP2C19 metabolizers are found in 5% of white people, but in up to 20% of Asians. 	CYP2C19	42147	42154	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:234	The first association of genetic polymorphisms with the metabolism of an anti-epileptic drug has been reported in the association of variation in drug-metabolizing enzymes CYP2C9 and CYP2C19 with phenytoin dose, providing hope for individualized therapy for patients. 	CYP2C19	44355	44362	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:243	Here, we show for the first time the number of miRNAs that targeting the CYP2C19 gene, which includes the following: hsa-miR-1270, hsa-miR-455-3p, hsa-miR-4325, hsa-miR-7703, hsa-miR-6880-5p, hsa-miR-6851-5p, hsa-miR-3689d, hsa-miR-4683, hsa-miR-6499-3p, hsa-miR-767-5p, hsa-miR-6134, hsa-miR-4537, hsa-miR-5186, hsa-miR-665, hsa-miR-4459, hsa-miR-92b-3p, hsa-miR-92a-3p, hsa-miR-367-3p, hsa-miR-363-3p, hsa-miR-32-5p, hsa-miR-25-3p, hsa-miR-3180-5p, hsa-miR-3912-5p, hsa-miR-874-3p, hsa-miR-3157-3p, hsa-miR-5195-3p, hsa-miR-145-5p, and hsa-miR-6886-3p. 	CYP2C19	45981	45988	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:244	Since, about 28 miRNAs can target the CYP2C19 gene, we believe that during the disease status in children with epilepsy, or during treatment with phenobarbital, one or multiple miRNA may be involved, along with the regulation of the CYP2C19 gene, which in turn up-regulates or down regulates the genes and also changes the genetic variations of the gene. 	CYP2C19	46501	46508	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:244	Since, about 28 miRNAs can target the CYP2C19 gene, we believe that during the disease status in children with epilepsy, or during treatment with phenobarbital, one or multiple miRNA may be involved, along with the regulation of the CYP2C19 gene, which in turn up-regulates or down regulates the genes and also changes the genetic variations of the gene. 	CYP2C19	46696	46703	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:279	Genomic variation of CYP2C19 was considered in drug pharmacokinetic proteins, in drug target proteins and finally across multiple candidate genes, thus providing three broad hypotheses as sources, housing potential influential genomic variations. 	CYP2C19	53309	53316	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2C19	13833	13840	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP2C19	13406	13413	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	CYP2C19	15187	15194	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	CYP2C19	15261	15268	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2C19	16587	16594	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:104	Enzalutamide, recognized as a strong CYP3A4 and a moderate CYP2C9 and CYP2C19 inducer, significantly reduces concentrations of several anti-HIV agents such as darunavir, ritonavir, etravirine, and raltegravir. 	CYP2C19	16685	16692	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:74	On the other hand, lopinavir/ritonavir induces CYP1A2, CYP2C9, CYP2C19 and glucuronidation. 	CYP2C19	12174	12181	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2C19	8235	8242	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2C19	15770	15777	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2C19	17261	17268	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2C19	18627	18634	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2C19	25806	25813	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2C19	14030	14037	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:80	In reference to the CYP2C9 and CYP2C19 genes (n = 183, n = 186), the majority phenotype was EM (57.38%, n = 105; 47.85%, n = 89). 	CYP2C19	14909	14916	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2C19	3033	3040	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14302	14308	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14302	14308	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14302	14308	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:97	Metoprolol metabolites segregated very well with CYP2D6 phenotype, suggesting that drug metabolism can be predicted based upon knowledge of CYP2D6 genotype and the presence of drug-drug interactions. 	CYP2D6	14302	14308	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:99	This may have contributed to our inability to identify endogenous metabolites predictive of clinical effectiveness, if CYP2D6 drug metabolism plays a major role in drug effectiveness, as hypothesized. 	CYP2D6	14608	14614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:99	This may have contributed to our inability to identify endogenous metabolites predictive of clinical effectiveness, if CYP2D6 drug metabolism plays a major role in drug effectiveness, as hypothesized. 	CYP2D6	14608	14614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:99	This may have contributed to our inability to identify endogenous metabolites predictive of clinical effectiveness, if CYP2D6 drug metabolism plays a major role in drug effectiveness, as hypothesized. 	CYP2D6	14608	14614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:99	This may have contributed to our inability to identify endogenous metabolites predictive of clinical effectiveness, if CYP2D6 drug metabolism plays a major role in drug effectiveness, as hypothesized. 	CYP2D6	14608	14614	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:136	CYP2D6 was genotyped using the Multiplex SNaPshot technique previously described. 	CYP2D6	20790	20796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:136	CYP2D6 was genotyped using the Multiplex SNaPshot technique previously described. 	CYP2D6	20790	20796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:136	CYP2D6 was genotyped using the Multiplex SNaPshot technique previously described. 	CYP2D6	20790	20796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:136	CYP2D6 was genotyped using the Multiplex SNaPshot technique previously described. 	CYP2D6	20790	20796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:137	This assay detects 20 CYP2D6 clinically significant variants and identifies copy number variants. 	CYP2D6	20894	20900	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:137	This assay detects 20 CYP2D6 clinically significant variants and identifies copy number variants. 	CYP2D6	20894	20900	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:137	This assay detects 20 CYP2D6 clinically significant variants and identifies copy number variants. 	CYP2D6	20894	20900	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:137	This assay detects 20 CYP2D6 clinically significant variants and identifies copy number variants. 	CYP2D6	20894	20900	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2D6	21167	21173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2D6	21167	21173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2D6	21167	21173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2D6	21167	21173	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:139	Genotyping was performed after subjects completed the protocol; thus, the investigators were blinded to the CYP2D6 genotype during treatment. 	CYP2D6	21329	21335	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:139	Genotyping was performed after subjects completed the protocol; thus, the investigators were blinded to the CYP2D6 genotype during treatment. 	CYP2D6	21329	21335	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:139	Genotyping was performed after subjects completed the protocol; thus, the investigators were blinded to the CYP2D6 genotype during treatment. 	CYP2D6	21329	21335	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:139	Genotyping was performed after subjects completed the protocol; thus, the investigators were blinded to the CYP2D6 genotype during treatment. 	CYP2D6	21329	21335	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21410	21416	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21410	21416	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21410	21416	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21410	21416	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21481	21487	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21481	21487	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21481	21487	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:140	Predicted phenotypes were determined utilizing CYP2D6 activity score, as described by Gaedigk et al.. Each identified CYP2D6 SNV was assigned a predicted enzyme activity score [,. 	CYP2D6	21481	21487	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP2D6	22162	22168	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP2D6	22162	22168	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP2D6	22162	22168	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:106	More specifically, midazolam biotransformation was equal to that of Primary Human Hepatocytes, whereas the biotransformation by CYP2D6, CYP1A2, and CYP2C9 were found to be in the range of 1-10% of the best PHH donor^,,,. 	CYP2D6	22162	22168	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP2D6	49331	49337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP2D6	49331	49337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP2D6	49331	49337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP2D6	49331	49337	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2D6	16596	16602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2D6	16596	16602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2D6	16596	16602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP2D6	16596	16602	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:139	Human P450 polymorphisms in what is now known as CYP2D6 were identified in the 1970s and in the 1980s in P450 2C19 [,. 	CYP2D6	18688	18694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:139	Human P450 polymorphisms in what is now known as CYP2D6 were identified in the 1970s and in the 1980s in P450 2C19 [,. 	CYP2D6	18688	18694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:139	Human P450 polymorphisms in what is now known as CYP2D6 were identified in the 1970s and in the 1980s in P450 2C19 [,. 	CYP2D6	18688	18694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:139	Human P450 polymorphisms in what is now known as CYP2D6 were identified in the 1970s and in the 1980s in P450 2C19 [,. 	CYP2D6	18688	18694	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19008	19014	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19008	19014	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19008	19014	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19008	19014	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19061	19067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19061	19067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19061	19067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:140	(Note: by definition a polymorphism is present at  1% incidence in a population, and the term variant includes not only polymorphisms but all rare changes, and the term single nucleotide variant (SNV) is probably more generally appropriate, ie,  160 CYP2D6 SNVs are known (https://www.pharmvar.org/gene/CYP2D6).) 	CYP2D6	19061	19067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:141	Today we realize that SNVs are seen in all human P450s (https://www.pharmvar.org/gene/CYP2D6). 	CYP2D6	19157	19163	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:141	Today we realize that SNVs are seen in all human P450s (https://www.pharmvar.org/gene/CYP2D6). 	CYP2D6	19157	19163	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:141	Today we realize that SNVs are seen in all human P450s (https://www.pharmvar.org/gene/CYP2D6). 	CYP2D6	19157	19163	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:141	Today we realize that SNVs are seen in all human P450s (https://www.pharmvar.org/gene/CYP2D6). 	CYP2D6	19157	19163	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:170	This is, for instance, how the CYP2D6 polymorphism was discovered, in that Robert Smith (personally) experienced a strong hypotensive effect of debrisoquine. 	CYP2D6	22711	22717	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:170	This is, for instance, how the CYP2D6 polymorphism was discovered, in that Robert Smith (personally) experienced a strong hypotensive effect of debrisoquine. 	CYP2D6	22711	22717	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:170	This is, for instance, how the CYP2D6 polymorphism was discovered, in that Robert Smith (personally) experienced a strong hypotensive effect of debrisoquine. 	CYP2D6	22711	22717	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:170	This is, for instance, how the CYP2D6 polymorphism was discovered, in that Robert Smith (personally) experienced a strong hypotensive effect of debrisoquine. 	CYP2D6	22711	22717	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:173	Conversely, some drugs are activated by P450s, and there are SNVs that involve higher activity than wild type enzyme, eg, CYP2D6*53 [,. 	CYP2D6	23226	23232	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:173	Conversely, some drugs are activated by P450s, and there are SNVs that involve higher activity than wild type enzyme, eg, CYP2D6*53 [,. 	CYP2D6	23226	23232	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:173	Conversely, some drugs are activated by P450s, and there are SNVs that involve higher activity than wild type enzyme, eg, CYP2D6*53 [,. 	CYP2D6	23226	23232	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:173	Conversely, some drugs are activated by P450s, and there are SNVs that involve higher activity than wild type enzyme, eg, CYP2D6*53 [,. 	CYP2D6	23226	23232	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:232	One deficiency is predicting the in vivo magnitude of P450 SNversus For instance, even the CYP2D6*3 polymorphism, which results in loss of the entire enzyme due to aberrant mRNA splicing, has varying effects in vivo with different drugs, and the results cannot be explained simply by the contribution of other P450s. 	CYP2D6	31300	31306	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:232	One deficiency is predicting the in vivo magnitude of P450 SNversus For instance, even the CYP2D6*3 polymorphism, which results in loss of the entire enzyme due to aberrant mRNA splicing, has varying effects in vivo with different drugs, and the results cannot be explained simply by the contribution of other P450s. 	CYP2D6	31300	31306	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:232	One deficiency is predicting the in vivo magnitude of P450 SNversus For instance, even the CYP2D6*3 polymorphism, which results in loss of the entire enzyme due to aberrant mRNA splicing, has varying effects in vivo with different drugs, and the results cannot be explained simply by the contribution of other P450s. 	CYP2D6	31300	31306	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:232	One deficiency is predicting the in vivo magnitude of P450 SNversus For instance, even the CYP2D6*3 polymorphism, which results in loss of the entire enzyme due to aberrant mRNA splicing, has varying effects in vivo with different drugs, and the results cannot be explained simply by the contribution of other P450s. 	CYP2D6	31300	31306	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2D6	8276	8282	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2D6	8276	8282	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2D6	8276	8282	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP2D6	8276	8282	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2D6	15779	15785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2D6	15779	15785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2D6	15779	15785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP2D6	15779	15785	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:94	Tested extracts and mitragynine were generally stronger inhibitors of CYP2D6 activity relative to the other isoforms^,. 	CYP2D6	15869	15875	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:94	Tested extracts and mitragynine were generally stronger inhibitors of CYP2D6 activity relative to the other isoforms^,. 	CYP2D6	15869	15875	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:94	Tested extracts and mitragynine were generally stronger inhibitors of CYP2D6 activity relative to the other isoforms^,. 	CYP2D6	15869	15875	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:94	Tested extracts and mitragynine were generally stronger inhibitors of CYP2D6 activity relative to the other isoforms^,. 	CYP2D6	15869	15875	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP2D6	16283	16289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP2D6	16283	16289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP2D6	16283	16289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP2D6	16283	16289	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP2D6	16415	16421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP2D6	16415	16421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP2D6	16415	16421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP2D6	16415	16421	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP2D6	16975	16981	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP2D6	16975	16981	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP2D6	16975	16981	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP2D6	16975	16981	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP2D6	32379	32385	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP2D6	32379	32385	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP2D6	32379	32385	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP2D6	32379	32385	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP2D6	32540	32546	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP2D6	32540	32546	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP2D6	32540	32546	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP2D6	32540	32546	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP2D6	32827	32833	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP2D6	32827	32833	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP2D6	32827	32833	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP2D6	32827	32833	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP2D6	33124	33130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP2D6	33124	33130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP2D6	33124	33130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP2D6	33124	33130	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2D6	17319	17325	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2D6	17319	17325	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2D6	17319	17325	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2D6	17319	17325	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2D6	18636	18642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2D6	18636	18642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2D6	18636	18642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2D6	18636	18642	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2D6	25815	25821	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2D6	25815	25821	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2D6	25815	25821	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2D6	25815	25821	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP2D6	13440	13446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP2D6	13440	13446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP2D6	13440	13446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP2D6	13440	13446	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2D6	14039	14045	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2D6	14039	14045	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2D6	14039	14045	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2D6	14039	14045	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP2D6	15093	15099	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP2D6	15093	15099	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP2D6	15093	15099	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP2D6	15093	15099	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21056	21062	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21056	21062	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21056	21062	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21056	21062	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21352	21358	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21352	21358	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21352	21358	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP2D6	21352	21358	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP2D6	21829	21835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP2D6	21829	21835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP2D6	21829	21835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP2D6	21829	21835	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2D6	3046	3052	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2D6	3046	3052	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2D6	3046	3052	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:19	However, of the total number of 57 human Cytochromes P450 coding genes with putative enzymatic activities, only 15 seem to metabolize drugs to date, and genetic polymorphisms of CYP2C9, CYP2C19, and CYP2D6 belong to the most frequently studied in pharmacogenomics. 	CYP2D6	3046	3052	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:189	This finding strongly suggests that hepatic CYP2E1-dependent ROS-elicited lipid peroxidation with consequent JNK1 activation and insulin resistance occur only when hepatic lipid is markedly elevated and available for peroxidation. 	CYP2E1	44155	44161	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:191	and Jiang et al., we conclude that a major determinant of the differential responses observed upon comparable CYP2E1-functional stabilization in Chip-KO and Gp78-KO mouse livers is the ER-stability of the Insig-SCAP-SREBP-1c complex. 	CYP2E1	44526	44532	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:191	and Jiang et al., we conclude that a major determinant of the differential responses observed upon comparable CYP2E1-functional stabilization in Chip-KO and Gp78-KO mouse livers is the ER-stability of the Insig-SCAP-SREBP-1c complex. 	CYP2E1	44526	44532	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:195	On the other hand, in Chip-KO mice, although the adiponectin-AMPK1ALPHA-FOXO1/3 signaling initially protects the livers, this beneficial signaling is suppressed as progressively augmented CYP2E1-dependent oxidative injury and sustained JNK-signaling activation trigger hepatic injury and hepatocyte dropout with age. 	CYP2E1	45642	45648	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:195	On the other hand, in Chip-KO mice, although the adiponectin-AMPK1ALPHA-FOXO1/3 signaling initially protects the livers, this beneficial signaling is suppressed as progressively augmented CYP2E1-dependent oxidative injury and sustained JNK-signaling activation trigger hepatic injury and hepatocyte dropout with age. 	CYP2E1	45642	45648	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:199	Thus, in principle, ALD-targeted CYP2E1 given its critical role in acetaminophen-mediated hepatotoxicity and contribution to alcoholic liver disease could be a prime candidate. 	CYP2E1	46815	46821	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:199	Thus, in principle, ALD-targeted CYP2E1 given its critical role in acetaminophen-mediated hepatotoxicity and contribution to alcoholic liver disease could be a prime candidate. 	CYP2E1	46815	46821	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47215	47221	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47215	47221	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47289	47295	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47289	47295	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47384	47390	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:200	However, while the protective effects of rapamycin-induced Autophagic-Lysosomal Degradation and the worsening effects of chloroquine-suppressed Autophagic-Lysosomal Degradation on acetaminophen-elicited hepatotoxicity seemingly reflect an inherent role of CYP2E1 in acetaminophen bioactivation, they are exerted at a stage beyond CYP2E1-dependent metabolic activation, and thus, quite independent of corresponding effects on CYP2E1-proteolytic stability. 	CYP2E1	47384	47390	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:203	This apparent discrepancy is due not only to reduced CYP2E1 content but also a persistent, compensatory activation of NRF2 that triggers the transcriptional activation of drug detoxification enzymes and GSH synthesis, as well as greater hepatocyte proliferation in the liver-specific Atg5-KO mice. 	CYP2E1	47810	47816	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:203	This apparent discrepancy is due not only to reduced CYP2E1 content but also a persistent, compensatory activation of NRF2 that triggers the transcriptional activation of drug detoxification enzymes and GSH synthesis, as well as greater hepatocyte proliferation in the liver-specific Atg5-KO mice. 	CYP2E1	47810	47816	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:205	Interestingly, CYP2E1-stabilization upon chemically-induced autophagic disruption in HepG2 cells promotes, as expected, CYP2E1-dependent oxidative stress, mitochondrial dysfunction, JNK and p38 MAPK-activation, and consequent cytotoxicity. 	CYP2E1	48226	48232	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:205	Interestingly, CYP2E1-stabilization upon chemically-induced autophagic disruption in HepG2 cells promotes, as expected, CYP2E1-dependent oxidative stress, mitochondrial dysfunction, JNK and p38 MAPK-activation, and consequent cytotoxicity. 	CYP2E1	48226	48232	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:205	Interestingly, CYP2E1-stabilization upon chemically-induced autophagic disruption in HepG2 cells promotes, as expected, CYP2E1-dependent oxidative stress, mitochondrial dysfunction, JNK and p38 MAPK-activation, and consequent cytotoxicity. 	CYP2E1	48331	48337	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:205	Interestingly, CYP2E1-stabilization upon chemically-induced autophagic disruption in HepG2 cells promotes, as expected, CYP2E1-dependent oxidative stress, mitochondrial dysfunction, JNK and p38 MAPK-activation, and consequent cytotoxicity. 	CYP2E1	48331	48337	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:216	Thus, CYP2E1 functional stabilization upon Chip-KO results in hepatic oxidative stress, JNK1-activation, insulin resistance, FA- and TG-accumulation and liver injury that contribute to NASH. 	CYP2E1	51245	51251	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:216	Thus, CYP2E1 functional stabilization upon Chip-KO results in hepatic oxidative stress, JNK1-activation, insulin resistance, FA- and TG-accumulation and liver injury that contribute to NASH. 	CYP2E1	51245	51251	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:217	By contrast, despite comparable CYP2E1 functional stabilization, no significant hepatic FA- and TG-accumulation is observed upon Gp78-KO due to the ER-stabilization of the Insig proteins that prevents SREBP-1c-elicited transcriptional activation of hepatic lipogenesis. 	CYP2E1	51462	51468	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:217	By contrast, despite comparable CYP2E1 functional stabilization, no significant hepatic FA- and TG-accumulation is observed upon Gp78-KO due to the ER-stabilization of the Insig proteins that prevents SREBP-1c-elicited transcriptional activation of hepatic lipogenesis. 	CYP2E1	51462	51468	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2E1	11438	11444	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2E1	11438	11444	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2E1	13932	13938	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2E1	13932	13938	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2E1	20783	20789	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2E1	20783	20789	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:76	Of note, we also found an AAGLY-mediated induction of CYP1A2 and CYP2E1 in the embryonic kidney line, HEK293 (Supplementary Fig. 	CYP2E1	14989	14995	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:76	Of note, we also found an AAGLY-mediated induction of CYP1A2 and CYP2E1 in the embryonic kidney line, HEK293 (Supplementary Fig. 	CYP2E1	14989	14995	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2E1	17355	17361	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:107	When Cyp18a1 (human orthologues: CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2R1, CYP21A2, CYP2A6, CYP2D6, CYP2 F1, CYP2S1, CYP2U1 and CYP2E1) was silenced, a 10% reduction of 3-OHCB 28 and a 70% reduction of 3-OHCB 28 was observed compared to control. 	CYP2E1	17355	17361	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2E1	18644	18650	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP2E1	18644	18650	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP2E1	19282	19288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP2E1	19282	19288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2E1	25823	25829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP2E1	25823	25829	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:177	In addition, the hydroxylation of some tri- and tetrachlorobiphenyls (PCB 20, 22, 52 and 74) by CYP2E1^ and the formation of 4-OHCB 101 from PCB 101 by CYP2A6 was detected in vitro^. 	CYP2E1	29131	29137	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:177	In addition, the hydroxylation of some tri- and tetrachlorobiphenyls (PCB 20, 22, 52 and 74) by CYP2E1^ and the formation of 4-OHCB 101 from PCB 101 by CYP2A6 was detected in vitro^. 	CYP2E1	29131	29137	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:106	were altering N-oxidation of 3,5-DCA, the ability of diethyldithiocarbamate (DEDTCA), an inhibitor of CYP2C, and to a lesser extent CYP2E1, to reduce DCNB formation was examined. 	CYP2E1	16759	16765	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:106	were altering N-oxidation of 3,5-DCA, the ability of diethyldithiocarbamate (DEDTCA), an inhibitor of CYP2C, and to a lesser extent CYP2E1, to reduce DCNB formation was examined. 	CYP2E1	16759	16765	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:109	Since the CYP2E1 inhibitor isoniazid had no effect on 3,5-DCA cytotoxicity, it appears that CYP2C enzymes are bioactivating 3,5-DCA to toxic metabolites via 3,5-DCPHA formation. 	CYP2E1	17095	17101	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC7796304_OgerInput.txtOger_out.csv:109	Since the CYP2E1 inhibitor isoniazid had no effect on 3,5-DCA cytotoxicity, it appears that CYP2C enzymes are bioactivating 3,5-DCA to toxic metabolites via 3,5-DCPHA formation. 	CYP2E1	17095	17101	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP3A	9381	9386	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:50	The individual roles of CHIP and gp78 in CYP3A and CYP2E1 ubiquitination and Endoplasmic Reticulum-Associated Degradation were verified upon lentiviral shRNA interference analyses targeted individually against each of these E3s in cultured rat hepatocytes,. 	CYP3A	11368	11373	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:51	Thus, upon CHIP-knockdown, CYP3A was stabilized largely as the parent (55 kDa) species along with a minor CYP3A fraction consisting of its high molecular mass ubiquitinated species. 	CYP3A	11612	11617	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:51	Thus, upon CHIP-knockdown, CYP3A was stabilized largely as the parent (55 kDa) species along with a minor CYP3A fraction consisting of its high molecular mass ubiquitinated species. 	CYP3A	11691	11696	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:52	Upon gp78 knockdown, CYP3A was largely found as its parent species along with a significant amount of its ubiquitinated species. 	CYP3A	11788	11793	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:53	However, upon either E3-knockdown, the functionally active CYP3A fraction not only was proportional to the relative amount of the stabilized unmodified parent species, but also considerably greater than that in the corresponding non-targeting shRNA-treated control hepatocytes, indicating that CYP3A-ERAD disruption could be therapeutically relevant. 	CYP3A	11955	11960	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:53	However, upon either E3-knockdown, the functionally active CYP3A fraction not only was proportional to the relative amount of the stabilized unmodified parent species, but also considerably greater than that in the corresponding non-targeting shRNA-treated control hepatocytes, indicating that CYP3A-ERAD disruption could be therapeutically relevant. 	CYP3A	12190	12195	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:54	Furthermore, each system by itself was capable of CYP3A4-ubiquitination as determined upon in vitro reconstitution studies of each individual CYP3A4 E2/E3-ubiquitination system. 	CYP3A	12297	12302	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:54	Furthermore, each system by itself was capable of CYP3A4-ubiquitination as determined upon in vitro reconstitution studies of each individual CYP3A4 E2/E3-ubiquitination system. 	CYP3A	12389	12394	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:55	However, CYP3A4 ubiquitination was both greatly accelerated and magnified when both E2/E3 systems were present simultaneously. 	CYP3A	12434	12439	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:56	The CYP3A4 ubiquitination profile observed upon sequential introduction of each E2/E3 in the reconstituted system suggested that UbcH5a/CHIP most likely serves as the E3, with UBC7/gp78 serving as the E4 involved in the elongation of CYP3A4 polyUb chains. 	CYP3A	12556	12561	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:56	The CYP3A4 ubiquitination profile observed upon sequential introduction of each E2/E3 in the reconstituted system suggested that UbcH5a/CHIP most likely serves as the E3, with UBC7/gp78 serving as the E4 involved in the elongation of CYP3A4 polyUb chains. 	CYP3A	12786	12791	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:63	This heterotrimeric p97-complex was documented to be required for CYP3A Ubiquitin-Dependent Proteasomal Degradation in Saccharomyces cerevisiae. 	CYP3A	14036	14041	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:64	Through chemical (formaldehyde)-crosslinking, immune affinity-purification and LC-MS/MS analyses, its close cellular association with ubiquitinated CYP3A23 in cultured rat hepatocytes was also documented, a finding subsequently verified by p97-targeted lentiviral Shrna Interference analyses in cultured rat hepatocytes. 	CYP3A	14263	14268	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:65	Lentiviral shRNAi-elicited p97-knockdown led to the accumulation of parent and ubiquitinated CYP3A23 species that remained largely anchored to the ER-membrane, unlike those from control shRNA-treated hepatocytes that were largely extracted into the cytosol. 	CYP3A	14529	14534	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:115	The serious, life-threatening Drug-Drug Interactions observed with the CYP3A4 mechanism-based inactivators grapefruit juice furanocoumarins and terfenadine, astemizole or amiodarone are some illustrative examples,. 	CYP3A	26456	26461	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:123	Similar hepatic stabilization of CYP3A-enzymes in these mice can significantly enhance the bioactivation of the breast cancer chemotherapeutic prodrug tamoxifen to its pharmacologically active end-product endoxifen. 	CYP3A	28106	28111	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP3A	31445	31450	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP3A	32092	32097	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:143	We find it intriguing that serum antibodies to one of the CYP3A peptides detected in clinical CBZ-elicited acute hypersensitivity reactions, corresponds to the same CYP3A4 helix K-region that is heme-modified upon cumene-hydroperoxide-elicited peroxidative CYP3A4 heme-fragmentation. 	CYP3A	32773	32778	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:143	We find it intriguing that serum antibodies to one of the CYP3A peptides detected in clinical CBZ-elicited acute hypersensitivity reactions, corresponds to the same CYP3A4 helix K-region that is heme-modified upon cumene-hydroperoxide-elicited peroxidative CYP3A4 heme-fragmentation. 	CYP3A	32880	32885	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:143	We find it intriguing that serum antibodies to one of the CYP3A peptides detected in clinical CBZ-elicited acute hypersensitivity reactions, corresponds to the same CYP3A4 helix K-region that is heme-modified upon cumene-hydroperoxide-elicited peroxidative CYP3A4 heme-fragmentation. 	CYP3A	32972	32977	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:170	The magnitude of CYP2E1 and CYP3A functional stabilization is comparable in Gp78-KO and Chip-KO mouse livers,. 	CYP3A	39476	39481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP3A	11289	11294	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP3A	11359	11364	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP3A	11367	11372	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP3A	13765	13770	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP3A	19505	19510	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP3A	19716	19721	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:129	CYP3A showed a similar pattern: petasin/neopetasin/isopetasin metabolism with CYP3A4 (human) was 34%/87%/86% versus CYP3A1 (rat): 37%/78%/86% versus CYP3A2 (rat): 34%/46%/73%. 	CYP3A	20162	20167	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:129	CYP3A showed a similar pattern: petasin/neopetasin/isopetasin metabolism with CYP3A4 (human) was 34%/87%/86% versus CYP3A1 (rat): 37%/78%/86% versus CYP3A2 (rat): 34%/46%/73%. 	CYP3A	20240	20245	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:129	CYP3A showed a similar pattern: petasin/neopetasin/isopetasin metabolism with CYP3A4 (human) was 34%/87%/86% versus CYP3A1 (rat): 37%/78%/86% versus CYP3A2 (rat): 34%/46%/73%. 	CYP3A	20278	20283	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:129	CYP3A showed a similar pattern: petasin/neopetasin/isopetasin metabolism with CYP3A4 (human) was 34%/87%/86% versus CYP3A1 (rat): 37%/78%/86% versus CYP3A2 (rat): 34%/46%/73%. 	CYP3A	20311	20316	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A	13292	13297	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A	13427	13432	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A	13474	13479	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A	13492	13497	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	CYP3A	15208	15213	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP3A	21046	21051	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:33	By day 20, hepatic transcripts, such as alpha1-antitrypsin and Na^+ -taurocholate cotransporting polypeptide, reached levels found in PHHs4A and Alpha1-Antitrypsin and activity of mature genes such as albumin or CYP3A4, the most important drug-biotransforming enzyme, remained lower than in Primary Human Hepatocytes or even 12 h plated Primary Human Hepatocytes (PHH 12 h). 	CYP3A	5361	5366	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:47	Induction of HNF1A, FOXA3, and PROX1 from D4 until D20 induced their expression to levels near those of Primary Human Hepatocytes and increased both Albumin and CYP3A4 mRNA. 	CYP3A	8705	8710	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:48	Transcript levels of Albumin now reached those of PHH 12 h and CYP3A4 expression was increased 50-fold was still very low or increased OCR was observed. 	CYP3A	8781	8786	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:63	Surprisingly, despite the clear correlation between metabolism, AA catabolism, and Cytochrome P450 expression observed in the WGCNA, AA3 only marginally induced the expression of CYP3A4 when exceeding the nutritional need (Supplementary Fig, C). 	CYP3A	11969	11974	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:65	We observed a concentration-dependent increase in CYP3A4 expression when HLC D20 or HC3X D20 were differentiated in AA3 medium supplemented with 2% glycine present in the media was replaced by 2% of a single AA, as the combination increased the osmolarity of the media to lethal levels (Supplementary Fig. 	CYP3A	12315	12320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	CYP3A	12585	12590	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:67	Importantly, Aa3 Medium Supplemented With 2% Glycine medium induced a gradual maturation of HLC and HC3X progeny, as extended culture resulted in a continuous increase in CYP3A4 expression and function to levels that were in the range of gold standard, freshly thawed Primary Human Hepatocytes. 	CYP3A	12958	12963	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:79	As we observed for Hepatocyte-Like Cells, Aa3 Medium Supplemented With 2% Glycine also induced a gradual increase in CYP3A4 expression and function of HepG2 cells over time. 	CYP3A	15570	15575	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:83	Based on the Rna-Sequencing data, we next analyzed the activity of the AKT-mTORC1, Amp-Activated Protein Kinase, and eIF2alpha pathways in HepG2 cultured with AA3 ALA or AA3GLY (strong inducers of CYP3A4) versus AA3 VAL (weak induction of CYP3A4). 	CYP3A	16668	16673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:83	Based on the Rna-Sequencing data, we next analyzed the activity of the AKT-mTORC1, Amp-Activated Protein Kinase, and eIF2alpha pathways in HepG2 cultured with AA3 ALA or AA3GLY (strong inducers of CYP3A4) versus AA3 VAL (weak induction of CYP3A4). 	CYP3A	16710	16715	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:84	This analysis linked induction of mature hepatic markers such as CYP3A4, Phosphoenolpyruvate Carboxykinase, and glutamine synthetase to an increased phosphorylation of S6, Amp-Activated Protein Kinase, and AKT. 	CYP3A	16784	16789	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:87	From these pathways, we were able to specifically link mTORC1 signaling to the induction of CYP3A4, as addition of the mTORC1 inhibitor rapamycin blocked the induction of CYP3A4, while Amp-Activated Protein Kinase phosphorylation and ATF4 levels remained unchanged (Supplementary Fig. 	CYP3A	17201	17206	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:87	From these pathways, we were able to specifically link mTORC1 signaling to the induction of CYP3A4, as addition of the mTORC1 inhibitor rapamycin blocked the induction of CYP3A4, while Amp-Activated Protein Kinase phosphorylation and ATF4 levels remained unchanged (Supplementary Fig. 	CYP3A	17280	17285	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:88	Furthermore, knockout of the upstream regulators of Amp-Activated Protein Kinase and eIF2alpha, LKB1 and GCN2, did not affect CYP3A4 levels both in control media or Aa3 Medium Supplemented With 2% Glycine media (Supplementary Fig B, C). 	CYP3A	17520	17525	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:89	In both HepG2, HLC and HC3X, mTORC1 appeared to regulate CYP3A4 expression rather than translation. 	CYP3A	17688	17693	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:90	Finally, although Knockout of the mTORC1 inhibitor Tuberous sclerosis (TSC)1 was not sufficient for driving maturation in HepG2, culture of TSC1 Knockout HepG2 in Aa3 Medium Supplemented With 2% Glycine medium yielded an even greater induction of CYP3A4 compared with wild-type HepG2^. 	CYP3A	17978	17983	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:99	However, we only found an increase in CYP3A4 and the gluconeogenic genes, G6PC and Phosphoenolpyruvate Carboxykinase, when HC6X were also cultured with Aa3 Medium Supplemented With 2% Glycine, indicating that mitochondrial biogenesis is not sufficient to drive maturation (Supplementary Fig E, F). 	CYP3A	20192	20197	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:100	The transcriptome of HC6X Aa3 Medium Supplemented With 2% Glycine D40 was similar to that of HC3X Aa3 Medium Supplemented With 2% Glycine D40, even if perhaps slightly closer to that of Primary Human Hepatocytes caused a significant decrease in CYP3A4 activity and to a lesser extent also decreased global maturity (Fig. 	CYP3A	20697	20702	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:108	In accordance, we found that HC6X Aa3 Medium Supplemented With 2% Glycine D40 stained positive for CYP3A4, with several cells displaying a binucleated phenotype (Supplementary Fig. 	CYP3A	22447	22452	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:136	Of the investigated signaling pathways, we only found inhibition of mTORC1 to be able to prevent the induction of CYP3A4 under conditions of AA supplementation. 	CYP3A	28093	28098	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:138	Nevertheless, the sole activation of mTORC1 through the genetic deletion of TSC1 was not sufficient to induce CYP3A4 expression. 	CYP3A	28362	28367	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:269	CYP3A4-dependent metabolization was determined using the fluorometric probe BFC as previously described^. 	CYP3A	47862	47867	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP3A	49323	49328	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:91	Moreover it is important to emphasize that tocilizumab decreases the concentration of several medications as a cytochrome P450, isoenzyme CYP3A4 inducer in terms of antagonisms or synergy but this is not yet entirely clear (;. 	CYP3A	14747	14752	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:92	Several drugs, such as CYP3A4 inhibitors, increase concentration of colchicine and attention should be paid when the latter is used with cisplatin or vinca alkaloids. 	CYP3A	14859	14864	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP3A	16607	16612	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:104	Enzalutamide, recognized as a strong CYP3A4 and a moderate CYP2C9 and CYP2C19 inducer, significantly reduces concentrations of several anti-HIV agents such as darunavir, ritonavir, etravirine, and raltegravir. 	CYP3A	16652	16657	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	CYP3A	34201	34206	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:72	One main source of risk is inhibition of CYP3A4 by lopinavir/ritonavir (perpetrator). 	CYP3A	11945	11950	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:73	Given that ritonavir irreversibly inhibits CYP3A4, the inhibitory effect may last up to 5 days after stopping ritonavir. 	CYP3A	12033	12038	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:8	Interestingly, we observed the same trend as with CYP3A enzymes: a diminished difference between the sexes in GF mice. 	CYP3A	1187	1192	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP3A	8312	8317	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP3A	8338	8343	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:74	The enzymatic activity of CYP3A was significantly decreased in GF mice compared to SPF mice. 	CYP3A	10614	10619	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:75	In the female groups, the activity of CYP3A did not differ significantly from the male groups but had a tendency to decrease. 	CYP3A	10719	10724	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:88	Even though in humans the differences are subtler, it is known that the CYP3A4 activity features apparent sexual dimorphism with higher activity in women due to differences in growth hormone patterns. 	CYP3A	12330	12335	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:93	The enzymatic activity of CYP3A (using midazolam as a substrate) in both the male and female mice lacking the microbiota was significantly decreased compared to their SPF counterparts. 	CYP3A	13068	13073	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:95	Further we have found that the activity of CYP3A did not differ significantly in female groups from the male groups, but had a tendency to decrease. 	CYP3A	13349	13354	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:96	This data suggests that the down-regulation of CYP3A enzymes may not be sex-specific and, above all, that the gut microbiome is crucial in the synthesis of CYP3A in both sexes. 	CYP3A	13502	13507	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:96	This data suggests that the down-regulation of CYP3A enzymes may not be sex-specific and, above all, that the gut microbiome is crucial in the synthesis of CYP3A in both sexes. 	CYP3A	13611	13616	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:99	Interestingly, we observed the same trend as with CYP3A enzymes: diminishing the changes between sexes in GF mice. 	CYP3A	14001	14006	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:103	In humans, CYP2C and CYP3A enzymes are abundantly present in the liver and, completely or partially, metabolize a large fraction of all prescribed drugs. 	CYP3A	14573	14578	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:112	CYP3A4 contributes to the oxidation of many steroids, and its activity in humans is sexually dimorphic. 	CYP3A	16109	16114	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:113	The exact mechanism for sex differences in CYP3A4 (and other CYPs) remains elusive but may include altered growth hormone signalling. 	CYP3A	16256	16261	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP3A	15791	15796	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:96	We evaluated whether the observed variability in alkaloid profile for kratom extracts results in altered inhibitory effects on three major CYPs, specifically CYP2C9, CYP2D6, and CYP3A. 	CYP3A	16295	16300	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:97	All three kratom extracts tested showed concentration-dependent inhibition of each CYP, with stronger effects on CYP2D6 compared to CYP2C9 and CYP3A. 	CYP3A	16445	16450	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:100	If the concentration of mitragynine in the liver upon kratom consumption nears the IC_50 values estimated from the screening assay (~ 1 M for CYP2D6; 10-100 M for CYP2C9 and CYP3A), a CYP-mediated kratom-drug interaction is possible. 	CYP3A	17007	17012	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:101	In addition, because CYP3A is also expressed in the intestine, mitragynine concentrations in the intestine could well exceed 10 M, increasing the possibility of CYP3A-mediated kratom-drug interactions. 	CYP3A	17088	17093	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:101	In addition, because CYP3A is also expressed in the intestine, mitragynine concentrations in the intestine could well exceed 10 M, increasing the possibility of CYP3A-mediated kratom-drug interactions. 	CYP3A	17228	17233	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:195	Mitragynine and 7-hydroxymitragynine (purchased), speciofoline (the isolated alkaloid), and three methanolic kratom extracts (prepared from commercial products K50, K51, and K52; Table ), were tested as inhibitors of CYP2C9, CYP2D6, and CYP3A activities using a cocktail approach^. 	CYP3A	32391	32396	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:196	Diclofenac (4 M), dextromethorphan (4 M), and midazolam (2 M) were used as probe substrates for CYP2C9, CYP2D6, and CYP3A activities, respectively. 	CYP3A	32552	32557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:198	Positive control inhibitors included sulfaphenazole (1 M; CYP2C9), quinidine (2 M; CYP2D6), and ketoconazole (0.1 M; CYP3A). 	CYP3A	32861	32866	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:200	After equilibrating the mixtures for 5 min at 37 C, the reaction was initiated by addition of NADPH (1 mM final concentration) and incubated for 10 min (CYP2C9 and CYP2D6 activities) or 2 min (CYP3A activity) at 37 C. Reactions were quenched with 2 volumes of cold methanol containing internal standard (alprazolam, 0.1 M). 	CYP3A	33153	33158	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7707949_OgerInput.txtOger_out.csv:97	In the context of Hepatocellular Carcinoma, treatment with 5-AZA conduced to tumor regression and a shift to a more differentiated phenotype, which was associated with regional demethylation of CpG regions upstream of the liver-specific genes SLC10A1, CYP3A4, ALB, and miR-122, which were downregulated pretreatments. 	CYP3A	14167	14172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP3A	18686	18691	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP3A	19293	19298	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP3A	25831	25836	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:66	The cytochrome through which more conflicts occur was CYP3A4 (n = 67), followed by 3A5 (n = 27) and 1A2 (n = 27). 	CYP3A	13072	13077	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP3A	13247	13252	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP3A	13264	13269	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A	13428	13433	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A	13472	13477	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A	13484	13489	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP3A	14047	14052	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP3A	14059	14064	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP3A	15126	15131	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP3A	15236	15241	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP3A	15602	15607	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP3A	15853	15858	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:88	As can be seen, the prescription of oral drugs whose metabolism is related to enzymes frequently altered in the study population, is reduced by between 20 and 100%, in favor of intramuscular prescriptions that either do not have liver metabolism, such as Paliperidone, which increases by 186.95%, or whose main route of metabolism is associated with an enzyme that usually has no alterations, such as Aripiprazole, whose prescriptions increase by 100%, predominantly metabolized by CYP3A4. 	CYP3A	17492	17497	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP3A	21073	21078	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP3A	21363	21368	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP3A	21840	21845	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:119	It should be noted that the use of DEPOT presentations of drugs such as paliperidone (not metabolized by the CYP450 system) or aripiprazole (whose predominant pathway within the CYP450 system is CYP3A4, which presents a wt-like genotype in the vast majority of the study population) has been the solution for the majority of problematic cases, because of the pharmacogenetic profile of the sample, even considering that each patient was studied individually attending its personal genetic implications. 	CYP3A	24986	24991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP3A	6107	6112	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:193	CYP3A5 catalyzes a comparable range of reactions as CYP3A4 but its role in drug and steroid metabolism is limited due to its generally low activity and expression in a relatively small percentage of individuals [,. 	CYP3A4	33059	33065	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:194	CYP3A7 is the major CYP3A isoform in prenatal and early postnatal life and differs from CYP3A4 in terms of expression and function. 	CYP3A4	33310	33316	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:198	CYP3A4-catalyzed 6BETA-hydroxylation is the most common hydroxylation for ^4 steroids, eg cortisol ((e)), while 6ALPHA-hydroxylated pregnanolones are quantitatively important urine steroid metabolites during pregnancy. 	CYP3A4	33690	33696	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:201	The differential substrate specificity, regioselectivity and catalytic activity of CYP3A4 and CYP3A7 and the dynamic expression pattern of the two isoforms throughout fetal development and the first year of life lead to substantial changes in the hepatic steroid metabolome during this period of life. 	CYP3A4	34231	34237	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:203	CYP3A4 levels are low in the fetus and newborn compared to the adult. 	CYP3A4	34578	34584	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:204	Thus, there is a switch from CYP3A7 to CYP3A4 during the first months after birth. 	CYP3A4	34687	34693	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:208	In fact, CYP2C19 and CYP3A4 can 21-hydroxylate progesterone and pregnenolone, possibly partially compensating mineralocorticoid deficiency in CAH due to 21-hydroxylase deficiency; however, the two enzymes are not capable of catalyzing the 21-hydroxylation of 17OHP to 11-deoxycortisol. 	CYP3A4	35306	35312	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:337	Cortisol can also be 6BETA-hydroxylated by CYP3A4 expressed in the liver, resulting in 6BETA-hydroxycortisol (6BETA-OHF). 	CYP3A4	56091	56097	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:405	Circulating Dehydroepiandrosterone is readily 16ALPHA-hydroxylated by CYP3A4/7 within the liver. 	CYP3A4	67378	67384	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP3A4	70253	70259	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP3A4	70515	70521	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP3A4	70821	70827	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP3A4	70867	70873	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP3A4	24783	24789	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP3A4	5114	5120	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP3A4	5190	5196	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP3A4	9246	9252	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP3A4	9381	9387	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:54	Furthermore, each system by itself was capable of CYP3A4-ubiquitination as determined upon in vitro reconstitution studies of each individual CYP3A4 E2/E3-ubiquitination system. 	CYP3A4	12297	12303	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:54	Furthermore, each system by itself was capable of CYP3A4-ubiquitination as determined upon in vitro reconstitution studies of each individual CYP3A4 E2/E3-ubiquitination system. 	CYP3A4	12389	12395	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:55	However, CYP3A4 ubiquitination was both greatly accelerated and magnified when both E2/E3 systems were present simultaneously. 	CYP3A4	12434	12440	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:56	The CYP3A4 ubiquitination profile observed upon sequential introduction of each E2/E3 in the reconstituted system suggested that UbcH5a/CHIP most likely serves as the E3, with UBC7/gp78 serving as the E4 involved in the elongation of CYP3A4 polyUb chains. 	CYP3A4	12556	12562	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:56	The CYP3A4 ubiquitination profile observed upon sequential introduction of each E2/E3 in the reconstituted system suggested that UbcH5a/CHIP most likely serves as the E3, with UBC7/gp78 serving as the E4 involved in the elongation of CYP3A4 polyUb chains. 	CYP3A4	12786	12792	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:115	The serious, life-threatening Drug-Drug Interactions observed with the CYP3A4 mechanism-based inactivators grapefruit juice furanocoumarins and terfenadine, astemizole or amiodarone are some illustrative examples,. 	CYP3A4	26456	26462	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:138	In patients with severe INH-induced liver injury, not only serum autoantibodies to CYP2E1, CYP3A4 and CYP2C9 (the three major P450s that metabolize and/or interact with INH), but also serum antibodies to INH-adducted CYP2E1 and other INH-adducted non-P450 proteins are detected. 	CYP3A4	31445	31451	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:143	We find it intriguing that serum antibodies to one of the CYP3A peptides detected in clinical CBZ-elicited acute hypersensitivity reactions, corresponds to the same CYP3A4 helix K-region that is heme-modified upon cumene-hydroperoxide-elicited peroxidative CYP3A4 heme-fragmentation. 	CYP3A4	32880	32886	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:143	We find it intriguing that serum antibodies to one of the CYP3A peptides detected in clinical CBZ-elicited acute hypersensitivity reactions, corresponds to the same CYP3A4 helix K-region that is heme-modified upon cumene-hydroperoxide-elicited peroxidative CYP3A4 heme-fragmentation. 	CYP3A4	32972	32978	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP3A4	11289	11295	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP3A4	13765	13771	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP3A4	19505	19511	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:126	However, for isopetasin and neopetasin, the cytochromes mainly involved in their metabolism were CYP3A4 (87% and 86%), CYP2D6 (61% and 83%), and CYP2C8 (44% and 71%). 	CYP3A4	19716	19722	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:129	CYP3A showed a similar pattern: petasin/neopetasin/isopetasin metabolism with CYP3A4 (human) was 34%/87%/86% versus CYP3A1 (rat): 37%/78%/86% versus CYP3A2 (rat): 34%/46%/73%. 	CYP3A4	20240	20246	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A4	13292	13298	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A4	13474	13480	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7006988_OgerInput.txtOger_out.csv:85	Studies had showed that the metabolism of Valproic Acid and DM can be metabolically and pharmacokinetically affected by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A; and that Valproic Acid inhibits CYP2C9, CYP3A4 or induces CYP3A4 gene expression in vitro which support the possible drug interaction of these two drugs. 	CYP3A4	13492	13498	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7037824_OgerInput.txtOger_out.csv:86	Meanwhile, the examined series inhibited the cytochrome P450 isomers, ie, CYP2C19, CYP2C9, and CYP3A4-except for Compound 2g, which did not inhibit CYP2C19. 	CYP3A4	15208	15214	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP3A4	21046	21052	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:33	By day 20, hepatic transcripts, such as alpha1-antitrypsin and Na^+ -taurocholate cotransporting polypeptide, reached levels found in PHHs4A and Alpha1-Antitrypsin and activity of mature genes such as albumin or CYP3A4, the most important drug-biotransforming enzyme, remained lower than in Primary Human Hepatocytes or even 12 h plated Primary Human Hepatocytes (PHH 12 h). 	CYP3A4	5361	5367	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:47	Induction of HNF1A, FOXA3, and PROX1 from D4 until D20 induced their expression to levels near those of Primary Human Hepatocytes and increased both Albumin and CYP3A4 mRNA. 	CYP3A4	8705	8711	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:48	Transcript levels of Albumin now reached those of PHH 12 h and CYP3A4 expression was increased 50-fold was still very low or increased OCR was observed. 	CYP3A4	8781	8787	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:63	Surprisingly, despite the clear correlation between metabolism, AA catabolism, and Cytochrome P450 expression observed in the WGCNA, AA3 only marginally induced the expression of CYP3A4 when exceeding the nutritional need (Supplementary Fig, C). 	CYP3A4	11969	11975	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:65	We observed a concentration-dependent increase in CYP3A4 expression when HLC D20 or HC3X D20 were differentiated in AA3 medium supplemented with 2% glycine present in the media was replaced by 2% of a single AA, as the combination increased the osmolarity of the media to lethal levels (Supplementary Fig. 	CYP3A4	12315	12321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	CYP3A4	12585	12591	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:67	Importantly, Aa3 Medium Supplemented With 2% Glycine medium induced a gradual maturation of HLC and HC3X progeny, as extended culture resulted in a continuous increase in CYP3A4 expression and function to levels that were in the range of gold standard, freshly thawed Primary Human Hepatocytes. 	CYP3A4	12958	12964	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:79	As we observed for Hepatocyte-Like Cells, Aa3 Medium Supplemented With 2% Glycine also induced a gradual increase in CYP3A4 expression and function of HepG2 cells over time. 	CYP3A4	15570	15576	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:83	Based on the Rna-Sequencing data, we next analyzed the activity of the AKT-mTORC1, Amp-Activated Protein Kinase, and eIF2alpha pathways in HepG2 cultured with AA3 ALA or AA3GLY (strong inducers of CYP3A4) versus AA3 VAL (weak induction of CYP3A4). 	CYP3A4	16668	16674	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:83	Based on the Rna-Sequencing data, we next analyzed the activity of the AKT-mTORC1, Amp-Activated Protein Kinase, and eIF2alpha pathways in HepG2 cultured with AA3 ALA or AA3GLY (strong inducers of CYP3A4) versus AA3 VAL (weak induction of CYP3A4). 	CYP3A4	16710	16716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:84	This analysis linked induction of mature hepatic markers such as CYP3A4, Phosphoenolpyruvate Carboxykinase, and glutamine synthetase to an increased phosphorylation of S6, Amp-Activated Protein Kinase, and AKT. 	CYP3A4	16784	16790	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:87	From these pathways, we were able to specifically link mTORC1 signaling to the induction of CYP3A4, as addition of the mTORC1 inhibitor rapamycin blocked the induction of CYP3A4, while Amp-Activated Protein Kinase phosphorylation and ATF4 levels remained unchanged (Supplementary Fig. 	CYP3A4	17201	17207	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:87	From these pathways, we were able to specifically link mTORC1 signaling to the induction of CYP3A4, as addition of the mTORC1 inhibitor rapamycin blocked the induction of CYP3A4, while Amp-Activated Protein Kinase phosphorylation and ATF4 levels remained unchanged (Supplementary Fig. 	CYP3A4	17280	17286	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:88	Furthermore, knockout of the upstream regulators of Amp-Activated Protein Kinase and eIF2alpha, LKB1 and GCN2, did not affect CYP3A4 levels both in control media or Aa3 Medium Supplemented With 2% Glycine media (Supplementary Fig B, C). 	CYP3A4	17520	17526	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:89	In both HepG2, HLC and HC3X, mTORC1 appeared to regulate CYP3A4 expression rather than translation. 	CYP3A4	17688	17694	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:90	Finally, although Knockout of the mTORC1 inhibitor Tuberous sclerosis (TSC)1 was not sufficient for driving maturation in HepG2, culture of TSC1 Knockout HepG2 in Aa3 Medium Supplemented With 2% Glycine medium yielded an even greater induction of CYP3A4 compared with wild-type HepG2^. 	CYP3A4	17978	17984	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:99	However, we only found an increase in CYP3A4 and the gluconeogenic genes, G6PC and Phosphoenolpyruvate Carboxykinase, when HC6X were also cultured with Aa3 Medium Supplemented With 2% Glycine, indicating that mitochondrial biogenesis is not sufficient to drive maturation (Supplementary Fig E, F). 	CYP3A4	20192	20198	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:100	The transcriptome of HC6X Aa3 Medium Supplemented With 2% Glycine D40 was similar to that of HC3X Aa3 Medium Supplemented With 2% Glycine D40, even if perhaps slightly closer to that of Primary Human Hepatocytes caused a significant decrease in CYP3A4 activity and to a lesser extent also decreased global maturity (Fig. 	CYP3A4	20697	20703	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:108	In accordance, we found that HC6X Aa3 Medium Supplemented With 2% Glycine D40 stained positive for CYP3A4, with several cells displaying a binucleated phenotype (Supplementary Fig. 	CYP3A4	22447	22453	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:136	Of the investigated signaling pathways, we only found inhibition of mTORC1 to be able to prevent the induction of CYP3A4 under conditions of AA supplementation. 	CYP3A4	28093	28099	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:138	Nevertheless, the sole activation of mTORC1 through the genetic deletion of TSC1 was not sufficient to induce CYP3A4 expression. 	CYP3A4	28362	28368	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:269	CYP3A4-dependent metabolization was determined using the fluorometric probe BFC as previously described^. 	CYP3A4	47862	47868	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:279	To assess the respective metabolization capacities, models were treated with a cocktail consisting of the probe substrates midazolam (10 M), dextromethorphan (20 M), phenacetin (100 M), and tolbutamide (100 M), to determine the activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. 	CYP3A4	49323	49329	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:91	Moreover it is important to emphasize that tocilizumab decreases the concentration of several medications as a cytochrome P450, isoenzyme CYP3A4 inducer in terms of antagonisms or synergy but this is not yet entirely clear (;. 	CYP3A4	14747	14753	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:92	Several drugs, such as CYP3A4 inhibitors, increase concentration of colchicine and attention should be paid when the latter is used with cisplatin or vinca alkaloids. 	CYP3A4	14859	14865	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	CYP3A4	16607	16613	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:104	Enzalutamide, recognized as a strong CYP3A4 and a moderate CYP2C9 and CYP2C19 inducer, significantly reduces concentrations of several anti-HIV agents such as darunavir, ritonavir, etravirine, and raltegravir. 	CYP3A4	16652	16658	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7402159_OgerInput.txtOger_out.csv:190	SIM-53B may inhibit some of the cytochrome P450 isoforms such as CYP1A2, CYP2C9 and CYP3A4. 	CYP3A4	34201	34207	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:72	One main source of risk is inhibition of CYP3A4 by lopinavir/ritonavir (perpetrator). 	CYP3A4	11945	11951	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:73	Given that ritonavir irreversibly inhibits CYP3A4, the inhibitory effect may last up to 5 days after stopping ritonavir. 	CYP3A4	12033	12039	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:56	For the determination of murine CYP activities, substrates of orthologous human CYP forms were used: CYP1A1/2, ethoxyresorufin (murine CYP1A2); CYP2C9, diclofenac (murine 2C subfamily); CYP2C19, diazepam (murine 2C subfamily); CYP2D6, bufuralol (murine 2D22) and CYP3A4, midazolam (murine CYP3A11 and 3A13). 	CYP3A4	8312	8318	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:88	Even though in humans the differences are subtler, it is known that the CYP3A4 activity features apparent sexual dimorphism with higher activity in women due to differences in growth hormone patterns. 	CYP3A4	12330	12336	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:112	CYP3A4 contributes to the oxidation of many steroids, and its activity in humans is sexually dimorphic. 	CYP3A4	16109	16115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:113	The exact mechanism for sex differences in CYP3A4 (and other CYPs) remains elusive but may include altered growth hormone signalling. 	CYP3A4	16256	16262	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7645423_OgerInput.txtOger_out.csv:93	Kratom extracts^ and mitragynine^, have been tested as inhibitors of several CYPs, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. 	CYP3A4	15791	15797	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7707949_OgerInput.txtOger_out.csv:97	In the context of Hepatocellular Carcinoma, treatment with 5-AZA conduced to tumor regression and a shift to a more differentiated phenotype, which was associated with regional demethylation of CpG regions upstream of the liver-specific genes SLC10A1, CYP3A4, ALB, and miR-122, which were downregulated pretreatments. 	CYP3A4	14167	14173	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:114	This system allowed us to simultaneously test whether the human orthologs of the dCYP enzymes identified within our in vivo screening were also involved in metabolizing PCB 28, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (drosophila ortholog: Cyp18a1) and CYP3A4 (drosophila ortholog: Cyp9f2) in concentration ranges corresponding to their endogenous abundance in the liver^. 	CYP3A4	18686	18692	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:117	All of the enzymatic activity on PCB 28 was found in the fraction containing CYP1A2, CYP2E1 and CYP3A4. 	CYP3A4	19293	19299	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:155	In vitro, PCB 28 could be converted into all OH-metabolites by the combination of six recombinant human cytochromes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), which are strongly expressed in the liver and thus reflect its metabolic properties. 	CYP3A4	25831	25837	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:66	The cytochrome through which more conflicts occur was CYP3A4 (n = 67), followed by 3A5 (n = 27) and 1A2 (n = 27). 	CYP3A4	13072	13078	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP3A4	13247	13253	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A4	13428	13434	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A4	13472	13478	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP3A4	14047	14053	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP3A4	15126	15132	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:88	As can be seen, the prescription of oral drugs whose metabolism is related to enzymes frequently altered in the study population, is reduced by between 20 and 100%, in favor of intramuscular prescriptions that either do not have liver metabolism, such as Paliperidone, which increases by 186.95%, or whose main route of metabolism is associated with an enzyme that usually has no alterations, such as Aripiprazole, whose prescriptions increase by 100%, predominantly metabolized by CYP3A4. 	CYP3A4	17492	17498	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP3A4	21073	21079	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:103	The pharmacogenetic profile of the population (CYP1A2 HI: 0.86; CYP2D6 EM: 0.85; CYP3A4 EM: 0.91) could explain the need to apply a higher dose with its consequent adverse effects in patients treated with olanzapine, clozapine, or asenapine, all related to CYP1A2, while favoring the use of aripiprazole or risperidone in those who have a wt-like haplotype in CYP2D6 and CYP3A4 cytochromes, a situation frequently found in our population. 	CYP3A4	21363	21369	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:105	Aripiprazole is a neuroleptic whose metabolism develops predominantly in the liver, through the CYP450 system, specifically by CYP2D6 and CYP3A4 cytochromes which, in the vast majority of our patients (more than 80%), presented an EM phenotype, favoring its use. 	CYP3A4	21840	21846	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:119	It should be noted that the use of DEPOT presentations of drugs such as paliperidone (not metabolized by the CYP450 system) or aripiprazole (whose predominant pathway within the CYP450 system is CYP3A4, which presents a wt-like genotype in the vast majority of the study population) has been the solution for the majority of problematic cases, because of the pharmacogenetic profile of the sample, even considering that each patient was studied individually attending its personal genetic implications. 	CYP3A4	24986	24992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP3A4	6107	6113	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:193	CYP3A5 catalyzes a comparable range of reactions as CYP3A4 but its role in drug and steroid metabolism is limited due to its generally low activity and expression in a relatively small percentage of individuals [,. 	CYP3A5	33007	33013	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP3A5	70371	70377	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP3A5	24795	24801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:67	Taking only neuroleptic therapy into account, 78 interactions were tested, most of which occur through cytochromes CYP3A4 (n = 27), CYP3A5 (n = 27), and CYP1A2 (n = 17). 	CYP3A5	13264	13270	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:68	Following the modification of pharmacotherapy motivated by the pharmacogenetic study, these interactions were reduced to 135 (CYP3A4, 57; CYP2D6, 22; CYP2C9, 19) and 25 (CYP3A4, 10; CYP3A5, 10; CYP1A2, 5), achieving a reduction in pharmacological interactions of 26.10% (p < 0.05) and. 	CYP3A5	13484	13490	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP3A5	14059	14065	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:81	Most patients had an EM phenotype (85.95%, n = 159; 91.49%, n = 172) with respect to CYP2D6 cytochromes (n = 183) and CYP3A4 (n = 188), and PM (Poor Metabolizer) phenotype (87.85%, n = 159) was the most frequent with respect to CYP3A5 cytochrome (n = 187). 	CYP3A5	15236	15242	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP3A5	15602	15608	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:82	In total, taking into account the liver metabolism, mediated through the previously mentioned CYP450 system members, from both antipsychotic therapy and concomitant therapy, 458 conflicts were discovered between the patients prescription and genotype, with most conflicts associated with concomitant therapy occurring through cytochrome CYP3A5 (n = 57), and those primarily related to the metabolism of neuroleptics occurring through CYP1A2 (n = 80); taking into account the minor metabolizers of the studied antipsychotics, the cytochrome with the highest number of incidences found was CYP3A5 (n = 93). 	CYP3A5	15853	15859	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:113	Therefore, further elucidation of the function of rs17102977 and mainly the whole gene locus 1p33 containing also CYP4B1, CYP4A11, CYP4Z1, and CYP4A22 genes is needed. 	CYP4A	16310	16315	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:113	Therefore, further elucidation of the function of rs17102977 and mainly the whole gene locus 1p33 containing also CYP4B1, CYP4A11, CYP4Z1, and CYP4A22 genes is needed. 	CYP4A	16331	16336	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:131	Thus, although previous studies identified Amino Acids as important for hepatocyte survival, proliferation, and protein synthesis^,, we here demonstrate that increasing Amino Acids to levels 30-fold above that of typical hepatocyte media, actively induces a metabolic switch, as well as Cytochrome P450 enzyme expression and function (Supplementary Table. 	Cytochrome P450	27125	27140	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:131	Thus, although previous studies identified Amino Acids as important for hepatocyte survival, proliferation, and protein synthesis^,, we here demonstrate that increasing Amino Acids to levels 30-fold above that of typical hepatocyte media, actively induces a metabolic switch, as well as Cytochrome P450 enzyme expression and function (Supplementary Table. 	Cytochrome P450	27125	27140	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:273	Comparative Cytochrome P450 biotransformation studies were performed to assess functionality across a number of gold standard primary hepatocyte models. 	Cytochrome P450	48297	48312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:273	Comparative Cytochrome P450 biotransformation studies were performed to assess functionality across a number of gold standard primary hepatocyte models. 	Cytochrome P450	48297	48312	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	Cytochrome P450	16453	16468	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:103	If one considers that the metabolism of most drugs is catalyzed by the enzyme group of Cytochrome P450, composed of a large number of isoenzymes, the most important of which in the metabolism of drugs are CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. 	Cytochrome P450	16453	16468	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:108	Tocilizumab decreases concentrations of many anticancer drugs due to interference with Cytochrome P450. 	Cytochrome P450	17381	17396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7239789_OgerInput.txtOger_out.csv:108	Tocilizumab decreases concentrations of many anticancer drugs due to interference with Cytochrome P450. 	Cytochrome P450	17381	17396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:21	Cytochrome P450 monooxygenases are known to be involved in the biosynthesis of numerous secondary metabolites and stress responses of plants to herbicides and pathogens^-. 	Cytochrome P450	4622	4637	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7283212_OgerInput.txtOger_out.csv:21	Cytochrome P450 monooxygenases are known to be involved in the biosynthesis of numerous secondary metabolites and stress responses of plants to herbicides and pathogens^-. 	Cytochrome P450	4622	4637	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:208	Previous studies reported that Mycophenolic Acid metabolized in inactive MPAG and AcMPAG metabolites by Cytochrome P450. 	Cytochrome P450	32512	32527	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:208	Previous studies reported that Mycophenolic Acid metabolized in inactive MPAG and AcMPAG metabolites by Cytochrome P450. 	Cytochrome P450	32512	32527	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:217	Meanwhile QC further improved the therapeutic efficacy by increasing the bioavailability of Mycophenolic Acid through inhibiting Cytochrome P450 enzyme. 	Cytochrome P450	34427	34442	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:217	Meanwhile QC further improved the therapeutic efficacy by increasing the bioavailability of Mycophenolic Acid through inhibiting Cytochrome P450 enzyme. 	Cytochrome P450	34427	34442	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:3	Thus, we investigated the potential of naturally occurring Alternaria toxin mixtures to induce Cytochrome P450 1A1/1A2/1B1 activity. 	Cytochrome P450	396	411	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:3	Thus, we investigated the potential of naturally occurring Alternaria toxin mixtures to induce Cytochrome P450 1A1/1A2/1B1 activity. 	Cytochrome P450	396	411	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:5	Sub-cytotoxic concentrations of the two toxin mixtures, as well as ATX-I, ATX-II and AOH, exhibited dose-dependent enhancements of Cytochrome P450 1 activity. 	Cytochrome P450	876	891	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:5	Sub-cytotoxic concentrations of the two toxin mixtures, as well as ATX-I, ATX-II and AOH, exhibited dose-dependent enhancements of Cytochrome P450 1 activity. 	Cytochrome P450	876	891	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:30	Besides, several Cytochrome P450 isoforms are frequently induced by their own substrates. 	Cytochrome P450	5130	5145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:30	Besides, several Cytochrome P450 isoforms are frequently induced by their own substrates. 	Cytochrome P450	5130	5145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:31	Hence, prominent ligands of the Aryl Hydrocarbon Receptor behave also as inducers of Cytochrome P450 1A1 activity, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and benzo[a]pyrene (B[a]P), which are suggested to be involved in increased breast cancer risk. 	Cytochrome P450	5288	5303	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:31	Hence, prominent ligands of the Aryl Hydrocarbon Receptor behave also as inducers of Cytochrome P450 1A1 activity, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and benzo[a]pyrene (B[a]P), which are suggested to be involved in increased breast cancer risk. 	Cytochrome P450	5288	5303	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:32	Furthermore, distinctively elevated Cytochrome P450 1A1 and Cytochrome P450 1B1 protein expression as well as 7-Ethoxy-Resorufin-O-Deethylase activity were previously reported for breast cancer tissues in comparison to adjacent non-tumor tissues. 	Cytochrome P450	5494	5509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:32	Furthermore, distinctively elevated Cytochrome P450 1A1 and Cytochrome P450 1B1 protein expression as well as 7-Ethoxy-Resorufin-O-Deethylase activity were previously reported for breast cancer tissues in comparison to adjacent non-tumor tissues. 	Cytochrome P450	5494	5509	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:32	Furthermore, distinctively elevated Cytochrome P450 1A1 and Cytochrome P450 1B1 protein expression as well as 7-Ethoxy-Resorufin-O-Deethylase activity were previously reported for breast cancer tissues in comparison to adjacent non-tumor tissues. 	Cytochrome P450	5518	5533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:32	Furthermore, distinctively elevated Cytochrome P450 1A1 and Cytochrome P450 1B1 protein expression as well as 7-Ethoxy-Resorufin-O-Deethylase activity were previously reported for breast cancer tissues in comparison to adjacent non-tumor tissues. 	Cytochrome P450	5518	5533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:35	A standard method used to determine Cytochrome P450 1A1 enzyme activity induction upon exposure to Aryl Hydrocarbon Receptor ligands is the 7-ethoxyresorufin-O-deethylase assay. 	Cytochrome P450	6063	6078	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:35	A standard method used to determine Cytochrome P450 1A1 enzyme activity induction upon exposure to Aryl Hydrocarbon Receptor ligands is the 7-ethoxyresorufin-O-deethylase assay. 	Cytochrome P450	6063	6078	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6337	6352	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6337	6352	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6370	6385	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6370	6385	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6394	6409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:36	The dealkylation of 7-ethoxyresorufin (7-ER) yielding the fluorescent substance resorufin was shown to be primarily exerted through Cytochrome P450 1A1, followed by Cytochrome P450 1A2 and Cytochrome P450 1B1. 	Cytochrome P450	6394	6409	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	Cytochrome P450	6503	6518	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	Cytochrome P450	6503	6518	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	Cytochrome P450	6545	6560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	Cytochrome P450	6545	6560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:38	Previous studiesuncovered the induction of Cytochrome P450 1A1 expression to be Aryl Hydrocarbon Receptor dependent for both dibenzo-ALPHA-pyrones in murine hepatoma cells and AOH in human esophageal cancer cells, whereas the latter turned out to be irrelevant for the genotoxic capabilities of AOH. 	Cytochrome P450	6666	6681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:38	Previous studiesuncovered the induction of Cytochrome P450 1A1 expression to be Aryl Hydrocarbon Receptor dependent for both dibenzo-ALPHA-pyrones in murine hepatoma cells and AOH in human esophageal cancer cells, whereas the latter turned out to be irrelevant for the genotoxic capabilities of AOH. 	Cytochrome P450	6666	6681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:39	Although data on the metabolism of altertoxins is scarce, ATX-II was reported to induce Cytochrome P450 1A1 activity and raise Cytochrome P450 1A1 transcript levels in KYSE 510 cells. 	Cytochrome P450	7011	7026	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:39	Although data on the metabolism of altertoxins is scarce, ATX-II was reported to induce Cytochrome P450 1A1 activity and raise Cytochrome P450 1A1 transcript levels in KYSE 510 cells. 	Cytochrome P450	7011	7026	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:39	Although data on the metabolism of altertoxins is scarce, ATX-II was reported to induce Cytochrome P450 1A1 activity and raise Cytochrome P450 1A1 transcript levels in KYSE 510 cells. 	Cytochrome P450	7050	7065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:39	Although data on the metabolism of altertoxins is scarce, ATX-II was reported to induce Cytochrome P450 1A1 activity and raise Cytochrome P450 1A1 transcript levels in KYSE 510 cells. 	Cytochrome P450	7050	7065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:43	Hence, this study aimed to uncover the potential of naturally occurring mixtures of Alternaria toxins to enhance Cytochrome P450 1 activity and their combinatory effects in this respect applying the 7-Ethoxy-Resorufin-O-Deethylase assay. 	Cytochrome P450	7751	7766	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:43	Hence, this study aimed to uncover the potential of naturally occurring mixtures of Alternaria toxins to enhance Cytochrome P450 1 activity and their combinatory effects in this respect applying the 7-Ethoxy-Resorufin-O-Deethylase assay. 	Cytochrome P450	7751	7766	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:45	Further, the Cytochrome P450 1 activating potential of single Alternaria toxins, as well as binary mixtures according to the complex extracts, was investigated utilizing the estrogen-sensitive mammary adenocarcinoma cell line MCF-7. 	Cytochrome P450	8176	8191	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:45	Further, the Cytochrome P450 1 activating potential of single Alternaria toxins, as well as binary mixtures according to the complex extracts, was investigated utilizing the estrogen-sensitive mammary adenocarcinoma cell line MCF-7. 	Cytochrome P450	8176	8191	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:99	Thus, the study at hand investigated the potential of complex Alternaria toxin mixtures as well as selected single toxins in corresponding binary mixtures to affect Cytochrome P450 1 enzyme activity in estrogen-sensitive MCF-7 mammary cancer cells. 	Cytochrome P450	17272	17287	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:99	Thus, the study at hand investigated the potential of complex Alternaria toxin mixtures as well as selected single toxins in corresponding binary mixtures to affect Cytochrome P450 1 enzyme activity in estrogen-sensitive MCF-7 mammary cancer cells. 	Cytochrome P450	17272	17287	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:100	The induction of both Cytochrome P450 1A1 mRNA transcription and the according enzymatic activity was reported to serve as indicators for Aryl Hydrocarbon Receptor activation. 	Cytochrome P450	17378	17393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:100	The induction of both Cytochrome P450 1A1 mRNA transcription and the according enzymatic activity was reported to serve as indicators for Aryl Hydrocarbon Receptor activation. 	Cytochrome P450	17378	17393	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:102	In contrast, E2 showed no estrogen-related induction of Cytochrome P450 1 activity in our MCF-7 cell model (a), which was suggested in a previously published study. 	Cytochrome P450	17782	17797	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:102	In contrast, E2 showed no estrogen-related induction of Cytochrome P450 1 activity in our MCF-7 cell model (a), which was suggested in a previously published study. 	Cytochrome P450	17782	17797	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:103	Both, the Complete Extract and the Reduced Extract (stripped from the two perylene quinones ATX-II and STTX-III), led to dose-dependent enhancements of Cytochrome P450 1A1 activity (a). 	Cytochrome P450	18043	18058	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:103	Both, the Complete Extract and the Reduced Extract (stripped from the two perylene quinones ATX-II and STTX-III), led to dose-dependent enhancements of Cytochrome P450 1A1 activity (a). 	Cytochrome P450	18043	18058	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:104	This is in line with a previous report of the Complete Extract to increase Cytochrome P450 1A1 expression levels in Ishikawa cells at concentrations comparable to the extracts 7-Ethoxy-Resorufin-O-Deethylase enzyme activity induction in MCF-7. 	Cytochrome P450	18152	18167	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:104	This is in line with a previous report of the Complete Extract to increase Cytochrome P450 1A1 expression levels in Ishikawa cells at concentrations comparable to the extracts 7-Ethoxy-Resorufin-O-Deethylase enzyme activity induction in MCF-7. 	Cytochrome P450	18152	18167	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:105	Notably, the REs capability to induce Cytochrome P450 1 activity surpassed the potent activity of the Complete Extract at higher concentrations. 	Cytochrome P450	18359	18374	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:105	Notably, the REs capability to induce Cytochrome P450 1 activity surpassed the potent activity of the Complete Extract at higher concentrations. 	Cytochrome P450	18359	18374	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:109	Single known extracts constituents, such as ATX-II and AOH were previously shown to activate the Aryl Hydrocarbon Receptor, increase Cytochrome P450 1A1 enzyme activity, which was shown via 7-Ethoxy-Resorufin-O-Deethylase assay and impact Cytochrome P450 1A1 mRNA transcription at corresponding concentrations in KYSE 510 oesophageal cancer cells, while Alternariol Monomethyl Ether exhibited its potency primarily in HepG2 cells. 	Cytochrome P450	19266	19281	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:109	Single known extracts constituents, such as ATX-II and AOH were previously shown to activate the Aryl Hydrocarbon Receptor, increase Cytochrome P450 1A1 enzyme activity, which was shown via 7-Ethoxy-Resorufin-O-Deethylase assay and impact Cytochrome P450 1A1 mRNA transcription at corresponding concentrations in KYSE 510 oesophageal cancer cells, while Alternariol Monomethyl Ether exhibited its potency primarily in HepG2 cells. 	Cytochrome P450	19266	19281	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:109	Single known extracts constituents, such as ATX-II and AOH were previously shown to activate the Aryl Hydrocarbon Receptor, increase Cytochrome P450 1A1 enzyme activity, which was shown via 7-Ethoxy-Resorufin-O-Deethylase assay and impact Cytochrome P450 1A1 mRNA transcription at corresponding concentrations in KYSE 510 oesophageal cancer cells, while Alternariol Monomethyl Ether exhibited its potency primarily in HepG2 cells. 	Cytochrome P450	19372	19387	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:109	Single known extracts constituents, such as ATX-II and AOH were previously shown to activate the Aryl Hydrocarbon Receptor, increase Cytochrome P450 1A1 enzyme activity, which was shown via 7-Ethoxy-Resorufin-O-Deethylase assay and impact Cytochrome P450 1A1 mRNA transcription at corresponding concentrations in KYSE 510 oesophageal cancer cells, while Alternariol Monomethyl Ether exhibited its potency primarily in HepG2 cells. 	Cytochrome P450	19372	19387	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:110	Testing single toxins revealed dose-dependent enzyme activation for ATX-I, ATX-II and AOH; in contrast, no evident induction of Cytochrome P450 1 enzyme activity was exerted by Alternariol Monomethyl Ether (b). 	Cytochrome P450	19692	19707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:110	Testing single toxins revealed dose-dependent enzyme activation for ATX-I, ATX-II and AOH; in contrast, no evident induction of Cytochrome P450 1 enzyme activity was exerted by Alternariol Monomethyl Ether (b). 	Cytochrome P450	19692	19707	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:112	Previously, ATX-II was found to increase Cytochrome P450 1 transcription and activity in oesophageal cancer cells starting at a concentration of 0.05 M and 0.1 M, respectively, indicating a higher sensitivity to Aryl Hydrocarbon Receptor activation compared to the breast cancer cell line MCF-7. 	Cytochrome P450	20050	20065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:112	Previously, ATX-II was found to increase Cytochrome P450 1 transcription and activity in oesophageal cancer cells starting at a concentration of 0.05 M and 0.1 M, respectively, indicating a higher sensitivity to Aryl Hydrocarbon Receptor activation compared to the breast cancer cell line MCF-7. 	Cytochrome P450	20050	20065	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:120	This enhancement of Cytochrome P450 1 enzyme activity was linked to Aryl Hydrocarbon Receptor activation. 	Cytochrome P450	21543	21558	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:120	This enhancement of Cytochrome P450 1 enzyme activity was linked to Aryl Hydrocarbon Receptor activation. 	Cytochrome P450	21543	21558	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:122	Preceding published experiments showed inconclusive efficacy of Alternariol Monomethyl Ether towards Cytochrome P450 1 enzyme activity alteration, increasing 7-Ethoxy-Resorufin-O-Deethylase activity in HepG2 cells at 10 M and in KYSE 510 at 50 M. This effect was diminished again at 50 M in HepG2, possibly due to the onset of cytotoxicity. 	Cytochrome P450	21872	21887	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:122	Preceding published experiments showed inconclusive efficacy of Alternariol Monomethyl Ether towards Cytochrome P450 1 enzyme activity alteration, increasing 7-Ethoxy-Resorufin-O-Deethylase activity in HepG2 cells at 10 M and in KYSE 510 at 50 M. This effect was diminished again at 50 M in HepG2, possibly due to the onset of cytotoxicity. 	Cytochrome P450	21872	21887	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26595	26610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26595	26610	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26619	26634	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26619	26634	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26771	26786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:148	Of note, B[a]P was shown to elevate Cytochrome P450 1A1 and Cytochrome P450 1B1 mRNA in MCF-7 cells; therefore, enhanced 7-Ethoxy-Resorufin-O-Deethylase enzyme activity cannot exclusively be ascribed to a single Cytochrome P450 1 enzyme as 7-ER poses a substrate for several above mentioned isoforms. 	Cytochrome P450	26771	26786	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:149	Nonetheless, previous studies on AOH, Alternariol Monomethyl Ether, and ATX-II as well as on the Alternaria extracts used showed Cytochrome P450 1A1 mRNA enhancements in various cell lines. 	Cytochrome P450	26989	27004	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:149	Nonetheless, previous studies on AOH, Alternariol Monomethyl Ether, and ATX-II as well as on the Alternaria extracts used showed Cytochrome P450 1A1 mRNA enhancements in various cell lines. 	Cytochrome P450	26989	27004	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:150	Therefore, a high correlation of 7-Ethoxy-Resorufin-O-Deethylase enzyme activity towards Cytochrome P450 1A1 could be assumed for the toxins and mixtures applied here as well. 	Cytochrome P450	27139	27154	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:150	Therefore, a high correlation of 7-Ethoxy-Resorufin-O-Deethylase enzyme activity towards Cytochrome P450 1A1 could be assumed for the toxins and mixtures applied here as well. 	Cytochrome P450	27139	27154	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:162	Nonetheless, further interference by other compounds not tested (or not identified) within the complex mixture affecting the Cytochrome P450 1 enzyme activity needs to be considered for interpretation of the current data. 	Cytochrome P450	29525	29540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:162	Nonetheless, further interference by other compounds not tested (or not identified) within the complex mixture affecting the Cytochrome P450 1 enzyme activity needs to be considered for interpretation of the current data. 	Cytochrome P450	29525	29540	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:164	We could decipher the two perylene quinone derivates ATX-I and ATX-II, as well as the dibenzo-ALPHA-pyrone AOH, as participants towards the Cytochrome P450 1A1 activity induction exerted by complex Alternaria extracts in mammary cancer cells and their combinatory effects to be major contributors. 	Cytochrome P450	30030	30045	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:164	We could decipher the two perylene quinone derivates ATX-I and ATX-II, as well as the dibenzo-ALPHA-pyrone AOH, as participants towards the Cytochrome P450 1A1 activity induction exerted by complex Alternaria extracts in mammary cancer cells and their combinatory effects to be major contributors. 	Cytochrome P450	30030	30045	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:118	Issues addressed at these research meetings (International Conferences on Cytochrome P450, https://www.p450meetings.com) include biochemistry, biophysics, gene regulation, and pharmaceutical and biotechnology applications. 	Cytochrome P450	16010	16025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:118	Issues addressed at these research meetings (International Conferences on Cytochrome P450, https://www.p450meetings.com) include biochemistry, biophysics, gene regulation, and pharmaceutical and biotechnology applications. 	Cytochrome P450	16010	16025	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:75	Increase in Cytochrome P450 activity has been observed even after short-course treatment with lopinavir/ritonavir. 	Cytochrome P450	12215	12230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7454591_OgerInput.txtOger_out.csv:75	Increase in Cytochrome P450 activity has been observed even after short-course treatment with lopinavir/ritonavir. 	Cytochrome P450	12215	12230	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7465820_OgerInput.txtOger_out.csv:140	Cytochrome P450 genes, which are involved in plant development, antioxidant, and detoxification of pollutants, are also involved in plant defense by protecting from various biotic and abiotic stresses. 	Cytochrome P450	22865	22880	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7465820_OgerInput.txtOger_out.csv:140	Cytochrome P450 genes, which are involved in plant development, antioxidant, and detoxification of pollutants, are also involved in plant defense by protecting from various biotic and abiotic stresses. 	Cytochrome P450	22865	22880	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:201	Therefore, we searched the genome of F. filiformis for proteins with a P450 conserved domain using the NCBI CDD tool and BLASTp and also by homology BLAST in the Fungal Cytochrome P450 Database (p450.riceblast.snu.ac.kr/index.php? 	Cytochrome P450	39799	39814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7568368_OgerInput.txtOger_out.csv:201	Therefore, we searched the genome of F. filiformis for proteins with a P450 conserved domain using the NCBI CDD tool and BLASTp and also by homology BLAST in the Fungal Cytochrome P450 Database (p450.riceblast.snu.ac.kr/index.php? 	Cytochrome P450	39799	39814	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:41	The homolog of MaCYP71CD2 in neem (AiCYP71CD2) was identified, the homolog of MaCYP71BQ5 (a characterized Cytochrome P450 from M. azedarach) in neem was fragmented. 	Cytochrome P450	5635	5650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:41	The homolog of MaCYP71CD2 in neem (AiCYP71CD2) was identified, the homolog of MaCYP71BQ5 (a characterized Cytochrome P450 from M. azedarach) in neem was fragmented. 	Cytochrome P450	5635	5650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:61	Extensive bioinformatic analysis of unigenes involving phylogenetic analysis, domain prediction, and molecular docking further provided 22 candidates for the putative biosynthetic pathway, including 1 2,3-Oxidosqualene Cyclase unigene, 2 Alcohol Dehydrogenase unigenes, 12 Cytochrome P450 unigenes, 2 Acyltransferase unigenes, and 5 Esterase unigenes. 	Cytochrome P450	8834	8849	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:61	Extensive bioinformatic analysis of unigenes involving phylogenetic analysis, domain prediction, and molecular docking further provided 22 candidates for the putative biosynthetic pathway, including 1 2,3-Oxidosqualene Cyclase unigene, 2 Alcohol Dehydrogenase unigenes, 12 Cytochrome P450 unigenes, 2 Acyltransferase unigenes, and 5 Esterase unigenes. 	Cytochrome P450	8834	8849	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:89	The length of two Cytochrome P450 unigenes (transcript/16971 and transcript/16742) was 1536 bp and 1527 bp, and they encoded proteins consisting of 511 and 508 amino acids, respectively. 	Cytochrome P450	12552	12567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:89	The length of two Cytochrome P450 unigenes (transcript/16971 and transcript/16742) was 1536 bp and 1527 bp, and they encoded proteins consisting of 511 and 508 amino acids, respectively. 	Cytochrome P450	12552	12567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:118	Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase are supposed to be involved in azadirachtin downstream pathway and thus their encoding-unigenes were chosen as candidates. 	Cytochrome P450	16694	16709	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:118	Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase are supposed to be involved in azadirachtin downstream pathway and thus their encoding-unigenes were chosen as candidates. 	Cytochrome P450	16694	16709	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:126	Among all the Differentially Expressed Genes in fruit and leaf transcriptome data, Differentially Expressed Genes encoding Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase and Esterase were discovered. 	Cytochrome P450	18053	18068	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:126	Among all the Differentially Expressed Genes in fruit and leaf transcriptome data, Differentially Expressed Genes encoding Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase and Esterase were discovered. 	Cytochrome P450	18053	18068	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:129	As for Cytochrome P450, sixteen Differentially Expressed Genes encoded Cytochrome P450 and ten Differentially Expressed Genes were selected. 	Cytochrome P450	18322	18337	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:129	As for Cytochrome P450, sixteen Differentially Expressed Genes encoded Cytochrome P450 and ten Differentially Expressed Genes were selected. 	Cytochrome P450	18322	18337	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:129	As for Cytochrome P450, sixteen Differentially Expressed Genes encoded Cytochrome P450 and ten Differentially Expressed Genes were selected. 	Cytochrome P450	18386	18401	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:129	As for Cytochrome P450, sixteen Differentially Expressed Genes encoded Cytochrome P450 and ten Differentially Expressed Genes were selected. 	Cytochrome P450	18386	18401	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:132	Among all the Differentially Expressed Genes in fruit and leaf transcriptome data, Differentially Expressed Genes encoding Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase were identified. 	Cytochrome P450	18955	18970	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:132	Among all the Differentially Expressed Genes in fruit and leaf transcriptome data, Differentially Expressed Genes encoding Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase were identified. 	Cytochrome P450	18955	18970	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:134	There were 16 Differentially Expressed Genes encoding Cytochrome P450, 10 out of these Differentially Expressed Genes were selected. 	Cytochrome P450	19263	19278	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:134	There were 16 Differentially Expressed Genes encoding Cytochrome P450, 10 out of these Differentially Expressed Genes were selected. 	Cytochrome P450	19263	19278	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:146	According to the phylogenetic analysis of unigenes encoding Cytochrome P450, 5 transcripts (transcript/16057, transcript/16577, transcript/16950, transcript/16777, and transcript/17001) were grouped with members in CYP71 and CYP72 clades, whose members are reported to be involved in terpenoid biosynthesis. 	Cytochrome P450	20593	20608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:146	According to the phylogenetic analysis of unigenes encoding Cytochrome P450, 5 transcripts (transcript/16057, transcript/16577, transcript/16950, transcript/16777, and transcript/17001) were grouped with members in CYP71 and CYP72 clades, whose members are reported to be involved in terpenoid biosynthesis. 	Cytochrome P450	20593	20608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:152	According to Cytochrome P450 domain analysis, transcript/17636 and transcript/16971 contained the same CypX domain as CYP81B1. 	Cytochrome P450	21407	21422	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:152	According to Cytochrome P450 domain analysis, transcript/17636 and transcript/16971 contained the same CypX domain as CYP81B1. 	Cytochrome P450	21407	21422	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:157	Therefore, 5 Differentially Expressed Genes (transcript/16057, transcript/ 16,577, transcript/17057, transcript/16777, and transcript/17001) contained domains found within Cytochrome P450 oxidases and the others contained domain found within Cytochrome P450 hydroxylase. 	Cytochrome P450	22123	22138	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:157	Therefore, 5 Differentially Expressed Genes (transcript/16057, transcript/ 16,577, transcript/17057, transcript/16777, and transcript/17001) contained domains found within Cytochrome P450 oxidases and the others contained domain found within Cytochrome P450 hydroxylase. 	Cytochrome P450	22123	22138	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:157	Therefore, 5 Differentially Expressed Genes (transcript/16057, transcript/ 16,577, transcript/17057, transcript/16777, and transcript/17001) contained domains found within Cytochrome P450 oxidases and the others contained domain found within Cytochrome P450 hydroxylase. 	Cytochrome P450	22193	22208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:157	Therefore, 5 Differentially Expressed Genes (transcript/16057, transcript/ 16,577, transcript/17057, transcript/16777, and transcript/17001) contained domains found within Cytochrome P450 oxidases and the others contained domain found within Cytochrome P450 hydroxylase. 	Cytochrome P450	22193	22208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:221	Upon bioinformatic analysis of these Differentially Expressed Genes, 2 transcripts (transcript/18833 and transcript/19291) encoding Alcohol Dehydrogenase, 12 transcripts encoding Cytochrome P450, 2 Acyltransferase transcripts (transcript/17792 and transcript/18214), and 5 transcripts encoding Esterase, were selected as candidates in the azadirachtin A downstream pathway. 	Cytochrome P450	31405	31420	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:221	Upon bioinformatic analysis of these Differentially Expressed Genes, 2 transcripts (transcript/18833 and transcript/19291) encoding Alcohol Dehydrogenase, 12 transcripts encoding Cytochrome P450, 2 Acyltransferase transcripts (transcript/17792 and transcript/18214), and 5 transcripts encoding Esterase, were selected as candidates in the azadirachtin A downstream pathway. 	Cytochrome P450	31405	31420	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:226	MaCYP71BQ5 is the Cytochrome P450 found to be involved in melianol formation. 	Cytochrome P450	32209	32224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:226	MaCYP71BQ5 is the Cytochrome P450 found to be involved in melianol formation. 	Cytochrome P450	32209	32224	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:239	Finally, 22 unigenes encoding enzymes including 2,3-Oxidosqualene Cyclase, Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase were selected as candidates involved in azadirachtin A downstream pathway. 	Cytochrome P450	34033	34048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:239	Finally, 22 unigenes encoding enzymes including 2,3-Oxidosqualene Cyclase, Alcohol Dehydrogenase, Cytochrome P450, Acyltransferase, and Esterase were selected as candidates involved in azadirachtin A downstream pathway. 	Cytochrome P450	34033	34048	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:277	The SwissProt database was queried to retrieve all reviewed sequences of alcohol dehydrogenase, Cytochrome P450, acyltransferase, and esterase. 	Cytochrome P450	39195	39210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:277	The SwissProt database was queried to retrieve all reviewed sequences of alcohol dehydrogenase, Cytochrome P450, acyltransferase, and esterase. 	Cytochrome P450	39195	39210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:284	Next, molecular docking was performed with Autodock 4.0 to predict the interactions of four triterpenoids (tirucalla-7,24-dien-3BETA-ol, azadirone, nimbin, and nimbolide) as substrates for the Cytochrome P450 proteins. 	Cytochrome P450	40333	40348	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:284	Next, molecular docking was performed with Autodock 4.0 to predict the interactions of four triterpenoids (tirucalla-7,24-dien-3BETA-ol, azadirone, nimbin, and nimbolide) as substrates for the Cytochrome P450 proteins. 	Cytochrome P450	40333	40348	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:285	For covering acting domains present in Cytochrome P450 protein, grid spacing was maintained at 0.375. 	Cytochrome P450	40398	40413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7592523_OgerInput.txtOger_out.csv:285	For covering acting domains present in Cytochrome P450 protein, grid spacing was maintained at 0.375. 	Cytochrome P450	40398	40413	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:79	In addition to the conjugation pathway and 17-ketosteroid pathway, hydroxylation and oxidation of hepatic Cytochrome P450 enzymes are additional pathways for testosterone metabolism. 	Cytochrome P450 enzymes	10617	10640	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:11	As these Cytochrome P450 enzymes differ significantly between species, drug biotransformation and hepatotoxicity can only be evaluated in freshly isolated primary human hepatocytes^. 	Cytochrome P450 enzymes	1809	1832	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:22	Hepatocyte-Like Cells differ from Primary Human Hepatocytes at the transcriptional, proteomic, and epigenetical level, and specifically express low levels of hepatic transcription factors and Cytochrome P450 enzymes^,,,. 	Cytochrome P450 enzymes	3421	3444	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:29	We also show that extracellular amino acids represent a tool to drive both metabolic maturation and the expression of Cytochrome P450 enzymes, and this in both Hepatocyte-Like Cells and HepG2 hepatoma cells. 	Cytochrome P450 enzymes	4476	4499	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:66	As aside from CYP3A4, also other Cytochrome P450 isoforms were induced in Aa3 Medium Supplemented With 2% Glycine medium (Supplementary Fig ), Amino Acids represent a valuable tool to induce Cytochrome P450 enzymes. 	Cytochrome P450 enzymes	12762	12785	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:69	The top deregulated pathways when comparing HLC Liver Differentiation Medium D20 with Primary Human Hepatocytes contained several genes involved in AA catabolism, glucose metabolism, metabolic pathways, and metabolism of xenobiotics by Cytochrome P450 enzymes and AMP-activated protein kinase), we next stratified these into four quadrants. 	Cytochrome P450 enzymes	13566	13589	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:37	AOH and Alternariol Monomethyl Ether were reported to serve as substrates for different Cytochrome P450 enzymes, particularly for Cytochrome P450 1A1, resulting in the generation of hydroxylated metabolites. 	Cytochrome P450 enzymes	6503	6526	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:181	The expression of additional CYPs (Cyp1a1, Cyp1b1, Cyp2e1) was observed in the skin of C57BL/6J mice by Flowers et al.. In the mouse skin the expression of several Cyp genes was demonstrated on the RNA level. 	Cyp2e1	29820	29826	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp2e1	30345	30351	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp2e1	30345	30351	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:190	Expression of Cyp1b1 and Cyp1a1 mRNAs peaked at 4 h, expression of Cyp3a11 mRNA peaked at 24 h (upregulation of Pregnane X Receptor in the DMBA-treated skin was confirmed at the protein level). 	Cyp1a1	31696	31702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:190	Expression of Cyp1b1 and Cyp1a1 mRNAs peaked at 4 h, expression of Cyp3a11 mRNA peaked at 24 h (upregulation of Pregnane X Receptor in the DMBA-treated skin was confirmed at the protein level). 	Cyp1a1	31696	31702	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:212	Western diet and benzo[a]pyrene can induce fatty liver in Cyp1a1 deficiency mice, but not in Wild Type mice. 	Cyp1a1	28278	28284	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:212	Western diet and benzo[a]pyrene can induce fatty liver in Cyp1a1 deficiency mice, but not in Wild Type mice. 	Cyp1a1	28278	28284	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:185	In agreement with previous studies, the mRNA levels of Cyp4a12 and Cyp4a14 were below the levels of detection in the hearts of both male and female mice in the current study (data not shown). 	Cyp4a	32890	32895	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5456333_OgerInput.txtOger_out.csv:174	ZHX2, described earlier as the repressor that targets H19 for silencing in postnatal liver, also regulates sexually dimorphic, developmentally-regulated P450 genes in the liver, including Cyp2a4, Cyp2b13 and Cyp4a12. 	Cyp4a	22514	22519	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:217	Meanwhile QC further improved the therapeutic efficacy by increasing the bioavailability of Mycophenolic Acid through inhibiting Cytochrome P450 enzyme. 	P450 enzyme	34438	34449	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:111	showed that the metabolism of a particular drug could be dominated by a single (putative) P450 enzyme. 	P450 enzyme	14852	14863	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:111	showed that the metabolism of a particular drug could be dominated by a single (putative) P450 enzyme. 	P450 enzyme	14852	14863	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:156	The metabolism of this polycyclic aromatic hydrocarbon molecule by oxidation reaction through cytochrome P450 enzyme from human host and monooxygenases and dioxygenase enzymes from bacterial species of skin microbiome is known from experimental studies, and reference databases such as the University of Minnesota Biocatalysis/Biodegradation Database (;. 	P450 enzyme	29732	29743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:156	The metabolism of this polycyclic aromatic hydrocarbon molecule by oxidation reaction through cytochrome P450 enzyme from human host and monooxygenases and dioxygenase enzymes from bacterial species of skin microbiome is known from experimental studies, and reference databases such as the University of Minnesota Biocatalysis/Biodegradation Database (;. 	P450 enzyme	29732	29743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:159	The ingestion of BaP is known to be toxic due to its metabolism by human cytochrome P450 enzyme and the products of its oxidation are known to cause carcinogenicity and other adverse health effects by reacting with the host DNA (;. 	P450 enzyme	30470	30481	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:159	The ingestion of BaP is known to be toxic due to its metabolism by human cytochrome P450 enzyme and the products of its oxidation are known to cause carcinogenicity and other adverse health effects by reacting with the host DNA (;. 	P450 enzyme	30470	30481	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:101	The gene CYP4X1 encodes an orphan Cytochromes P450 enzyme expressed mainly in the brain, aorta, or breast. 	P450 enzyme	14801	14812	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:101	The gene CYP4X1 encodes an orphan Cytochromes P450 enzyme expressed mainly in the brain, aorta, or breast. 	P450 enzyme	14801	14812	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:118	Detailed stopped-flow kinetics of binding of camphor to cytochrome P450cam have been studied for site-directed mutants of P450cam. 	P450cam	20533	20540	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:118	Detailed stopped-flow kinetics of binding of camphor to cytochrome P450cam have been studied for site-directed mutants of P450cam. 	P450cam	20588	20595	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	Cytochrome P450 Enzymes	22341	22364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	Cytochrome P450 Enzymes	23497	23520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	Cytochrome P450 Enzymes	23884	23907	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	Cytochrome P450 Enzymes	24189	24212	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450 Enzymes	38170	38193	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450 Enzymes	38205	38228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	Cytochrome P450 Enzymes	41220	41243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	P450 Enzymes	22352	22364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	P450 Enzymes	22352	22364	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	P450 Enzymes	23508	23520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	P450 Enzymes	23508	23520	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	P450 Enzymes	23895	23907	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	P450 Enzymes	23895	23907	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	P450 Enzymes	24200	24212	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	P450 Enzymes	24200	24212	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	P450 Enzymes	38181	38193	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	P450 Enzymes	38181	38193	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	P450 Enzymes	38216	38228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	P450 Enzymes	38216	38228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	P450 Enzymes	41231	41243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	P450 Enzymes	41231	41243	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:120	It indicates that cytochrome c can be used for pathology assessment for living cells. 	cytochrome c	22363	22375	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:120	It indicates that cytochrome c can be used for pathology assessment for living cells. 	cytochrome c	22363	22375	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:123	Thus, the peak at 1337 cm^1 can be useful to distinguish between cytochrome c and b, as the vibration at 1337 cm^1 represents a unique peak of the reduced cyt b (ferrous (Fe^2+) cytochrome). 	cytochrome c	22822	22834	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:123	Thus, the peak at 1337 cm^1 can be useful to distinguish between cytochrome c and b, as the vibration at 1337 cm^1 represents a unique peak of the reduced cyt b (ferrous (Fe^2+) cytochrome). 	cytochrome c	22822	22834	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:127	Hence, the ratio of intensities 750/1126 can be used to estimate the relative amount of reduced cytochromes c, c_1 versus reduced cytochromes b. The vibrations of cytochrome c that are resonance Raman enhanced in the brain and breast tissues are demonstrated (with green arrows) in,  and. 	cytochrome c	23546	23558	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:127	Hence, the ratio of intensities 750/1126 can be used to estimate the relative amount of reduced cytochromes c, c_1 versus reduced cytochromes b. The vibrations of cytochrome c that are resonance Raman enhanced in the brain and breast tissues are demonstrated (with green arrows) in,  and. 	cytochrome c	23546	23558	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:131	Symmetric vibrational modes of the porphyrin ligand in cytochrome c are resonance Raman enhanced to a greater degree using excitation wavelengths within the Soret absorption peaks at 408 nm (ferric, Fe^3+), 416 nm (ferrous, Fe^2+) states, whereas asymmetric modes are enhanced to a greater degree using excitation wavelengths within the Q absorption peak at 500-550 nm. 	cytochrome c	24200	24212	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:131	Symmetric vibrational modes of the porphyrin ligand in cytochrome c are resonance Raman enhanced to a greater degree using excitation wavelengths within the Soret absorption peaks at 408 nm (ferric, Fe^3+), 416 nm (ferrous, Fe^2+) states, whereas asymmetric modes are enhanced to a greater degree using excitation wavelengths within the Q absorption peak at 500-550 nm. 	cytochrome c	24200	24212	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:132	Detailed vibrational assignment of cytochrome c can be found in ref Q-resonant Raman spectra contain unusually strong depolarized bands. 	cytochrome c	24550	24562	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:132	Detailed vibrational assignment of cytochrome c can be found in ref Q-resonant Raman spectra contain unusually strong depolarized bands. 	cytochrome c	24550	24562	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:134	The bands of cytochrome c at 750, 1126, 1248, 1310, 1363 cm^1 are depolarized and represent the reduced form. 	cytochrome c	24767	24779	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:134	The bands of cytochrome c at 750, 1126, 1248, 1310, 1363 cm^1 are depolarized and represent the reduced form. 	cytochrome c	24767	24779	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:137	The band at 1584 cm^1 represents the reduced form of cytochrome c and it is not observed in the oxidized form. 	cytochrome c	25119	25131	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:137	The band at 1584 cm^1 represents the reduced form of cytochrome c and it is not observed in the oxidized form. 	cytochrome c	25119	25131	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:138	Some of the peaks of the oxidized form of cytochrome c (around 750, 1130, 1172, 1314, 1374, 1570-1573 and 1634 cm^1) have the same positions as the reduced form, but their intensities are significantly lower except the band 1634 cm^1 corresponding to the ferric cytochrome c as presented in. 	cytochrome c	25219	25231	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:138	Some of the peaks of the oxidized form of cytochrome c (around 750, 1130, 1172, 1314, 1374, 1570-1573 and 1634 cm^1) have the same positions as the reduced form, but their intensities are significantly lower except the band 1634 cm^1 corresponding to the ferric cytochrome c as presented in. 	cytochrome c	25219	25231	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:138	Some of the peaks of the oxidized form of cytochrome c (around 750, 1130, 1172, 1314, 1374, 1570-1573 and 1634 cm^1) have the same positions as the reduced form, but their intensities are significantly lower except the band 1634 cm^1 corresponding to the ferric cytochrome c as presented in. 	cytochrome c	25439	25451	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:138	Some of the peaks of the oxidized form of cytochrome c (around 750, 1130, 1172, 1314, 1374, 1570-1573 and 1634 cm^1) have the same positions as the reduced form, but their intensities are significantly lower except the band 1634 cm^1 corresponding to the ferric cytochrome c as presented in. 	cytochrome c	25439	25451	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:140	Our results in  show that the Raman intensities of the reduced form of cytochrome c (cyt c Fe^2+) are significantly higher than those of the oxidized form (cyt c Fe^3+) and they support earlier results presented in the literature. 	cytochrome c	25714	25726	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:140	Our results in  show that the Raman intensities of the reduced form of cytochrome c (cyt c Fe^2+) are significantly higher than those of the oxidized form (cyt c Fe^3+) and they support earlier results presented in the literature. 	cytochrome c	25714	25726	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:141	We used 1584 cm^1 vibrational mode (_19) as a marker band of ferrous cyt c in brain and breast cancer tissues, _19 of ferrous heme c (1582 cm^1), _2 of ferric heme c (1585 cm^1), _19 of ferrous heme cyt b (1586 cm^1) and _2 of ferrous heme b (1583 cm^1) we can eliminate from our discussion all ferric modes due to the fact that the resonance Raman intensities of the ferric modes are very weak in comparison to the ferrous bands except the band 1634 cm^1 corresponding to the ferric cytochrome c. Thus, the bands at 1584 cm^1 (reduced cyt c) and at 1634 cm^1 (oxidized cyt c) of cytochrome c can be used as a very important parameter controlling the level of reduction in cancer tissues. 	cytochrome c	26358	26370	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:141	We used 1584 cm^1 vibrational mode (_19) as a marker band of ferrous cyt c in brain and breast cancer tissues, _19 of ferrous heme c (1582 cm^1), _2 of ferric heme c (1585 cm^1), _19 of ferrous heme cyt b (1586 cm^1) and _2 of ferrous heme b (1583 cm^1) we can eliminate from our discussion all ferric modes due to the fact that the resonance Raman intensities of the ferric modes are very weak in comparison to the ferrous bands except the band 1634 cm^1 corresponding to the ferric cytochrome c. Thus, the bands at 1584 cm^1 (reduced cyt c) and at 1634 cm^1 (oxidized cyt c) of cytochrome c can be used as a very important parameter controlling the level of reduction in cancer tissues. 	cytochrome c	26358	26370	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:141	We used 1584 cm^1 vibrational mode (_19) as a marker band of ferrous cyt c in brain and breast cancer tissues, _19 of ferrous heme c (1582 cm^1), _2 of ferric heme c (1585 cm^1), _19 of ferrous heme cyt b (1586 cm^1) and _2 of ferrous heme b (1583 cm^1) we can eliminate from our discussion all ferric modes due to the fact that the resonance Raman intensities of the ferric modes are very weak in comparison to the ferrous bands except the band 1634 cm^1 corresponding to the ferric cytochrome c. Thus, the bands at 1584 cm^1 (reduced cyt c) and at 1634 cm^1 (oxidized cyt c) of cytochrome c can be used as a very important parameter controlling the level of reduction in cancer tissues. 	cytochrome c	26454	26466	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:141	We used 1584 cm^1 vibrational mode (_19) as a marker band of ferrous cyt c in brain and breast cancer tissues, _19 of ferrous heme c (1582 cm^1), _2 of ferric heme c (1585 cm^1), _19 of ferrous heme cyt b (1586 cm^1) and _2 of ferrous heme b (1583 cm^1) we can eliminate from our discussion all ferric modes due to the fact that the resonance Raman intensities of the ferric modes are very weak in comparison to the ferrous bands except the band 1634 cm^1 corresponding to the ferric cytochrome c. Thus, the bands at 1584 cm^1 (reduced cyt c) and at 1634 cm^1 (oxidized cyt c) of cytochrome c can be used as a very important parameter controlling the level of reduction in cancer tissues. 	cytochrome c	26454	26466	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:142	The Raman spectra in,  and  do not provide information about the distribution of cytochrome c in the cancer tissue. 	cytochrome c	26644	26656	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:142	The Raman spectra in,  and  do not provide information about the distribution of cytochrome c in the cancer tissue. 	cytochrome c	26644	26656	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:143	To learn about the distribution of cytochrome c we used Raman polarized imaging. 	cytochrome c	26714	26726	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:143	To learn about the distribution of cytochrome c we used Raman polarized imaging. 	cytochrome c	26714	26726	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:147	The anomalously polarized band at 1584 cm^1 appearing in the Q-resonant Raman spectra is characteristic of cytochrome c. This result additionally supports our previous findings from  and  that the Q-resonant Raman band at 1584 cm^1 in the breast and brain tissues represents cytochrome c. shows microscopy image, Raman image, and the average Raman spectra of lipids (blue), proteins (red), cytochrome (green), mitochondrion (magenta) at 532 nm at different experimental geometries for Raman scattering: without polarization analyzer, at parallel and perpendicular polarizations of the incident and Raman scattered beams for infiltrating ductal cancer (malignancy grade G2). 	cytochrome c	27573	27585	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:147	The anomalously polarized band at 1584 cm^1 appearing in the Q-resonant Raman spectra is characteristic of cytochrome c. This result additionally supports our previous findings from  and  that the Q-resonant Raman band at 1584 cm^1 in the breast and brain tissues represents cytochrome c. shows microscopy image, Raman image, and the average Raman spectra of lipids (blue), proteins (red), cytochrome (green), mitochondrion (magenta) at 532 nm at different experimental geometries for Raman scattering: without polarization analyzer, at parallel and perpendicular polarizations of the incident and Raman scattered beams for infiltrating ductal cancer (malignancy grade G2). 	cytochrome c	27573	27585	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:147	The anomalously polarized band at 1584 cm^1 appearing in the Q-resonant Raman spectra is characteristic of cytochrome c. This result additionally supports our previous findings from  and  that the Q-resonant Raman band at 1584 cm^1 in the breast and brain tissues represents cytochrome c. shows microscopy image, Raman image, and the average Raman spectra of lipids (blue), proteins (red), cytochrome (green), mitochondrion (magenta) at 532 nm at different experimental geometries for Raman scattering: without polarization analyzer, at parallel and perpendicular polarizations of the incident and Raman scattered beams for infiltrating ductal cancer (malignancy grade G2). 	cytochrome c	27741	27753	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:147	The anomalously polarized band at 1584 cm^1 appearing in the Q-resonant Raman spectra is characteristic of cytochrome c. This result additionally supports our previous findings from  and  that the Q-resonant Raman band at 1584 cm^1 in the breast and brain tissues represents cytochrome c. shows microscopy image, Raman image, and the average Raman spectra of lipids (blue), proteins (red), cytochrome (green), mitochondrion (magenta) at 532 nm at different experimental geometries for Raman scattering: without polarization analyzer, at parallel and perpendicular polarizations of the incident and Raman scattered beams for infiltrating ductal cancer (malignancy grade G2). 	cytochrome c	27741	27753	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:149	Since Raman scattering at 1584 cm^1 is not observed in the oxidized form of cytochrome c the band at 1584 cm^1 originates from the reduced form of cytochromes c. Our results demonstrate that the Raman intensity of 1584 cm^1 peak is the most sensitive vibration of redox status in the cell and is related to the amount of the reduced cytochromes c. Therefore, we used 1584 cm^1 to study the redox state of mitochondrial cytochrome c in brain and breast ex vivo human tissues. 	cytochrome c	28347	28359	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:149	Since Raman scattering at 1584 cm^1 is not observed in the oxidized form of cytochrome c the band at 1584 cm^1 originates from the reduced form of cytochromes c. Our results demonstrate that the Raman intensity of 1584 cm^1 peak is the most sensitive vibration of redox status in the cell and is related to the amount of the reduced cytochromes c. Therefore, we used 1584 cm^1 to study the redox state of mitochondrial cytochrome c in brain and breast ex vivo human tissues. 	cytochrome c	28347	28359	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:149	Since Raman scattering at 1584 cm^1 is not observed in the oxidized form of cytochrome c the band at 1584 cm^1 originates from the reduced form of cytochromes c. Our results demonstrate that the Raman intensity of 1584 cm^1 peak is the most sensitive vibration of redox status in the cell and is related to the amount of the reduced cytochromes c. Therefore, we used 1584 cm^1 to study the redox state of mitochondrial cytochrome c in brain and breast ex vivo human tissues. 	cytochrome c	28690	28702	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:149	Since Raman scattering at 1584 cm^1 is not observed in the oxidized form of cytochrome c the band at 1584 cm^1 originates from the reduced form of cytochromes c. Our results demonstrate that the Raman intensity of 1584 cm^1 peak is the most sensitive vibration of redox status in the cell and is related to the amount of the reduced cytochromes c. Therefore, we used 1584 cm^1 to study the redox state of mitochondrial cytochrome c in brain and breast ex vivo human tissues. 	cytochrome c	28690	28702	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:150	To check whether the redox state of cytochrome c is related to cancer aggressiveness we used the Raman redox state biomarker represented by the Raman intensity of 1584 cm^1 peak. 	cytochrome c	28782	28794	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:150	To check whether the redox state of cytochrome c is related to cancer aggressiveness we used the Raman redox state biomarker represented by the Raman intensity of 1584 cm^1 peak. 	cytochrome c	28782	28794	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:163	A shows the intensity of the 750, 1126, 1337 and 1584 cm^1 Raman peak of cytochrome c as a function of grade. 	cytochrome c	30832	30844	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:163	A shows the intensity of the 750, 1126, 1337 and 1584 cm^1 Raman peak of cytochrome c as a function of grade. 	cytochrome c	30832	30844	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:164	B shows the data for 1584 cm^1 band of reduced cytochrome c for breast normal (G0) and cancer (invasive ductal cancer) human tissue (G1, G2, G3). 	cytochrome c	30916	30928	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:164	B shows the data for 1584 cm^1 band of reduced cytochrome c for breast normal (G0) and cancer (invasive ductal cancer) human tissue (G1, G2, G3). 	cytochrome c	30916	30928	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:165	Based on the average values (number of patients n = 39) obtained for the Raman biomarker of cytochrome c I_1584 we obtained a plot as a function of cancer grade malignancy. 	cytochrome c	31107	31119	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:165	Based on the average values (number of patients n = 39) obtained for the Raman biomarker of cytochrome c I_1584 we obtained a plot as a function of cancer grade malignancy. 	cytochrome c	31107	31119	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:166	In the view of the results presented in  it is evident that the Raman biomarker I_1584 measuring contribution of cytochrome c in the human breast tissues correlates with breast cancer aggressiveness. 	cytochrome c	31301	31313	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:166	In the view of the results presented in  it is evident that the Raman biomarker I_1584 measuring contribution of cytochrome c in the human breast tissues correlates with breast cancer aggressiveness. 	cytochrome c	31301	31313	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:167	The intensity of the 1584 cm^1 Raman signal corresponding to the amount of reduced cytochrome c increases with increasing cancer aggressiveness. 	cytochrome c	31471	31483	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:167	The intensity of the 1584 cm^1 Raman signal corresponding to the amount of reduced cytochrome c increases with increasing cancer aggressiveness. 	cytochrome c	31471	31483	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:168	It indicates that cytochrome c plays a crucial role in the development and progression of cancer. 	cytochrome c	31551	31563	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:168	It indicates that cytochrome c plays a crucial role in the development and progression of cancer. 	cytochrome c	31551	31563	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:169	The parabolic dependence of the Raman biomarker I_1584 of the reduced cytochrome c in  vs cancer malignancy shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized intensity of 0.006  0.003 for the breast tissues. 	cytochrome c	31701	31713	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:169	The parabolic dependence of the Raman biomarker I_1584 of the reduced cytochrome c in  vs cancer malignancy shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized intensity of 0.006  0.003 for the breast tissues. 	cytochrome c	31701	31713	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:169	The parabolic dependence of the Raman biomarker I_1584 of the reduced cytochrome c in  vs cancer malignancy shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized intensity of 0.006  0.003 for the breast tissues. 	cytochrome c	31779	31791	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:169	The parabolic dependence of the Raman biomarker I_1584 of the reduced cytochrome c in  vs cancer malignancy shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized intensity of 0.006  0.003 for the breast tissues. 	cytochrome c	31779	31791	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:170	The concentrations of the reduced cytochrome c at this level modulate protective, signaling-response pathways, resulting in positive effects on life-history traits. 	cytochrome c	31955	31967	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:170	The concentrations of the reduced cytochrome c at this level modulate protective, signaling-response pathways, resulting in positive effects on life-history traits. 	cytochrome c	31955	31967	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:171	The reduced cytochrome c level above the value of 0.06  0.02 triggers a toxic runaway process and aggressive breast cancer development. 	cytochrome c	32098	32110	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:171	The reduced cytochrome c level above the value of 0.06  0.02 triggers a toxic runaway process and aggressive breast cancer development. 	cytochrome c	32098	32110	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:172	The plot provides an important cell-physiologic response, normally the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	32301	32313	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:172	The plot provides an important cell-physiologic response, normally the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	32301	32313	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:173	It is interesting to check if the other characteristic bands of cytochrome c and cytochrome b correlate with breast cancer grade malignancy G0-G3. 	cytochrome c	32502	32514	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:173	It is interesting to check if the other characteristic bands of cytochrome c and cytochrome b correlate with breast cancer grade malignancy G0-G3. 	cytochrome c	32502	32514	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:178	We analyzed the Raman intensity ratio of the peaks at 750 cm^1 and 1126 cm^1 to evaluated the relative contribution of cytochrome c and b (see B,C).  	cytochrome c	33279	33291	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:178	We analyzed the Raman intensity ratio of the peaks at 750 cm^1 and 1126 cm^1 to evaluated the relative contribution of cytochrome c and b (see B,C).  	cytochrome c	33279	33291	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:181	It indicates that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases. 	cytochrome c	33630	33642	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:181	It indicates that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases. 	cytochrome c	33630	33642	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:184	C,F show that the intensity of the 1584 cm^1 Raman signal corresponding to the concentration of reduced cytochrome c increases with increasing brain tumor aggressiveness. 	cytochrome c	34200	34212	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:184	C,F show that the intensity of the 1584 cm^1 Raman signal corresponding to the concentration of reduced cytochrome c increases with increasing brain tumor aggressiveness. 	cytochrome c	34200	34212	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:186	To check whether cytochromes c is upregulated in brain tumors we studied the Raman signals at 1584 cm^1 corresponding to concertation of cytochrome c as a function of brain tumor malignancy by using WHO grade. 	cytochrome c	34513	34525	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:186	To check whether cytochromes c is upregulated in brain tumors we studied the Raman signals at 1584 cm^1 corresponding to concertation of cytochrome c as a function of brain tumor malignancy by using WHO grade. 	cytochrome c	34513	34525	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:187	shows the Raman intensities of characteristic vibrations in brain tissue corresponding to concentration of reduced cytochrome c. One can see that for the brain tumors the Raman intensity of all characteristic vibrations of cytochrome c increases with increasing cancer aggressiveness up to G3 and then slightly decreases for G4. 	cytochrome c	34701	34713	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:187	shows the Raman intensities of characteristic vibrations in brain tissue corresponding to concentration of reduced cytochrome c. One can see that for the brain tumors the Raman intensity of all characteristic vibrations of cytochrome c increases with increasing cancer aggressiveness up to G3 and then slightly decreases for G4. 	cytochrome c	34701	34713	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:187	shows the Raman intensities of characteristic vibrations in brain tissue corresponding to concentration of reduced cytochrome c. One can see that for the brain tumors the Raman intensity of all characteristic vibrations of cytochrome c increases with increasing cancer aggressiveness up to G3 and then slightly decreases for G4. 	cytochrome c	34809	34821	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:187	shows the Raman intensities of characteristic vibrations in brain tissue corresponding to concentration of reduced cytochrome c. One can see that for the brain tumors the Raman intensity of all characteristic vibrations of cytochrome c increases with increasing cancer aggressiveness up to G3 and then slightly decreases for G4. 	cytochrome c	34809	34821	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:191	The results presented in the paper suggest that the redox-sensitive peak observed at 1584 cm^1 with excitation at 532 nm is specifically linked to cytochrome c. and can be considered to be a redox state marker of the ferric low spin heme in cyt c, assigned to the v_19 mode, vibrations of methine bridges (CALPHAC, CALPHACH bonds) and the CALPHACBETA bond. 	cytochrome c	35675	35687	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:191	The results presented in the paper suggest that the redox-sensitive peak observed at 1584 cm^1 with excitation at 532 nm is specifically linked to cytochrome c. and can be considered to be a redox state marker of the ferric low spin heme in cyt c, assigned to the v_19 mode, vibrations of methine bridges (CALPHAC, CALPHACH bonds) and the CALPHACBETA bond. 	cytochrome c	35675	35687	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:193	We found that concentration of cytochrome c is upregulated in brain and breast cancers. 	cytochrome c	36032	36044	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:193	We found that concentration of cytochrome c is upregulated in brain and breast cancers. 	cytochrome c	36032	36044	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:194	The intensities of the 1584 cm^1 Raman signal corresponding to the amount of the reduced cytochrome c increases with increasing cancer aggressiveness. 	cytochrome c	36178	36190	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:194	The intensities of the 1584 cm^1 Raman signal corresponding to the amount of the reduced cytochrome c increases with increasing cancer aggressiveness. 	cytochrome c	36178	36190	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:195	It indicates that cytochrome c plays a crucial role in the development and progression of cancer. 	cytochrome c	36258	36270	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:195	It indicates that cytochrome c plays a crucial role in the development and progression of cancer. 	cytochrome c	36258	36270	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:196	We found the dependence of the Raman biomarker I_1584 of the reduced cytochrome c vs grade of cancer malignancy which shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized Raman intensity of 0.006  0.003 for the breast tissue and 0.074  0.005 for the brain tissue. 	cytochrome c	36407	36419	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:196	We found the dependence of the Raman biomarker I_1584 of the reduced cytochrome c vs grade of cancer malignancy which shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized Raman intensity of 0.006  0.003 for the breast tissue and 0.074  0.005 for the brain tissue. 	cytochrome c	36407	36419	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:196	We found the dependence of the Raman biomarker I_1584 of the reduced cytochrome c vs grade of cancer malignancy which shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized Raman intensity of 0.006  0.003 for the breast tissue and 0.074  0.005 for the brain tissue. 	cytochrome c	36496	36508	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:196	We found the dependence of the Raman biomarker I_1584 of the reduced cytochrome c vs grade of cancer malignancy which shows that the optimal concentration of cytochrome c that are needed to maintain cellular homeostasis corresponds to the normalized Raman intensity of 0.006  0.003 for the breast tissue and 0.074  0.005 for the brain tissue. 	cytochrome c	36496	36508	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:197	The concentrations of the reduced cytochrome c at this level modulate protective, signaling-response pathways, resulting in positive effects on life-history traits. 	cytochrome c	36715	36727	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:197	The concentrations of the reduced cytochrome c at this level modulate protective, signaling-response pathways, resulting in positive effects on life-history traits. 	cytochrome c	36715	36727	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:198	The reduced cytochrome c level above these values triggers a toxic runaway process and aggressive cancer development. 	cytochrome c	36858	36870	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:198	The reduced cytochrome c level above these values triggers a toxic runaway process and aggressive cancer development. 	cytochrome c	36858	36870	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:199	The relation between the Raman signal intensity at 1584 cm^1 of the reduced cytochrome c vs cancer grade provides an important cell-physiologic response demonstrating that the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	37040	37052	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:199	The relation between the Raman signal intensity at 1584 cm^1 of the reduced cytochrome c vs cancer grade provides an important cell-physiologic response demonstrating that the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	37040	37052	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:199	The relation between the Raman signal intensity at 1584 cm^1 of the reduced cytochrome c vs cancer grade provides an important cell-physiologic response demonstrating that the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	37148	37160	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:199	The relation between the Raman signal intensity at 1584 cm^1 of the reduced cytochrome c vs cancer grade provides an important cell-physiologic response demonstrating that the reduced cytochrome c operates at low, basal level in normal cells, but it is strongly induced to very high levels in pathological cancer states. 	cytochrome c	37148	37160	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:202	We analyzed the Raman intensity ratio of the peaks at 750 cm^1 and 1126 cm^1 to evaluate the relative contribution of cytochrome c and b in human breast tissue as a function of breast cancer grade malignancy G0-G3 at excitation 532 nm. 	cytochrome c	37672	37684	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:202	We analyzed the Raman intensity ratio of the peaks at 750 cm^1 and 1126 cm^1 to evaluate the relative contribution of cytochrome c and b in human breast tissue as a function of breast cancer grade malignancy G0-G3 at excitation 532 nm. 	cytochrome c	37672	37684	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:203	We found that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases.	cytochrome c	37833	37845	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:203	We found that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases.	cytochrome c	37833	37845	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:131	Given that the Raman spectra underling the relRI trends were recorded from individual cells in a monolayer of cells, this indicated a significantly higher active cytochrome-c content per cell for N. eutropha and Nitrosospira grown under oxygen-deprived conditions than was seen in cells grown in oxygen abundance. 	cytochrome-c	21151	21163	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:131	Given that the Raman spectra underling the relRI trends were recorded from individual cells in a monolayer of cells, this indicated a significantly higher active cytochrome-c content per cell for N. eutropha and Nitrosospira grown under oxygen-deprived conditions than was seen in cells grown in oxygen abundance. 	cytochrome-c	21151	21163	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450 superfamily	2279	2306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450 superfamily	2279	2306	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:18	The metabolic activation of PCBs is initiated by cytochrome p450 (CYP) family members and includes the oxidation of PCBs to OH-PCBs. 	cytochrome p450	2329	2344	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:96	As synthetic OH-metabolites of PCB 28-induced cytotoxicity in a model cell culture system^, we conclude that PCB 28 bioactivation by cytochrome p450 (Cyp) enzymes leads to toxicity in Drosophila. 	cytochrome p450	15177	15192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:96	As synthetic OH-metabolites of PCB 28-induced cytotoxicity in a model cell culture system^, we conclude that PCB 28 bioactivation by cytochrome p450 (Cyp) enzymes leads to toxicity in Drosophila. 	cytochrome p450	15177	15192	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:148	However, several factors, including differences in intracellular pH, membrane lipid composition of the ER (relevant for ER-membrane-anchored OSCs and P450s), and availability of dedicated co-factors, such as, for example, specialized cytochrome b5 enzymes, are generally regarded to cause a plant enzyme not to function properly in a yeast cell. 	cytochrome b	25382	25394	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:325	The Photosynthetic Electron Transfer Chain employs three membrane protein complexes: PSI, PSII, their respective light-harvesting complexes (LHCI and LHCII), and the cytochrome b6/f complex (Cyt b6f, a plastoquinol-plastocyanin-oxidoreductase). 	cytochrome b	46621	46633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:405	Formation of 21 mol O_2^ (mg Chl)^1 h^1, measured as an SOD-dependent cytochrome c reduction, was observed in D1/D2/cytochrome b559 complexes illuminated at 200 W m^2 in the presence of an artificial electron donor. 	cytochrome b	59494	59506	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:63	Subcellular localization of Carbon Monoxide can also regulate ROS production, for instance Taill and colleagues have demonstrated that CORM-2 treatment inhibited the activity of NAD(P)H oxidase cytochrome b_558, which decreases plasmatic membrane ROS production, while there is an increase on mitochondrial ROS generation by targeting cytochrome c oxidase. 	cytochrome b	10428	10440	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7306483_OgerInput.txtOger_out.csv:112	Under Coos1 Is Frame-Shifted conditions, the expression levels of hyd-3b genes (KKC1_RS10620-KKC1_RS10635) encoding group 3b [NiFe] hydrogenase catalytic subunits and their maturation protease were upregulated, whereas those of hyd-1a genes (KKC1_RS00385-KKC1_RS00400) encoding group 1a [NiFe] hydrogenase catalytic subunits, a cytochrome b subunit, and their maturation protease were downregulated. 	cytochrome b	21082	21094	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7306483_OgerInput.txtOger_out.csv:116	Conversely, the group 1a [NiFe] hydrogenase is a periplasmic, unidirectional H_2-uptake hydrogenase, and the cytochrome b subunit is considered a putative electron carrier, as are other group 1 hydrogenases (Greening et al. 	cytochrome b	21525	21537	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7311756_OgerInput.txtOger_out.csv:9	One of these peaks characterizes more than 1,000 different sequences of mitochondrial cytochrome b molecules at p = 379. 	cytochrome b	1242	1254	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7311756_OgerInput.txtOger_out.csv:49	However, in the case p = 379, out of 1,889 proteins, 1,048 (two-thirds) are mitochondrial cytochrome b. This value is approximately equal to that part of the peak that rises above the total mass of protein lengths in. 	cytochrome b	8037	8049	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7311756_OgerInput.txtOger_out.csv:89	For a large number of differing amino acid residue sequences, but with the same p-value, cytochrome b is precisely typical as being representative of animals. 	cytochrome b	14378	14390	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:98	Some of the major topics that the speakers discussed were whether P450 was synthesized in the rough or smooth endoplasmic reticulum, whether there were one or two P450s (some questioned whether changes in phospholipids might be responsible for the altered activities), the role of cytochrome b_5 (Estabrook, Mannering), the purification of P450 from rabbit liver (Coon, Sato), the chemical mechanism(s) of catalysis (Ullrich, McMahon, Udenfriend, Daly, Witkop, Jerina), and the biological basis of P450 induction. 	cytochrome b	13066	13078	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:11	Curiously, plant-like hallmark electron transfer enzymes and transporters are found throughout the genome, such as a cytochrome b6c1 complex and a CO2-concentrating transporter. 	cytochrome b	1304	1316	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:193	In the previous genome an operon annotated as a cytochrome b_6f was annotated. 	cytochrome b	26040	26052	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:194	However, while genes indeed include a cytochrome b_6, there is no homology to a cytochrome f, but there is to a cytochrome c_1. 	cytochrome b	26109	26121	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:195	This leads us to believe that this organism has a cytochrome b_6c_1, which is a novel-hybrid type complex III also found in G. stearothermophilus (Sone et al.. Curiously, the iron-sulfur cluster of C. thermarum TA2. 	cytochrome b	26249	26261	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:198	Supporting this proposition, while a b_6c_1 has not been examined, a synthetically constructed b_6c_1 was constructed and was able to functionally replace a cytochrome b_6f in Rhodobacter capsulatus in the process of cellular photosynthesis (Saribas et al.. At the electron-accepting end of the respiratory chain, C. thermarum TA2. 	cytochrome b	26743	26755	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:241	These similarities include a cytochrome b_6c_1 complex that is a possible homolog of the plant cytochrome b_6f, the similarity in F_1F_O-ATP synthase c-subunit rotor ring size, and the means to capture inorganic carbon. 	cytochrome b	32073	32085	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7561548_OgerInput.txtOger_out.csv:241	These similarities include a cytochrome b_6c_1 complex that is a possible homolog of the plant cytochrome b_6f, the similarity in F_1F_O-ATP synthase c-subunit rotor ring size, and the means to capture inorganic carbon. 	cytochrome b	32139	32151	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:31	The family of cytochromes are localized in the third complex in the electron transport chain, also known as complex III or Coenzyme Q - Cyt c reductase, sometimes called the cytochrome bc_1 complex (cytochrome b, cytochrome c_1), as well as in cytochrome c loosely associated with the inner membrane of the mitochondrion. 	cytochrome b	5499	5511	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:38	Using different excitations, we are able to monitor contribution of cytochrome family in the electron transfer chain in the mitochondrial respiration originating from cytochrome b, c_1 in complex III, cytochrome c, and a, a_3 cytochromes in complex IV. 	cytochrome b	6906	6918	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:173	It is interesting to check if the other characteristic bands of cytochrome c and cytochrome b correlate with breast cancer grade malignancy G0-G3. 	cytochrome b	32519	32531	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:181	It indicates that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases. 	cytochrome b	33658	33670	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:188	The amount of cytochrome b is practically the same for all grades of brain tumor. 	cytochrome b	34929	34941	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:203	We found that the relative contribution of cytochrome c is higher than cytochrome b when the grade of malignancy increases.	cytochrome b	37861	37873	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:196	(presence of CYP and cytochrome b5). 	cytochrome b5	32182	32195	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:34	In addition, plants express redox co-factors dedicated to secondary metabolism, such as specialized cytochrome b5 proteins, and many CYPs depend on such co-factors for optimal activity. 	cytochrome b5	5629	5642	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:34	In addition, plants express redox co-factors dedicated to secondary metabolism, such as specialized cytochrome b5 proteins, and many CYPs depend on such co-factors for optimal activity. 	cytochrome b5	5629	5642	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:148	However, several factors, including differences in intracellular pH, membrane lipid composition of the ER (relevant for ER-membrane-anchored OSCs and P450s), and availability of dedicated co-factors, such as, for example, specialized cytochrome b5 enzymes, are generally regarded to cause a plant enzyme not to function properly in a yeast cell. 	cytochrome b5	25382	25395	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:148	However, several factors, including differences in intracellular pH, membrane lipid composition of the ER (relevant for ER-membrane-anchored OSCs and P450s), and availability of dedicated co-factors, such as, for example, specialized cytochrome b5 enzymes, are generally regarded to cause a plant enzyme not to function properly in a yeast cell. 	cytochrome b5	25382	25395	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:148	EROD activity was determined using the methods of Peters et al., with mild modifications. 	EROD	19864	19868	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC7407958_OgerInput.txtOger_out.csv:76	EROD enzyme activity assay was conducted applying the complex mixtures of Alternaria toxins to test their potential to activate the Aryl Hydrocarbon Receptor signalling pathway. 	EROD	13372	13376	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:9	Progestin receptor membrane component 1 is a single transmembrane heme-binding protein containing a cytochrome b_5 motif, which has been proposed as a progesterone binding protein in vertebrates (,. 	cytochrome b_5	1572	1586	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:127	For example, Progestin Receptor Membrane Component 1 is a heme-binding protein with a cytochrome b_5 motif, which binds and activates P450 proteins and is involved in steroidogenesis and drug metabolism. 	cytochrome b_5	22001	22015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:127	For example, Progestin Receptor Membrane Component 1 is a heme-binding protein with a cytochrome b_5 motif, which binds and activates P450 proteins and is involved in steroidogenesis and drug metabolism. 	cytochrome b_5	22001	22015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:156	Pgrmc1 has a role in the regulation of cholesterol and steroid synthesis because of its cytochrome b_5 motif and its ability to bind and activate P450 proteins (,. 	cytochrome b_5	27423	27437	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:156	Pgrmc1 has a role in the regulation of cholesterol and steroid synthesis because of its cytochrome b_5 motif and its ability to bind and activate P450 proteins (,. 	cytochrome b_5	27423	27437	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	cytochrome b_5	18458	18472	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:124	The recombinant baculosomes with hyperexpressed CYP3A4 and coexpressed NADPH cytochrome P450 reductase and cytochrome b_5, was used as source of enzyme. 	cytochrome b_5	18458	18472	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:10	Progesterone receptor membrane component 1 is a multifunctional protein with a C-terminal cytochrome b_5 domain^. 	cytochrome b_5	1992	2006	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:10	Progesterone receptor membrane component 1 is a multifunctional protein with a C-terminal cytochrome b_5 domain^. 	cytochrome b_5	1992	2006	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:16	Progesterone Receptor Membrane Component1 regulates cell proliferation and apoptosis in granulosa and luteal cells via interaction between its cytoplasmic cytochrome b_5 binding domain (amino acids 70-130) and plasminogen activator inhibitor RNA-binding protein-1 (PAIR-BP1)^,. 	cytochrome b_5	3247	3261	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6345922_OgerInput.txtOger_out.csv:16	Progesterone Receptor Membrane Component1 regulates cell proliferation and apoptosis in granulosa and luteal cells via interaction between its cytoplasmic cytochrome b_5 binding domain (amino acids 70-130) and plasminogen activator inhibitor RNA-binding protein-1 (PAIR-BP1)^,. 	cytochrome b_5	3247	3261	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	cytochrome b_5	12858	12872	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:76	It should be noted that the 17,20-lyase activity of CYP17A1 is dependent on augmentation by cytochrome b_5 (CYB5A) in addition to electron transfer from P450 Oxidoreductase. 	cytochrome b_5	12858	12872	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:9	In the mammalian liver, the endoplasmic reticulum (ER)-anchored P450s function together with their redox partners cytochrome P450 reductase and cytochrome b_5 in the oxidative metabolism and elimination of numerous endobiotics (arachidonic acid, retinoic acid, steroids, vitamin D) as well as xenobiotics (pharmacological and recreational drugs, carcinogens, toxins and other foreign substances of dietary or environmental origin),. 	cytochrome b_5	2383	2397	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:9	In the mammalian liver, the endoplasmic reticulum (ER)-anchored P450s function together with their redox partners cytochrome P450 reductase and cytochrome b_5 in the oxidative metabolism and elimination of numerous endobiotics (arachidonic acid, retinoic acid, steroids, vitamin D) as well as xenobiotics (pharmacological and recreational drugs, carcinogens, toxins and other foreign substances of dietary or environmental origin),. 	cytochrome b_5	2383	2397	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:98	Some of the major topics that the speakers discussed were whether P450 was synthesized in the rough or smooth endoplasmic reticulum, whether there were one or two P450s (some questioned whether changes in phospholipids might be responsible for the altered activities), the role of cytochrome b_5 (Estabrook, Mannering), the purification of P450 from rabbit liver (Coon, Sato), the chemical mechanism(s) of catalysis (Ullrich, McMahon, Udenfriend, Daly, Witkop, Jerina), and the biological basis of P450 induction. 	cytochrome b_5	13066	13080	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC7431904_OgerInput.txtOger_out.csv:98	Some of the major topics that the speakers discussed were whether P450 was synthesized in the rough or smooth endoplasmic reticulum, whether there were one or two P450s (some questioned whether changes in phospholipids might be responsible for the altered activities), the role of cytochrome b_5 (Estabrook, Mannering), the purification of P450 from rabbit liver (Coon, Sato), the chemical mechanism(s) of catalysis (Ullrich, McMahon, Udenfriend, Daly, Witkop, Jerina), and the biological basis of P450 induction. 	cytochrome b_5	13066	13080	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6431835_OgerInput.txtOger_out.csv:5	Hepatocyte spheroids formed in this device were subjected to different flow rates, of which a flow rate of 50 L/min provided the optimal microenvironment for spheroid formation, maintained significantly higher rates of albumin and urea synthesis, yielded higher CYP3A1 (cytochrome P450 3A1) and CYP2C11 (cytochrome P450 2C11) enzyme activities for metabolism, and demonstrated higher expression levels of liver-specific genes. 	cytochrome P450 3A	670	688	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450 3A	17863	17881	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450 3A4	17863	17882	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6358801_OgerInput.txtOger_out.csv:117	Moreover, up-regulation of genes coding for cytochrome P-450 and monooxygenase by the red and blue light, respectively, which was observed in our analysis, seem to support the role of putative white collar proteins or phytochromes in AMPK and MAPK based signal transduction. 	cytochrome P-450	22551	22567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6358801_OgerInput.txtOger_out.csv:117	Moreover, up-regulation of genes coding for cytochrome P-450 and monooxygenase by the red and blue light, respectively, which was observed in our analysis, seem to support the role of putative white collar proteins or phytochromes in AMPK and MAPK based signal transduction. 	cytochrome P-450	22551	22567	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:34	The low-spin soluble cyt c of mitochondria in which the heme-attachment site is located towards the N-terminus, and the sixth ligand located towards the C-terminus belongs to class I. Cytochrome c transfers electrons from complex III to complex IV, also known as cytochrome oxidase, which is the final enzyme of the electron transport system. 	Cytochrome c	6059	6071	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:34	The low-spin soluble cyt c of mitochondria in which the heme-attachment site is located towards the N-terminus, and the sixth ligand located towards the C-terminus belongs to class I. Cytochrome c transfers electrons from complex III to complex IV, also known as cytochrome oxidase, which is the final enzyme of the electron transport system. 	Cytochrome c	6059	6071	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:36	Cytochrome c, which is reduced to cyt c Fe^2+ (ferrous) by the electron from the complex III, passes an electron to the copper binuclear center, being oxidized back to cytochrome c (cyt c Fe^3+ (ferric)). 	Cytochrome c	6292	6304	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:36	Cytochrome c, which is reduced to cyt c Fe^2+ (ferrous) by the electron from the complex III, passes an electron to the copper binuclear center, being oxidized back to cytochrome c (cyt c Fe^3+ (ferric)). 	Cytochrome c	6292	6304	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7956250_OgerInput.txtOger_out.csv:63	The overall human brain samples statistic was: n(G0) = 1, n(G1) = 17, n(G2) = 9, n(G3) = 4, n(G4) = 13, where G0 describes healthy tissue, G1, G2, G3, G4 the cancer tissues with increasing malignancy grade Cytochrome c from the equine heart (C7752, Sigma-Aldrich, Pozna, Poland) was used without additional purification. 	Cytochrome c	12205	12217	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7956250_OgerInput.txtOger_out.csv:63	The overall human brain samples statistic was: n(G0) = 1, n(G1) = 17, n(G2) = 9, n(G3) = 4, n(G4) = 13, where G0 describes healthy tissue, G1, G2, G3, G4 the cancer tissues with increasing malignancy grade Cytochrome c from the equine heart (C7752, Sigma-Aldrich, Pozna, Poland) was used without additional purification. 	Cytochrome c	12205	12217	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:156	The metabolism of this polycyclic aromatic hydrocarbon molecule by oxidation reaction through cytochrome P450 enzyme from human host and monooxygenases and dioxygenase enzymes from bacterial species of skin microbiome is known from experimental studies, and reference databases such as the University of Minnesota Biocatalysis/Biodegradation Database (;. 	cytochrome P450 enzyme	29721	29743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC7772573_OgerInput.txtOger_out.csv:159	The ingestion of BaP is known to be toxic due to its metabolism by human cytochrome P450 enzyme and the products of its oxidation are known to cause carcinogenicity and other adverse health effects by reacting with the host DNA (;. 	cytochrome P450 enzyme	30459	30481	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:113	In summary, we conclude that nicotine metabolism by CYP2B6 is stereoselective, and common polymorphisms in CYP2B6 significantly influence the oxidation of both (S) and (R)nicotine to nicotine iminium and nornicotine. 	CYP2B6	21622	21628	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:113	In summary, we conclude that nicotine metabolism by CYP2B6 is stereoselective, and common polymorphisms in CYP2B6 significantly influence the oxidation of both (S) and (R)nicotine to nicotine iminium and nornicotine. 	CYP2B6	21622	21628	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:113	In summary, we conclude that nicotine metabolism by CYP2B6 is stereoselective, and common polymorphisms in CYP2B6 significantly influence the oxidation of both (S) and (R)nicotine to nicotine iminium and nornicotine. 	CYP2B6	21677	21683	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:113	In summary, we conclude that nicotine metabolism by CYP2B6 is stereoselective, and common polymorphisms in CYP2B6 significantly influence the oxidation of both (S) and (R)nicotine to nicotine iminium and nornicotine. 	CYP2B6	21677	21683	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:114	However, the small contribution of CYP2B6 to nicotine metabolism in the liver, and its undetectable activity in human brain tissue, make it highly unlikely that this genetic variation influences complex smoking behaviors. 	CYP2B6	21822	21828	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:114	However, the small contribution of CYP2B6 to nicotine metabolism in the liver, and its undetectable activity in human brain tissue, make it highly unlikely that this genetic variation influences complex smoking behaviors. 	CYP2B6	21822	21828	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:100	Moreover, even if sorafenib is not a substrate for the cytochrome isoforms CYP2B6, CYP2C8, and CYP2C9 and the UDP glucuronosyltransferase UGT1A1, the biological agent in vivo inhibits activity of these enzymes with potential pharmacological consequences and drug-interaction events. 	CYP2B6	18731	18737	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:100	Moreover, even if sorafenib is not a substrate for the cytochrome isoforms CYP2B6, CYP2C8, and CYP2C9 and the UDP glucuronosyltransferase UGT1A1, the biological agent in vivo inhibits activity of these enzymes with potential pharmacological consequences and drug-interaction events. 	CYP2B6	18731	18737	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2B6	39803	39809	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2B6	39803	39809	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2B6	39924	39930	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP2B6	39924	39930	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2B6	11196	11202	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:72	For human cells: phenacetin (CYP1A2), efavirenz (CYP2B6), amodiaquine (CYP2C8), diclofenac (CYP2C9), dextromethorphan (CYP2D6), testosterone (CYP3A4), and for rat cells phenacetin (CYP1A2), testosterone (CYP2A1, CYP3A1, CYP3A2), diclofenac (CYP2C6) testosterone (CYP2C11), and Pnitrophenol (CYP2E1) were used. 	CYP2B6	11196	11202	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2B6	13958	13964	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:89	To investigate whether metabolic activation by human phase I enzymes-at least in part-contributes to the cytotoxic effect, Ze 339 (concentrations up to 100 g/ml) was coincubated in HepaRG cells for 4 hr with different single cytochromes inhibitors: ketoconazole (CYP3A4), sulfaphenazole (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), ALPHAnaphthoflavone (CYP1A2), quinidine (CYP2D6), xanthotoxin (CYP2A6), chlormethiazole (CYP2E1), and ticlopidine (CYP2B6)-(each at a concentration of 10 M). 	CYP2B6	13958	13964	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2B6	19519	19525	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:124	The incubation with single human cytochromes revealed that petasin was mainly metabolized by CYP2D6 (80.2%) and to an intermediate extent by CYP3A4 (34%), CYP2B6 (50%), CYP2C8 (54%), and CYP2C9 (51%). 	CYP2B6	19519	19525	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:127	For CYP2C9, diverging effects were observed (8% and 58%), and for CYP2B6, virtually no metabolism (13% and 20%) was noted. 	CYP2B6	19852	19858	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:127	For CYP2C9, diverging effects were observed (8% and 58%), and for CYP2B6, virtually no metabolism (13% and 20%) was noted. 	CYP2B6	19852	19858	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B6	20764	20770	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7004140_OgerInput.txtOger_out.csv:133	CYP2B6 (human) and CYP2E1 (rat) could not be compared between species because the respective analogue of the other species was not available to us.. Positive controls for each of the isolated cytochromes showed an extent of metabolism between 31.2% (CYP1A2) and 100% (CYP2C9) for human cytochromes and between 23.1% (CYP2D2) and 100% (CYP2B1) for rat cytochromes (data not shown). 	CYP2B6	20764	20770	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2B6	21054	21060	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7066769_OgerInput.txtOger_out.csv:138	While other hepatic cytochromes contribute to metoprolol metabolism, namely CYP3A4, CYP2B6, and CYP2C9, these isoforms contribute to less than 20% of the drugs metabolism; thus, we have focused on CYP2D6 since it is the primary pathway of metabolism. 	CYP2B6	21054	21060	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:101	One knockdown (CYP303a1, human orthologue CYP2B6) never showed the uptake of PCB 28 and was therefore excluded from further analysis. 	CYP2B6	16180	16186	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:101	One knockdown (CYP303a1, human orthologue CYP2B6) never showed the uptake of PCB 28 and was therefore excluded from further analysis. 	CYP2B6	16180	16186	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2B6	14014	14020	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:72	The presence of the alleles listed in  of the CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 genes was analyzed in the Pharmacogenetics and Precision Medicine Unit of the University Hospital of Salamanca.  	CYP2B6	14014	14020	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:78	Among the 166 patients who were tested for the CYP2B6 gene, the most common phenotype was EM (Extensive Metabolizer) (50.00%, n. 	CYP2B6	14791	14797	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC7767089_OgerInput.txtOger_out.csv:78	Among the 166 patients who were tested for the CYP2B6 gene, the most common phenotype was EM (Extensive Metabolizer) (50.00%, n. 	CYP2B6	14791	14797	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC7308462_OgerInput.txtOger_out.csv:217	Meanwhile QC further improved the therapeutic efficacy by increasing the bioavailability of Mycophenolic Acid through inhibiting Cytochrome P450 enzyme. 	Cytochrome P450 enzyme	34427	34449	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:134	The genes that are overexpressed in Theca cells (cluster 4) are particularly involved in cholesterol import (SCARB1, STARD5), bile acid metabolism (CH25H), HDL-mediated lipid transport (APOA1, PLTP, SCARB1), lipid degradation (LPL, PLIN5), and steroidogenesis (CYP27A, CYP7B1, TM7SF2). 	CYP7	25478	25482	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_655', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:134	The genes that are overexpressed in Theca cells (cluster 4) are particularly involved in cholesterol import (SCARB1, STARD5), bile acid metabolism (CH25H), HDL-mediated lipid transport (APOA1, PLTP, SCARB1), lipid degradation (LPL, PLIN5), and steroidogenesis (CYP27A, CYP7B1, TM7SF2). 	CYP7	25478	25482	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_653', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:102	Further analysis showed a significant negative correlation between LC3II/I ratio and cell viability (P < .01), and apoptosis rate, cytochrome C and cleaved caspase3 correlated positively with LC3II/I ratio. 	cytochrome C	11754	11766	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:102	Further analysis showed a significant negative correlation between LC3II/I ratio and cell viability (P < .01), and apoptosis rate, cytochrome C and cleaved caspase3 correlated positively with LC3II/I ratio. 	cytochrome C	11754	11766	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:104	As shown in Figure BE, cell viability was significantly increased, apoptosis rate, expressions of cytochrome C and cleaved caspase3 were remarkably decreased by 3MA pretreatment compared with the corresponding bubble alone groups of 10, 20 and 30 minutes (P < .05). 	cytochrome C	12103	12115	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:104	As shown in Figure BE, cell viability was significantly increased, apoptosis rate, expressions of cytochrome C and cleaved caspase3 were remarkably decreased by 3MA pretreatment compared with the corresponding bubble alone groups of 10, 20 and 30 minutes (P < .05). 	cytochrome C	12103	12115	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:105	3MA induced a significant decrease in cell viability as well increases in apoptosis rate, cytochrome C and cleaved caspase3 in 1 or 5 minutes groups (P < .05). 	cytochrome C	12361	12373	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:105	3MA induced a significant decrease in cell viability as well increases in apoptosis rate, cytochrome C and cleaved caspase3 in 1 or 5 minutes groups (P < .05). 	cytochrome C	12361	12373	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450 3a	41236	41254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450 3a	50224	50242	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450 3a	52236	52254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450 3a4	41236	41255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450 3a4	50224	50243	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450 3a4	52236	52255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2275	2289	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2275	2289	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17278	17293	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17278	17293	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17455	17470	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17455	17470	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17502	17517	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b _5	17502	17517	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b _5	18060	18075	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b _5	18060	18075	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b _5	19426	19441	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b _5	19426	19441	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	cytochrome b _5	20690	20705	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	cytochrome b _5	20690	20705	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:19	CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b _5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described.,  Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymorphisms on metabolism. 	cytochrome b _5	3406	3421	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:19	CYP2B6 variants, reference allele P450 oxidoreductase (POR), and reference allele cytochrome b _5 vectors were previously generated, and recombinant proteins previously expressed in insect cells, as described.,  Haplotype selection was based on the known clinical significance and frequency of the polymorphism, and a desire to inform the mechanistic basis for the influence of these polymorphisms on metabolism. 	cytochrome b _5	3406	3421	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:71	In the case of the Cyp1a2 and Cyp2c29, the mRNA expression was significantly decreased in SPF and GF female mice compared to the control. 	Cyp1a2	10173	10179	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:71	In the case of the Cyp1a2 and Cyp2c29, the mRNA expression was significantly decreased in SPF and GF female mice compared to the control. 	Cyp1a2	10173	10179	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:90	Interestingly, the sex differences were erased in GF mice, and the expression of Cyp3a11 was about the same in both sexes. 	Cyp3a	12676	12681	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:91	In other words, there is significant interaction between the gender and presence of the gut microbiome, which together influence the Cyp3a11 mRNA expression. 	Cyp3a	12851	12856	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP11B2	25456	25463	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP11B2	25456	25463	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:182	Sort=Bait interacts with cytochrome P450 CYP2E1 and CYP11B2, while the affinity of TBXAS1CYP2E1 complex formation is fivefold higher in the presence of low-molecular-weight non-peptide endogenous bioregulator isatin (2,3-dioxindole). 	CYP11B2	25456	25463	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:68	CYP11B2, which is also known as aldosterone synthase, additionally exhibits 18-hydroxylase and 18-methyl oxidase activity, which are required to convert corticosterone to aldosterone via the 18-hydroxycorticosterone intermediate. 	CYP11B2	11437	11444	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:68	CYP11B2, which is also known as aldosterone synthase, additionally exhibits 18-hydroxylase and 18-methyl oxidase activity, which are required to convert corticosterone to aldosterone via the 18-hydroxycorticosterone intermediate. 	CYP11B2	11437	11444	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:68	CYP11B2, which is also known as aldosterone synthase, additionally exhibits 18-hydroxylase and 18-methyl oxidase activity, which are required to convert corticosterone to aldosterone via the 18-hydroxycorticosterone intermediate. 	CYP11B2	11437	11444	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:68	CYP11B2, which is also known as aldosterone synthase, additionally exhibits 18-hydroxylase and 18-methyl oxidase activity, which are required to convert corticosterone to aldosterone via the 18-hydroxycorticosterone intermediate. 	CYP11B2	11437	11444	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:123	In CYP90B1, the active site is characterized by the conformations side-chain in and steroid-core out, similar to CYP11A1, and for CYP90B1 the 3-hydroxy group hydrogen is bonded with H385 and the carbonyl oxygen of V216 via a water molecule. 	CYP11A1	17567	17574	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:123	In CYP90B1, the active site is characterized by the conformations side-chain in and steroid-core out, similar to CYP11A1, and for CYP90B1 the 3-hydroxy group hydrogen is bonded with H385 and the carbonyl oxygen of V216 via a water molecule. 	CYP11A1	17567	17574	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:123	In CYP90B1, the active site is characterized by the conformations side-chain in and steroid-core out, similar to CYP11A1, and for CYP90B1 the 3-hydroxy group hydrogen is bonded with H385 and the carbonyl oxygen of V216 via a water molecule. 	CYP11A1	17567	17574	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:124	However, due to the perpendicular position of the CYP90B1 steroid core, the C-22 is located closer to the heme iron (4.1 ) and gets hydrolyzed, whereas 20-C is too far from the heme group (4.9 ) to get hydrolyzed, unlike in CYP11A1 where both positions are hydroxylated. 	CYP11A1	17919	17926	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:124	However, due to the perpendicular position of the CYP90B1 steroid core, the C-22 is located closer to the heme iron (4.1 ) and gets hydrolyzed, whereas 20-C is too far from the heme group (4.9 ) to get hydrolyzed, unlike in CYP11A1 where both positions are hydroxylated. 	CYP11A1	17919	17926	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:124	However, due to the perpendicular position of the CYP90B1 steroid core, the C-22 is located closer to the heme iron (4.1 ) and gets hydrolyzed, whereas 20-C is too far from the heme group (4.9 ) to get hydrolyzed, unlike in CYP11A1 where both positions are hydroxylated. 	CYP11A1	17919	17926	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:124	However, due to the perpendicular position of the CYP90B1 steroid core, the C-22 is located closer to the heme iron (4.1 ) and gets hydrolyzed, whereas 20-C is too far from the heme group (4.9 ) to get hydrolyzed, unlike in CYP11A1 where both positions are hydroxylated. 	CYP11A1	17919	17926	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:111	Within the adrenal, A4 can serve as a substrate for CYP11B1, yielding the 11-oxygenated androgen precursor, 11OHA4, with conversion of testosterone to 11BETA-hydroxytestosterone (11OHT), also occurring. 	CYP11B1	18922	18929	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_447', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:111	Within the adrenal, A4 can serve as a substrate for CYP11B1, yielding the 11-oxygenated androgen precursor, 11OHA4, with conversion of testosterone to 11BETA-hydroxytestosterone (11OHT), also occurring. 	CYP11B1	18922	18929	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_780', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:172	The EV CYPs (CYP 1A1 and 2A6) exert an additive effect on the basal CYPs of the recipient cells. 	CYP 1A1	30011	30018	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:172	The EV CYPs (CYP 1A1 and 2A6) exert an additive effect on the basal CYPs of the recipient cells. 	CYP 1A1	30011	30018	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:133	The genetic variation of cytochrome B and MHC-DRB differed in Chinese woodchucks with different susceptibility to WHV infection. 	cytochrome B	20566	20578	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:134	These data will be benefit for understanding the pathogenesis of hepadnavirus infection, and cytochrome B and MHC-DRB alleles will be helpful for selection suitable animals for WHV infection.	cytochrome B	20763	20775	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6329513_OgerInput.txtOger_out.csv:28	5 per species) for the cytochrome oxidase subunit 1 (CO1) and cytochrome B (CytB) gene regions for the shark and teleost species commonly encountered in the West Coast and Gascoyne Coast bioregions of Western Australia were downloaded from GenBank/BOLD databases where available. 	cytochrome B	5002	5014	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP19	6119	6124	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP19	6119	6124	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP19	6119	6124	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:40	The lowest counts of variants were found in CYP21A2 (one variant), CYP26C1 (seven), CYP3A4, and CYP19A1 (both eight variants). 	CYP19	6119	6124	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:174	Orthochlorinated PCBs such as PCB 128, PCB 153, PCB 155 and PCB 180 induce the expression of CYP2B1. 	CYP2B1	28808	28814	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_500', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:174	Orthochlorinated PCBs such as PCB 128, PCB 153, PCB 155 and PCB 180 induce the expression of CYP2B1. 	CYP2B1	28808	28814	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:174	Orthochlorinated PCBs such as PCB 128, PCB 153, PCB 155 and PCB 180 induce the expression of CYP2B1. 	CYP2B1	28808	28814	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC7726022_OgerInput.txtOger_out.csv:174	Orthochlorinated PCBs such as PCB 128, PCB 153, PCB 155 and PCB 180 induce the expression of CYP2B1. 	CYP2B1	28808	28814	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:103	While berberine increased CYP1A1 mRNA to a level approaching that of TCDD-exposed HepG2 cells, our findings suggested that an increase in miR-21-3p might be the reason for the mild increase in CYP1A1 protein level by berberine as compared to that induced by TCDD. 	CYP1A1 protein	14359	14373	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:107	While the CYP1A1 mRNA was increased, berberine-induced miR-21-3p suppressed the increase in CYP1A1 protein and function. 	CYP1A1 protein	15003	15017	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:613	Likewise Guth did not detect PROD activity in StrataTest^ (LOD 4 pmol/min/mg protein). 	PROD	93478	93482	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:614	Attempts to induce PROD activities in the human reconstructed skin model EpiDerm^ using quite a number of CYP2B6 inducers (phenobarbital, rifampicin, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) as well as cyclophosphamide) also failed (Gtz et al.. In contrast to these negative findings Baron et al. 	PROD	93555	93559	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:614	Attempts to induce PROD activities in the human reconstructed skin model EpiDerm^ using quite a number of CYP2B6 inducers (phenobarbital, rifampicin, 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime (CITCO) as well as cyclophosphamide) also failed (Gtz et al.. In contrast to these negative findings Baron et al. 	PROD	93555	93559	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:615	report detection of PROD activity in proliferating human keratinocytes in culture and its induction by phenobarbital. 	PROD	93909	93913	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:615	report detection of PROD activity in proliferating human keratinocytes in culture and its induction by phenobarbital. 	PROD	93909	93913	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:679	reported that native human skin had a low level of CYP3A4 protein, moderately induced after 24 h by 2 mM phenobarbital, which, however, was not accompanied by an increase in CYP3A4-dependent BROD activity by phenobarbital (0.5-2 mM for 24, 48 and 72 h) nor by rifampicin (50 and 100 M for 24 h) nor by dexamethasone (10 and 50 M for 24, 48 and 72 h). 	BROD	103807	103811	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:69	It is unclear why our patient did not exhibit any side or adverse effects; however, it could be that the Carbamazepine he received played a role, although studies have shown that there is little or no in vivo effects of CYP 2D6 on Paliperidone. 	CYP 2D6	10685	10692	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:69	It is unclear why our patient did not exhibit any side or adverse effects; however, it could be that the Carbamazepine he received played a role, although studies have shown that there is little or no in vivo effects of CYP 2D6 on Paliperidone. 	CYP 2D6	10685	10692	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:194	CYP26B1 metabolizes retinoic acid, a compound with potential anticancer abilities. 	CYP26B1	27052	27059	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:195	In this regard, a recent Genome-Wide Association Study revealed an association of CYP26B1 with esophageal squamous cell carcinoma risk. 	CYP26B1	27217	27224	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:452	In isolated RCs of PSII, D1/D2/Cytochrome B559 was found to exhibit SOD activity. 	Cytochrome B	67229	67241	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:453	As proposed by Pospil, the catalytic formation of H_2O_2 by D1/D2/Cytochrome B559 proceeds as a two-step reduction-oxidation reaction involving two molecules of O_2^. 	Cytochrome B	67346	67358	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:454	The first step is reduction of D1/D2/Cytochrome B559 (Fe^3+) to D1/D2/Cytochrome B559 (Fe^2+), Reaction (106). 	Cytochrome B	67484	67496	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:454	The first step is reduction of D1/D2/Cytochrome B559 (Fe^3+) to D1/D2/Cytochrome B559 (Fe^2+), Reaction (106). 	Cytochrome B	67517	67529	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:455	The second step is the oxidation of D1/D2/Cytochrome B559 (Fe^2+) by HO_2^, the protonated form of O_2^, with formation of D1/D2/Cytochrome B559 (Fe^3+) and H_2O_2, Reaction (107). 	Cytochrome B	67600	67612	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:455	The second step is the oxidation of D1/D2/Cytochrome B559 (Fe^2+) by HO_2^, the protonated form of O_2^, with formation of D1/D2/Cytochrome B559 (Fe^3+) and H_2O_2, Reaction (107). 	Cytochrome B	67687	67699	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7762604_OgerInput.txtOger_out.csv:423	In addition, they isolated mitochondrial and cytosol fractions and observed a time-dependent release of Cytochrome C to cytosol. 	Cytochrome C	73097	73109	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7762604_OgerInput.txtOger_out.csv:425	On the other hand, the release of Cytochrome C from the mitochondria was simultaneous with Aif1p (apoptosis-inducing factor) release; Aif1p is involved in chromatin condensation and DNA degradation; these are related to a function of mitochondrial permeabilization induced by Human Lf. 	Cytochrome C	73537	73549	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7762604_OgerInput.txtOger_out.csv:425	On the other hand, the release of Cytochrome C from the mitochondria was simultaneous with Aif1p (apoptosis-inducing factor) release; Aif1p is involved in chromatin condensation and DNA degradation; these are related to a function of mitochondrial permeabilization induced by Human Lf. 	Cytochrome C	73537	73549	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:35	It has been shown that the kinetics of human CYP17A1 favors the conversion of 17OH-pregnenolone to dehydroepiandrosterone over that of 17OH-progesterone to androstenedione. 	CYP17	4373	4378	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:35	It has been shown that the kinetics of human CYP17A1 favors the conversion of 17OH-pregnenolone to dehydroepiandrosterone over that of 17OH-progesterone to androstenedione. 	CYP17	4373	4378	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:36	The apparent K_m and v_max of CYP17A1 for 17OH-progesterone are 10-fold higher (K_m) and 10-fold lower (v_max) than those for 17OH-pregnenolone. 	CYP17	4531	4536	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:36	The apparent K_m and v_max of CYP17A1 for 17OH-progesterone are 10-fold higher (K_m) and 10-fold lower (v_max) than those for 17OH-pregnenolone. 	CYP17	4531	4536	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:37	Thus, the catalytic efficiency (k_cat/K_m) for the 17,20-lyase reaction by one mole of CYP71A1 is about 100-fold higher for 17OH-pregnenolone than for 17OH-progesterone. 	17,20-lyase	4697	4708	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:37	Thus, the catalytic efficiency (k_cat/K_m) for the 17,20-lyase reaction by one mole of CYP71A1 is about 100-fold higher for 17OH-pregnenolone than for 17OH-progesterone. 	17,20-lyase	4697	4708	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:153	The absence of SOAT1 can increase the availability for the retina of fatty acids, which are used as the enzyme substrates, whereas the absence of Cytochromes P450 27a1 and CYP46A1 abolishes the production of 27-hydroxycholesterol and 24-hydroxycholesterol, which are activating ligands for LXRs. 	CYP46A1	27965	27972	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:153	The absence of SOAT1 can increase the availability for the retina of fatty acids, which are used as the enzyme substrates, whereas the absence of Cytochromes P450 27a1 and CYP46A1 abolishes the production of 27-hydroxycholesterol and 24-hydroxycholesterol, which are activating ligands for LXRs. 	CYP46A1	27965	27972	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:141	The present work provides insights into potential mechanisms that could underlie the deteriorations in retinal function in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46	25587	25592	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:149	Further studies are required to target more precisely the major contributors to changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46	27190	27195	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:150	In Cyp27a1^/Cyp46a1^/Apoe^/ mice, retinal function was dependent on sex and was normal in female animals, in agreement with our previous findings that Apolipoprotein E absence elicits strong compensatory mechanisms that minimize retinal impact of this protein absence. 	Cyp46	27227	27232	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:151	Future work will map these responses by retinal proteomics in Cyp27a1^/Cyp46a1^/Apoe^/ mice for comparison to Apoe^/ results. 	Cyp46	27555	27560	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:152	We propose the following model to unify the available data and to identify the questions that remain unanswered to completely explain changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46	27768	27773	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:155	Accordingly, glucose utilization and fatty acid BETA-oxidation could be increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as a compensatory response to decreased LXR activation and/or increased fatty acid availability. 	Cyp46	28402	28407	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:158	Apparently, other processes could also become affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as suggested by retinal proteomics. 	Cyp46	29034	29039	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46	29216	29221	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46	29246	29251	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:141	The present work provides insights into potential mechanisms that could underlie the deteriorations in retinal function in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	25587	25594	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:141	The present work provides insights into potential mechanisms that could underlie the deteriorations in retinal function in Cyp27a1^/Cyp46a1^/Soat1^/ mice. 	Cyp46a1	25587	25594	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:149	Further studies are required to target more precisely the major contributors to changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46a1	27190	27197	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:149	Further studies are required to target more precisely the major contributors to changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46a1	27190	27197	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:150	In Cyp27a1^/Cyp46a1^/Apoe^/ mice, retinal function was dependent on sex and was normal in female animals, in agreement with our previous findings that Apolipoprotein E absence elicits strong compensatory mechanisms that minimize retinal impact of this protein absence. 	Cyp46a1	27227	27234	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:150	In Cyp27a1^/Cyp46a1^/Apoe^/ mice, retinal function was dependent on sex and was normal in female animals, in agreement with our previous findings that Apolipoprotein E absence elicits strong compensatory mechanisms that minimize retinal impact of this protein absence. 	Cyp46a1	27227	27234	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:151	Future work will map these responses by retinal proteomics in Cyp27a1^/Cyp46a1^/Apoe^/ mice for comparison to Apoe^/ results. 	Cyp46a1	27555	27562	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:151	Future work will map these responses by retinal proteomics in Cyp27a1^/Cyp46a1^/Apoe^/ mice for comparison to Apoe^/ results. 	Cyp46a1	27555	27562	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:152	We propose the following model to unify the available data and to identify the questions that remain unanswered to completely explain changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46a1	27768	27775	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:152	We propose the following model to unify the available data and to identify the questions that remain unanswered to completely explain changes in the Cyp27a1^/Cyp46a1^/Soat1^/ retina. 	Cyp46a1	27768	27775	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:155	Accordingly, glucose utilization and fatty acid BETA-oxidation could be increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as a compensatory response to decreased LXR activation and/or increased fatty acid availability. 	Cyp46a1	28402	28409	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:155	Accordingly, glucose utilization and fatty acid BETA-oxidation could be increased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as a compensatory response to decreased LXR activation and/or increased fatty acid availability. 	Cyp46a1	28402	28409	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:158	Apparently, other processes could also become affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as suggested by retinal proteomics. 	Cyp46a1	29034	29041	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:158	Apparently, other processes could also become affected in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as suggested by retinal proteomics. 	Cyp46a1	29034	29041	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46a1	29216	29223	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46a1	29216	29223	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46a1	29246	29253	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:160	We comprehensively characterized the retina of Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice and identified some of the homeostatic responses to the blockage of the major pathways of retinal cholesterol output and storage. 	Cyp46a1	29246	29253	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:168	Cyp27b1-KO rats and Vdr (R270L) rats were fed 25(OH)D_3 for comparison of its effects on rickets symptoms. 	Cyp27b1	26846	26853	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:170	During 25D-F-2 feeding, the average daily food intake was 18.6  3.7 g in Cyp27b1-KO rats and 18.1  0.7 g in Vdr (R270L) rats, whereas the body weight of Cyp27b1-KO rats was significantly lower than that of Vdr (R270L) rats. 	Cyp27b1	27124	27131	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:170	During 25D-F-2 feeding, the average daily food intake was 18.6  3.7 g in Cyp27b1-KO rats and 18.1  0.7 g in Vdr (R270L) rats, whereas the body weight of Cyp27b1-KO rats was significantly lower than that of Vdr (R270L) rats. 	Cyp27b1	27124	27131	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:170	During 25D-F-2 feeding, the average daily food intake was 18.6  3.7 g in Cyp27b1-KO rats and 18.1  0.7 g in Vdr (R270L) rats, whereas the body weight of Cyp27b1-KO rats was significantly lower than that of Vdr (R270L) rats. 	Cyp27b1	27204	27211	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:170	During 25D-F-2 feeding, the average daily food intake was 18.6  3.7 g in Cyp27b1-KO rats and 18.1  0.7 g in Vdr (R270L) rats, whereas the body weight of Cyp27b1-KO rats was significantly lower than that of Vdr (R270L) rats. 	Cyp27b1	27204	27211	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:171	Consequently, the food intake per kg body weight was calculated to be 113.2  16.9 g/kg bw/day in Cyp27b1-KO rats and 56.0  6.4 g/kg bw/day in Vdr (R270L) rats. 	Cyp27b1	27372	27379	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:171	Consequently, the food intake per kg body weight was calculated to be 113.2  16.9 g/kg bw/day in Cyp27b1-KO rats and 56.0  6.4 g/kg bw/day in Vdr (R270L) rats. 	Cyp27b1	27372	27379	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:172	Thus, the dose of 25(OH)D_3 was calculated to be 168.9  25.1 g/kg bw/day in Cyp27b1-KO rats and 80.9  7.7 g/kg bw/day in Vdr (R270L) rats (the values are shown as the means  SEMs (n = 2-3 animals/group)). 	Cyp27b1	27511	27518	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:172	Thus, the dose of 25(OH)D_3 was calculated to be 168.9  25.1 g/kg bw/day in Cyp27b1-KO rats and 80.9  7.7 g/kg bw/day in Vdr (R270L) rats (the values are shown as the means  SEMs (n = 2-3 animals/group)). 	Cyp27b1	27511	27518	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:205	Liver mitochondrial and microsomal fractions were prepared from Cyp27b1-KO rats using the same methods as described in our previous study^. 	Cyp27b1	32533	32540	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:205	Liver mitochondrial and microsomal fractions were prepared from Cyp27b1-KO rats using the same methods as described in our previous study^. 	Cyp27b1	32533	32540	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:212	Two-way ANOVA was performed for the analysis of the bone mineral density and levels of plasma Ca, Parathyroid Hormone, 1,25(OH)_2D_3, 25(OH)D_3 and its metabolites in Cyp27b1-KO and mutant Vdr (R270L) rats fed the F-2 or 25D-F-2 diet. 	Cyp27b1	33963	33970	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:212	Two-way ANOVA was performed for the analysis of the bone mineral density and levels of plasma Ca, Parathyroid Hormone, 1,25(OH)_2D_3, 25(OH)D_3 and its metabolites in Cyp27b1-KO and mutant Vdr (R270L) rats fed the F-2 or 25D-F-2 diet. 	Cyp27b1	33963	33970	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
